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Abstract 
 
i 
 
The role of ERK5 in tumour angiogenesis and drug resistance 
Extracellular regulated signal protein kinase 5 (ERK5) is the most recently 
identified member of the MAPK family which are involved in cellular 
proliferation, differentiation, migration. ERK5 differs from other MAPKs, in 
that contains an unusually long carboxyl-terminal tail. ERK5 is activated by 
growth factors and cellular stresses. Targeted deletion of erk5 in mice results 
in death around E9.5-11.5 due to severe defects in vasculature revealed the 
importance of the ERK5 signalling pathway. Aberrant ERK5 signalling has 
already been reported in several different cancers such as breast, prostate, 
hepatocellular and melanoma.  
This project investigated the differences in ERK5 activation between VEGF 
in endothelial cells and EGF in HeLa cells. It was revealed that VEGF has 
only the ability to induce the dual phosphorylation of the kinase domain of 
ERK5, without any effect on the phosphorylation of the C-terminal residues 
suggesting that phosphorylation of Thr
218
/Tyr
220 
in the kinase domain and C-
terminal phosphorylation are not mutually inclusive events and that ERK5 
can be activated in the absence of C-terminal phosphorylation. Furthermore, 
this study also investigated the role of ERK5 in drug resistance and tumour 
angiogenesis. It was showed that inhibition of MEK5/ERK5 signalling 
pathway by BIX02189 or XMD8-92 in combination with anti-cancer drug 
increased the sensitivity of melanoma and ovarian cancer cells to 
vemurafenib and doxorubicin respectively. VEGF plays a key role in 
angiogenesis and it has been reported that ERK5 is required for VEGF-
mediated survival and tubular morphogenesis. Targeting MEK5/ERK5 
signalling cascade resulted in inhibition of VEGF-induced angiogenesis in 
HDMEC/NHDF/cancer cells co-culture angiogenesis in vitro assay. 
Taken together, this data has suggested that the ERK5 signalling axis is a 
viable target to restore sensitivity to chemotherapy in drug-resistant cells and 
inhibit aberrant angiogenesis which could present a possibility of ERK5 
serving as a therapeutic target for drug resistance in cancer. 
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1.1   Vascular system 
The human body requires a mechanism to deliver oxygen and nutrients to the 
tissues and organs adequately and remove toxic metabolites. The vascular 
system accomplishes these functions and also carries immune cells to sites of 
infection and inflammation, and transports endocrine signals to responder 
cells (Rossant and Howard, 2002) 
The vascular system functions via two main parts, blood vessels and 
lymphatic vessels. The lumens of these vessels are lined by the endothelium, 
a monolayer of endothelial cells. The endothelial cells of capillaries and small 
vessels are surrounded by a basement membrane and covered by smooth 
muscle cells, pericytes, giving the vessels stabilization (Figure 1.1 B). The 
large vessels such as arteries and veins consisted of three layers. The inner 
layer is composed of the endothelium, as tunica intima, surrounded by extra 
cellular matrix proteins. This layer is surrounded by two layers; a thick layer 
of smooth muscle cells that promote the stabilization called tunica media and 
the tight outermost layer, the tunica adventia, which comprises connective 
tissue, collagen and elastic fibres (Figure 1.1 A). The vascular system is 
formed by the process of vasculogenesis and modified and remodelled by the 
process of angiogenesis (Gerhardt and Betsholtz, 2003). 
 
Figure 1.1 Blood Vessel structure. (A) Illustration of a cross section of large blood vessel such 
as artery or vein. (B) Illustration of a cross section of a small blood vessel such as a capillary or 
arteriole. 
A B 
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 1.1.1   Vasculogenesis 
Vasculogenesis is defined as the process by which new blood vessels form 
from endothelial precursor cells (Risau and Flamme, 1995). In the yolk sac, 
the mesoderm cells differentiate into haemangioblasts, precursor cells, which 
in turn differentiate into angioblasts and aggregate to form blood islands. The 
blood islands consist of an outer layer of endothelial precursor cells that 
surround the inner mass of hematopoietic precursor cells. The angioblasts 
differentiate into endothelial cells and form a primitive vascular plexus of 
blood vessels. The haematopoietic precursor cells differentiate to form 
mature hematopoietic precursor cells. The fusion of blood islands and the 
differentiated angioblasts and haematopoietic precursor cells to form primary 
vascular plexus of blood vessels in yolk sac that surrounds the embryo (Choi 
et al., 1998). New capillaries appear by either sprouting or intussusception 
from the first vessels and the plexus will then expand remodel through 
angiogenesis.  
1.1.2   Angiogenesis 
Angiogenesis is the formation of blood vessels from pre-existing tissues 
(Risau, 1997). Angiogenesis is important in embryonic development. It 
important in the female reproductive cycle, during pregnancy and in wound 
healing (Groothuis, 2005). The body tightly regulates angiogenesis by 
producing a precise balance of pro-angiogenic factors such as vascular 
endothelial growth factor (VEGF) and anti-angiogenic factors such as 
angiostatin, endostatin and thrombospondin. Disturbance of this balance 
results in abnormal growth of blood vessels by either excessive or insufficient 
angiogenesis (Figure 1.2). Abnormal angiogenesis is implicated in many 
diseases and deadly conditions such as cancer, diabetic retinopathy, 
cardiovascular disease and stroke result of insufficient angiogenesis 
(Carmeliet, 2005) (Figure 1.2). 
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Angiogenesis occurs through two distinct mechanisms; sprouting 
angiogenesis and intussusceptive or splitting angiogenesis. In sprouting 
angiogenesis, new blood vessels are formed from pre-existing vessels (Risau, 
1997). The balance of growth factors regulates endothelial cell quiescence. 
An increase in pro-angiogenic factors such as VEGF or decrease in anti-
angiogenic factors, such as thrombospondin, induces changes in the 
phenotype of endothelial cells which switch on the angiogenic switch and 
endothelial cells become activated (Carmeliet and Jain, 2000). The blood 
vessels have oxygen and hypoxia-induced receptors to supply a sufficient 
amount of oxygen to tissues. The endogenous signals or hypoxia activate 
cells to release signalling factors, for example VEGF, bFGF, to develop new 
blood vessels from pre-existing vessels. VEGF, a pro-angiogenic factor, 
binds to its cognate receptor on the endothelial cell membrane called VEGFR 
(Carmeliet and Jain, 2011). An endothelial tip cell releases proteases such as 
matrix metalloproteinases, MMP, to degrade the basement membrane 
surrounding the endothelial cell and remodel the extracellular matrix. The tip 
cell migrates toward stimuli that release VEGF by extending various filopodi. 
Stalk endothelial cells extend the sprouting and proliferate to establish 
junctions with neighbouring endothelial cells and regulate formation of 
vascular lumen. Two tip endothelial cells encounter each other and constitute 
endothelial cell-endothelial cell junctions and form the lumen (Lamalice et 
al., 2007). The extracellular matrix forms a new basement membrane and the 
pericytes are recruited to stabilize the newly-formed tubes. When the blood 
flow is established, the resting state of blood vessels is re-established 
(Carmeliet and Jain, 2000). Intussusceptive angiogenesis is the grow of new 
blood vessels from the pre-existing vasculature via insertion of pillars into the 
lumen of capillaries, small arteries and veins which subsequently fuse to form 
new capillary network (Djonov and Makanya, 2005). The formation of pillar, 
which is the hallmark of intussusceptive angiogenesis, progresses through a 
multistep process; the endothelial walls of the opposite side of a vessel 
protrude until they contact each other to form intraluminal pillar. The 
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interendothelial junctions are reorganized by which the endothelial bilayer is 
perforated centrally in the core of the pillar. The pericytes and myofibroblasts 
invade the pillar and deposit extracellular matrix into it. The endothelial cells 
retract and the new pillars increase in size and fuse with each other and 
finally splitting up the original capillary into two new capillaries (De 
Spiegelaere et al., 2012, Makanya et al., 2009).  
 
Figure 1.2 Angiogenic balance in physiological angiogenesis. The pathologies distinguished 
by excessive and insufficient angiogenesis which are associated with up-regulation of pro-
angiogenic factors and/or down regulation of anti-angiogenic factors.  
 
1.1.3   Tumour angiogenesis 
Cancer represents a progression from normal cellular homeostasis to a 
neoplastic condition with the cellular acquisition of a number of defined 
hallmarks: sustained proliferative signalling, evading suppressors, resisting 
cell death, enabling replicative immortality, inducing angiogenesis, activating 
invasion and metastasis, reprogramming energy metabolism and evading 
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immune destruction (Hanahan and Weinberg, 2011). Cancer cells require an 
adequate blood supply that contains nutrients and oxygen. Tumour cells are 
able to penetrate the cardiovascular system and proliferate to any organ of the 
body forming metastasis (Folkman, 1971). Metastasis is angiogenesis-
dependent as the formation of vascular networks is a vital step in its process 
and in supplying oxygen and nutrients to the tumour (Folkman, 1971). 
Angiogenesis is essential for tumour growth progression as without an 
adequate blood supply tumours will stop growing and become apoptotic 
(Parangi et al., 1996). Thus, a tumour without blood supply grows to 1-2 mm³ 
and then stops while with a blood supply it grows beyond 2 mm³ 
(Muthukkaruppan et al., 1982). Hypoxic conditions that result from 
insufficient new blood vessels induce the expression of different pro-
angiogenic growth factors such as VEGF and bFGF in tumour cells which 
bind to their cognate growth factor receptors on the surface of the endothelial 
cells of neighbouring vessels (Bottaro and Liotta, 2003). Pro-angiogenic 
growth factors activate endothelial cells that launch the angiogenic responses 
which result in tumour angiogenesis (Figure 1.3). The newly-formed vessels 
are disorganised, leaky and lack the quiescent state compared with normal 
vessels (Bergers and Benjamin, 2003). Therefore, tumour vessels lose their 
proper functions and induce more angiogenesis to supply the tumour. 
Angiogenesis depends on the type of tumour and the cancerous organ as each 
organ has different stromal cells that release various pro- and anti-angiogenic 
factors (Carmeliet and Jain, 2000). 
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Figure 1.3 Steps of tumour angiogenesis. Tumour cells release angiogenic factors such as 
VEGF and FGF (1) which in turn bind to their receptors (e.g. VEGFR-2 or FGFR-1) on the 
surface of the endothelial cells neighbouring capillary blood vessel (2). Binding of these 
growth factors to their receptors on ECs surface, activates ECs and direct angiogenic 
response by activating many intracellular signalling pathways (3). Activated endothelial cells 
secrete proteases to dissolve the basement membrane (3). Degradation of basement 
membrane and tip cell formation, EC migrate, followed by stalk cell proliferation to form 
unstable lumen (4). Endothelial cells secrete extracellular matrix protein such as matrix 
metalloproteinases (MMPs) and growth factors for degradation of most component of extra 
cellular matrix (ECM) and reconstruct the basement membrane (5). ECs differentiate to 
form a lumen containing vessel (6). The new vessel is stabilised by recruitment of pericytes 
(7). 
 
1.1.4   Therapeutic Angiogenesis 
In ischaemic diseases, angiogenesis inducers stimulate therapeutic 
angiogenesis while in cancer, angiogenesis inhibitors can be used to debilitate 
therapeutic angiogenesis. Therapeutic angiogenesis that targets treating 
ischaemic disorders by inducing growth of new blood vessels has had success 
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in animal models. However, it is yet to be proven as relevant as a human 
therapy (Chu and Wang, 2012). In 1977 the Food and Drug Administration 
(FDA) approved becaplermin as the first angiogenesis stimulator as 
therapeutic angiogenesis (Regranex, recombinant human PDGF-BB) for 
treating diabetic foot ulcer disease (Yoo and Kwon, 2013). 
1.1.5   Anti-angiogenic therapy 
The last 20 years has seen an intensive research interest in developing anti-
angiogenic agents for the treatment of diseases with aberrant angiogenesis 
(Ferrara and Kerbel, 2005). Targeting VEGF and its cognate VEGFR is the 
most common strategy to inhibit angiogenic signal transduction. In 2004, 
bevacizumab (Avastin®), a recombinant humanized monoclonal antibody 
that specifically targets the VEGF-A isoform of VEGF, became the first 
angiogenesis inhibitor to be approved by the U.S. FDA for cancer treatment. 
It prevents human VEGF from binding to its receptors by binding to VEGF 
(Jain, 2005). Combination of anti-angiogenic treatment, bevacizumab, with 
chemotherapeutic agents has been shown to increase the efficacy of treatment 
(Jain, 2005). It is believed that blocking VEGF signalling normalizes the 
tumour vasculature and improves therapeutic agents to the tumour and 
increases the beneficial aspects for chemotherapy treatment (Bergers and 
Hanahan, 2008). In 2006, the FDA approved sunitinib (Sutent®) which is a 
small molecule receptor tyrosine kinase (RTK) inhibitor that specifically 
inhibits VEGFR-2 tyrosine kinase activity and other RTKs such as platelet 
derived growth factor (PDGF) to treat renal cell carcinoma (Motzer et al., 
2006). Nonetheless, although the anti angiogenic agents, bevacizumab and 
sunitinib, have shown relative success for treating cancers, there is a 
limitation due to the development of drug resistance (Bergers and Hanahan, 
2008). 
Two mechanisms can cause drug resistance, by classical multidrug resistance, 
drug efflux as a resistance mechanism, and mutations of the growth factor 
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signalling receptor (Broxterman et al., 2009). These types of mutations target 
the tumour endothelium instead of the tumour itself. Therefore, the 
development of drug resistance to anti-angiogenic treatment by these 
mutations can be escapable as the tumour recruits endothelial cells for 
vascularization to survive and these endothelial cells are more stable 
genetically compared with tumour cells, making them less sensitive to 
development of drug resistance (Abdollahi and Folkman, 2010). Despite the 
development of drug resistance associated with anti-angiogenic treatment 
such as bevacizumab and sunitinib, promising results have been seen and also 
cooperative effects when combined with chemotherapy and radiation therapy 
(Abdollahi and Folkman, 2010). Therefore, these complications need to be 
investigated to identify new promising targets of anti-angiogenic treatment.  
 
1.2   The role of growth factors in angiogenesis 
Growth factors are polypeptides that induce cell proliferation and affect cell 
growth and differentiation either positively and/or negatively (Steed, 1997). 
These soluble growth factors bind to specific cell surface receptors to control 
the cellular processes (Steed, 1997). Growth factors usually act in a paracrine 
and autocrine manners but not in an endocrine manner to maintain 
biochemical processes required for cell proliferation (Goustin et al., 1986, 
Favoni and de Cupis, 2000). Growth factors play an important role in wound 
healing in vivo and are released by multiple cells types and from platelets in 
clotting (Goustin et al., 1986). Recently, researchers identified many cancer 
molecular targets that are protein kinases. Protein kinases control protein 
activity and are found on the cell surface as transmembrane receptors or 
inside the cell as intracellular stimulators or even inside the nucleus to 
regulate transcription (Yasui and Imai, 2008). Thus, protein kinases are 
considered as an important target for cancer therapy. As a result of this, a 
number of growth factor receptors such as epidermal growth factor receptor 
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(EGFR) and VEGFRs have been studied as potential drug targets 
(Bennasroune et al., 2004).  
1.2.1   Epidermal Growth Factors (EGFs) 
Epidermal growth factors were discovered when researchers tried to identify 
the active agent in a tumour extract (Cohen, 1962). Subsequently, Cohen 
investigated EGF in the mouse salivary gland and named it EGF due to its 
mitogenic effect on chick embryo epidermal cells (Cohen, 1965). The EGF 
family consists of more than 10 related peptide growth factors that activate 
epidermal growth factor receptors. EGF family ligands contain one or more 
repeats of six conserved cysteine residues that have the ability to form three 
intramolecular disulphide bond loops that are required for high affinity 
binding to the receptors (Groenen et al., 1994, Harris et al., 2003). These 
ligands are derived from type1 transmembrane precursor which signal via the 
juxtacrine pathway resulting in proteolytic cleavage within the cell surface 
and release of a soluble structure of growth factors (Harris et al., 2003).  
Among the EGF ligand family are the following: EGF, transforming growth 
factor (TGF-α), amphiregulin (AR), epiregulin (ER), betacellulin (BTC), 
heparin-binding EGF (HP-EGF) and neuregulin 1,2,3,4 (NRG-1, 2, 3, 4) 
(Harris et al., 2003). These ligands bind to a special set of receptors as the 
binding affinity of EGFRs is changeable. Therefore, EGF, TGF-α and AR 
bind exclusively to EGFR1 while BTC, ER and AR use both EGFR1 and 
EGFR4 and factors like NRGs bind specifically to EGFR3 and EGFR4 while 
EGFR2 lacks a known ligand, making it the only orphan receptor in the ErbB 
family (Holbro and Hynes, 2004) (Figure 1.4). 
1.2.2   Epidermal growth factor receptors (EGFRs) 
EGF receptor family or ErbB, derived from the erythroblast leukaemia viral 
oncogene to which this receptor is homologous, is a transmembrane receptor 
tyrosine kinase (RTK). Four structurally related EGF receptors are found in 
mammals: ErbB1 (also called Her1 or EGFR1), ErbB2 (Her2 or c-Neu), 
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ErbB3 (Her3) and ErbB4 (Her4) (Yarden and Sliwkowski, 2001) (Figure 
1.4). EGF receptors form homo- or hetero-dimers in response to ligand-
dependent activation (Jorissen et al., 2003). They are involved in different 
biological processes such as metabolism, proliferation and differentiation. 
The prototypic member of EGF receptor family, EGFR1, is a transmembrane 
glycoprotein receptor of 170 KDa and expressed by most cells such as 
epithelial cells. It consists of three domains; an amino-terminal 622 amino 
acid extracellular domain, transmembrane domain and carboxyl-terminal 542 
amino acid intracellular domains (Figure 1.5).  
1.2.2.1   Extracellular domain 
The extracellular domain consists of four subdomains referred to as L1 and 
L2, ligand binding domains and CR1 and CR2, cysteine rich domains. At a 
low affinity state, ligand binds L1 resulting in conformational change of the 
receptor extracellular domain. Consequently, ligand binds L2 resulting in 
high affinity binding (Pralhad et al., 2003). In a closed conformation, low 
affinity, the CR1 is in contact with CR2 while in opened conformation, high 
affinity, due to ligand binding CR1 exposes a loop from the back interacting 
with a second ligand bound EGF receptors (Mottet et al., 2007) (Figure 1.5). 
Furthermore, CR2 presumed to play a role in dimerization and stabilisation 
(Pralhad et al., 2003). Also CR2 is considered to involve in targeting of the 
EGFR to the caveolae/raft component of the plasma membrane (Yamabhai 
and Anderson, 2002). 
1.2.2.2   Transmembrane domain (TM) 
EGFR uses a single 23 amino acid alpha helical domain to pass the cell 
membrane. The TM domain has a role in the regulation of receptor 
dimerization and spanning membrane (Shpitz et al., 2003). Bargmann and his 
colleagues found that mutation in the transmembrane of EGFR2 could 
increase the receptor dimerization (Cheng et al., 2014). The TM domain 
reportedly plays a role in regulating EGFR activity via blocking the receptor 
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auto phosphorylation and downstream signalling after exposing cells to TM 
domain peptides (Arjaans et al., 2013). 
1.2.2.3   Intracellular domain   
The intracellular domain consists of three subdomains; a juxtamembrane 
domain (JM), a tyrosine kinase domain (TK) and a carboxyl terminal domain 
(CT) (Figure 1.5). This CT domain has a number of tyrosine residues that 
regulate EGFR mediated signal transduction after phosphorylation where 
there are binding sites to proteins containing src homology 2 (SH2) (Chen 
and Bonaldo, 2013). Beside the existence of tyrosine residues, there are 
serine/threonine residues that are phosphorylated by downstream kinases 
(Schlessinger, Plotnikov et al. 2000). The JM domain has regulatory 
functions as it regulates downstream proteins and ligand internalisation (Ohta 
et al., 2009).  
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Figure 1.4 ErbB receptors. The ErbB receptor tyrosine kinases consist of four related 
members; ErbB1, ErbB2, ErbB3 and ErbB4. The ErbB receptor tyrosine kinases are activated 
by the EGF family of ligands.  The EGF family of ligands share most of the identity in their 
EGF-like domain, however the binding affinity of ErbB receptors is highly variable (Hedlund 
et al., 2009). EGF and TGF-α bind specifically to ErbB1 (EGFR) while BTC and HB-EGF bind to 
ErbB1 and ErbB4. The neuregulin (NRG) consist of two subclasses; NRG1 and NRG2 which 
bind to ErbB3 and ErbB4 and the second subclass is NRG3 and NRG4 which bind to ErbB4. 
The inactive ligand binding domains of ErbB2 and inactive kinase domain of ErbB3 are 
marked with an X. L1 and L2, ligand binding domains; CR1 and CR2, cysteine rich domains; 
TM , transmembrane domain; KD, kinase domain. Diagram adapted from (Shepard et al., 
2008).   
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Figure 1.5 Structure of ErbB receptors and activation. Each of the EGF receptors consists of 
three subdomains; Extracellular domain (EC), Transmembrane domain (TM) and 
Intracellular domain (IC). The extracellular domain is divided into four sections; ligand 
binding domains L1 and L2 and cysteine rich domains CR1 and CR2. The transmembrane 
domain is followed by the intracellular domain which consists of the juxtramembrane (JM) 
domain, tyrosine kinase (TK) domain and carboxyl terminal domain. The EC present in two 
conformations; low-affinity or closed conformation, (left) and high-affinity or opened 
conformation (right). In closed conformation, the CR1 contacts CR2 while in opened 
conformation CR1 locates to expose a dimerization arm. In the absence of ligands such as 
EGF, TGF-α, ErbB receptors present in an inactive state, closed conformation. EGFR is 
activated by binding of ligands (e.g. EGF) in an opened conformation between L1 and L2 
which exposes the dimerization arm leading to formation of homo- or hetero-dimer via 
interacting with another ErbB receptor. The TM domain is followed by the IC domain which 
has JM, TK and CT domains responsible for regulation and phosphorylation of proteins in 
signalling pathways that are stimulated by ErbB receptors. Diagram adapted from (Burgess 
et al., 2003). 
  
1.2.3   Epidermal growth factor receptor and cancer 
EGFR activation has been reported to trigger numerous cellular events 
including cellular differentiation, proliferation, migration, blocking apoptosis 
and angiogenesis. These processes have a role in uncontrolled cell division in 
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conditions such as cancer beside their vital role in healthy cells (Pralhad et 
al., 2003). In the last 20 years, EGFR has been a target for intensive research 
as a cancer therapy as it is overexpressed in many types of human cancer 
such as breast, lung, prostate and ovarian cancer (Baselga, 2002, 
Mendelsohn, 2002).The progressions of some types of cancers and lack of 
treatment response shows a correlation with expression of EGFR (Baselga, 
2002). Furthermore, the overexpression of EGFR in tumour cells has been 
correlated with increased release of ligands such as EGF and TGF 
(Mendelsohn, 2002). There are claims that EGFR also plays a role in 
malignant melanoma as Zhu and his colleagues showed upregulation of 
EGFR in cells that were taken from metastatic melanoma patient biopsies 
(Cohen et al., 2000). In response to hypoxia, colon cancer release TGFα 
which binds to its receptor (EGFR) and activates the cell survival 
programmes (Rajput et al., 2007). Furthermore, increased TGFα expression 
in ovarian cancer may implicated in ovarian resistance to cisplatin, and also 
the increased EGF-related proteins is associated with advanced stage of 
ovarian cancer (Niikura et al., 1997b). The activation of EGFR signalling 
pathway stimulates the intracellular pathways MAPK and PI3K which play a 
role in cell proliferation and differentiation (Mendelsohn, 2001). 
Overexpression of EGFR in breast cancer has been reported to associate with 
poor differentiation and poor prognosis with large tumour size (Sainsbury et 
al., 1987).  
1.2.4   Vascular Endothelial Growth Factors (VEGFs) 
VEGFs are a family of dimeric glycoproteins of about 40 KDa that are 
secreted from many cell types such as endothelial, fibroblast and tumour cells 
(Olsson et al., 2006). In mammals, the VEGF family is comprised of five 
members: VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor 
(PLGF). Structurally related VEGFs are parapoxvirus (VEGF-E) and snake 
venom (VEGF-F) (Hug et al., 1984, Ohuchi, 2005, Nemeth et al., 1988). 
VEGF-A which is also named as vascular permeability factor (VPF), was the 
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first described VEGF, and has the ability to trigger vascular leakage (Kiritsy 
et al., 1993). Alternative splicing of a human VEGF-A gene leads to generate 
six different variants of 121, 145, 165, 183, 189 and 206 amino acids in 
length assigned VEGF121, VEGF145, VEGF165, VEGF183, VEGF189 and 
VEGF206 respectively (Lynch et al., 1987, Lippman et al., 1986, Jingjing et 
al., 1999, Robinson and Stringer, 2001). Furthermore, these isoforms have 
overlapping functions because they have different abilities to bind to heparin 
sulphate and neuropilins. The heparin binding domain is the area encoded by 
exon 6 and exon 7. VEGF-A121 does not contain exon 6 and exon 7 so that it 
does not bind heparin sulphate and is freely diffusible (Zhang et al., 2004). 
VEGF-A145 has the heparin sulphate domain and the ability to bind to 
extracellular matrix (Lei et al., 1998). VEGF-A165 is the predominant isoform 
and is the most extensively and biologically active VEGF isoform in humans 
and is released by different types of cells such as tumour cells, vascular 
smooth muscle and macrophages (Berse et al., 1992). In addition, VEGF-A165 
contains the heparin sulphate domain (Zhang et al., 2004). VEGF-A189 and 
VEGF-A206 bind to heparin sulphate and extracellular matrix at the cell 
surface more strongly than the other isoforms (Zhang et al., 2004). 
1.2.5   Vascular Endothelial Growth Factor Receptors 
VEGFs make their biological effects by binding to three highly homologous 
receptors denoted VEGF receptor-1 (Flt-1), VEGF receptor-2 (KDR/Flk-1) 
and VEGF receptor-3 (Flt-4), as well as two transmembrane glycoproteins 
that act as co-receptors for VEGFs termed neuropilin-1 (NRP-1) and 
neuropilin-2 (NRP-2). VEGFRs are members of the RTK family and are 
closely related to the PDGF receptor family (PDGFR). Unlike PDGFRs that 
contain 5 immunoglobulin-like domains at the extracellular domain, VEGFRs 
have 7 Ig-like domains on their extracellular domain. VEGFRs are expressed 
in different cell types; VEGFR-1 is expressed on ECs, pericytes, 
macrophages, renal mesangial cells and osteoblasts (Zachary and Gliki, 
2001). Beside the vascular ECs, VEGFR-2 is expressed on pancreatic duct 
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cells and retinal progenitor cells (Ferrara et al., 2003). VEGFR-3 is 
specifically expressed on lymphatic endothelial cells which are specialised 
ECs which line the lymphatic system (Partanen et al., 2000). Different types 
of VEGF bind to the different VEGFR; VEGF-A binds to both VEGFR-1 and 
-2 and it also binds to NRP-1 and NRP-2 while VEGF-B and PLGF are the 
ligands for VEGFR-1 and NRP-1 (Klagsbrun et al., 2002, Olofsson et al., 
1999). Both VEGF-C and VEGF-D have a high affinity for VEGFR-2 and 
VEGFR-3 whereas VEGF-E binds to VEGFR-2 (McColl et al., 2004, Suto et 
al., 2005). VEGFRs structurally consist of three domains; the extracellular 
ligand-binding domain, transmembrane domain and intracellular domains 
containing two kinase domains (Figure 1.6). 
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Figure 1.6 Diagram of VEGF family and VEGFRs. Each VEGF ligand binds to specific VEGFRs. 
PLGF and VEGF-B bind to VEGFR-1 while VEGF-A binds to both VEGFR-1 and VEGFR-2. VEGF-
C and –D bind to VEGFR-3 and VEGFR-2 whereas VEGF-E only binds to VEGFR-2. VEGFR-1 is 
expressed on haematopoietic stem cells and vascular endothelium. VEGFR-2 is expressed on 
both vascular and lymphatic endothelium whereas VEGFR-3 is only expressed on lymphatic 
endothelium. The downstream effects of VEGFR-2 activation involve cell proliferation, 
migration and survival resulting in vasculogenesis and angiogenesis. Diagram adapted from 
(Holmes et al., 2007). 
 
1.2.5.1   VEGFR-1 
VEGFR-1, also known Fms-like tyrosine kinase 1 (Flt1), is expressed on 
haematopoietic stem cells, monocytes and vascular endothelial cells and can 
bind to VEGF-A, VEGF-B and PLGF. A splice variant of VEGFR-1 which 
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lacks the transmembrane and internal signalling domains of VEGFR-1 is 
called soluble VEGFR-1 (sVEGFR-1). sVEGFR-1 acts as trap receptor to 
bind VEGF and negatively regulate VEGFR-2 signalling (Kendall and 
Thomas, 1993, Roberts et al., 2004). Knockout of the vegfr-1 gene in mice 
resulted in death at E8.5- E9.0 due to overproduction of haemangioblasts 
leading to disorganised vasculature (Fong et al., 1995). It has been 
demonstrated in endothelial cells that the extracellular domain of VEGFR-1 
and transmembrane domain were essential for normal development while 
downstream signalling of the VEGFR-1 c-terminal domain was disposable 
for normal vascular development (Hiratsuka et al., 2005). 
1.2.5.2   VEGFR-2 
VEGFR-2 is considered to be the main VEGF receptor expressed on vascular 
endothelial cells and plays a major role in transducing the intracellular 
signalling cascade leading to physiological and pathological angiogenesis 
(Waltenberger et al., 1994). VEGFR-2 is involved in vascular development as 
knockout of vegfr-2 gene in mice results in embryonic lethality between 
E8.5-9.5 due to defects of development of endothelial cells and lack of blood 
vessels (Shalaby et al., 1995). VEGFR-2 is also named in humans as kinase-
insert domain receptor (KDR) and foetal liver kinase (Flk)-1 in mice. 
Although Flk-1 is 2 amino acids shorter than KDR, it shares about 85% 
sequence homology with KDR (Holmes et al., 2007). In early embryogenesis, 
VEGFR-2 is widely expressed in vascular endothelial progenitors; however 
the expression is low in quiescent ECs in adults. 
1.2.5.3   VEGFR-3 
VEGFR-3 is expressed in all endothelial cells during development, and this 
expression is restricted in lymphatic endothelial cells in adults (Olsson et al., 
2006, Lohela et al., 2009). Ablation of Flt-4 in mice led to fluid accumulation 
in pericardial cavity and cardiovascular failure which led to embryonic 
lethality at E9.0 prior the beginning of lymphangiogenesis (Dumont et al., 
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1998).  VEGFR-3 (Flt-4) only binds to VEGF-C and VEGF-D ligands and 
the ablation of vegfc gene leads to complete absence of lymph vessels in 
mouse embryos demonstrating a pivotal role of vegfc in lymphangiogenesis 
(Karkkainen et al., 2002, Karkkainen et al., 2004).   
 
1.2.6   VEGFs/VEGFRs and tumour angiogenesis 
As previously mentioned, tumour growth and metastasis events depend on 
angiogenesis. VEGF plays an important role in tumour angiogenesis such as 
breast cancer, ovarian cancer, prostate cancer and lung cancer and as a result, 
tumour angiogenesis has become a novel therapeutic target for cancer 
(Yoshiji et al., 1996, Santin et al., 1999, Grivas et al., 2016, Herbst et al., 
2005). The VEGF neutralizing monoclonal antibody, bevacizumab, was the 
first anti-angiogenic drug approved for treatment of colorectal cancer (Willett 
et al., 2004). 
The expression of VEGF-B and PLGF has a role in tumour angiogenesis via 
VEGFR-1. Highly activation of PIGF has been shown in non-small cell lung 
cancer cells while increased VEGF-B expression is associated with oral 
squamous cancer cells (Zhang et al., 2005, Hanahan et al., 2003). As the 
lymphatic vasculature provides another path to tumour metastasis, VEGF-C, 
VEGF-D and their receptor VEGFR-3 are associated with tumour 
lymphangiogenesis and metastatic cancer (Stacker et al., 2002). Furthermore, 
VEGFR-2 can drive tumour angiogenesis in response to VEGF-C and VEGF-
D binding (Zachary and Gliki, 2001). VEGF-A is activated in both normal 
and malignant cells in response to hypoxia which is a key mediator for 
hypoxic responses (Semenza, 2003). As a result of triggering VEGF-A gene 
expression via hypoxia, VEGF-A gene transcription is increased through 
mediation of hypoxia inducible factor-1 (HIF-1) (Forsythe et al., 1996). 
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1.3   Mitogen-activated protein kinases signalling pathway  
Mitogen activated protein kinases (MAPKs) are a highly conserved family of 
signalling proteins that mediate a multitude of intracellular processes such as 
gene transcription, differentiation, migration, proliferation and apoptosis. 
MAPKs are combined with a broad array of stimuli including growth factors, 
environmental stress, hormones and cytokines (Kyriakis and Avruch, 2012). 
Furthermore, MAPKs are the last terminal member of a three tiered 
hierarchical kinase cascade and they are activated by this canonical kinase 
cascade. Extracellular stimuli activate MAPK kinase kinase (MAPKKK) 
(also recognized as MAP3K, ERK kinase kinase/MEKK) which in turn 
phosphorylates its downstream object, MAPK kinase (MAPKK) (also known 
MAP2K, ERK kinase/MEK) on specific serine and threonine residues. 
Consequently, MAPKK induces the activation of MAPK by phosphorylating 
the threonine and tyrosine residues in a conserved T-X-Y motif which is 
located on the activation loop of MAPK (Zhang and Dong, 2007). 
Downstream effector proteins of MAPK generate a specific intracellular 
response in response to activation and phosphorylation of MAPK by a 
sequential cascade. These specific intracellular proteins involve other protein 
kinases, transcription factors, cytoplasmic enzymes and phospholipases 
(Yoon and Seger, 2006). MAPKK can be activated by more than one 
MAPKKK and that explains the complexity and diversity of MAPK (Chang 
and Karin, 2001). The scaffold proteins and specific docking interaction 
between individual components of each MAPK cascade maintain the 
specificity of signal transfer to MAPK which results in required cellular 
response via efficient signal transfer (Tanoue and Nishida, 2003, Raman et 
al., 2007). Dual specificity protein phosphatases (DUSPs) also known as 
MAP kinase phosphatases (MKPs) maintain the phosphorylation of MAPK 
via inducing de-phosphorylation of threonine and tyrosine in the activation 
loop of MAPKs to inactivate them (Keyse, 2008).  
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1.3.1   Classification of MAPKs 
The MAPK pathway consists of two subdivisions; conventional and atypical 
pathways. The conventional mammalian MAPK pathway divides into four 
distinct pathways; extracellular  signal-regulated  kinases  (ERK)  1/2,  c-Jun  
NH 2 -terminal  kinases  (JNK)  1/2/3,  p38  proteins α/β/γ/δ and ERK5 
(Payne et al., 1991, Cuenda and Rousseau, 2007, Nakamura and Johnson, 
2007, Zhou et al., 1995). The kinase domain of MAPKs is activated by dual 
phosphorylation of threonine and tyrosine residues within a T-X-Y motif in 
the activation loop. ERK1/2 contains the activation motif threonine-glutamic 
acid-tyrosine (T-E-Y) whereas JNK contains a dual phosphorylation motif 
threonine-proline-tyrosine (T-P-Y) and p38 MAPK contains a threonine-
glycine-tyrosine (T-G-Y) activation motif (Widmann et al., 1999). Finally, 
ERK5 which is the most recently identified MAPK cascade and is similar to 
ERK1/2 as it contains a T-E-Y dual phosphorylation motif but is larger than 
ERK1/2 and has a unique structure as it has a carboxyl-terminal (Nishimoto 
and Nishida, 2006) (Figure 1.7). 
 
The atypical MAPK pathways are not organised in the classical three tiered 
kinase cascades, divided into four subdivisions; ERK3, ERK4, ERK7/8 and 
Nemo like kinase (NLK) (Cargnello and Roux, 2011b). The atypical MAPKs 
are also distinct from the conventional MAPKs as they do not contain the T-
X-Y dual phosphorylation motif in ERK3, ERK4 and NLK, while ERK7/8 
has a T-G-Y activation motif but these residues are not phosphorylated by an 
upstream MAPKK as it is in the conventional (Cargnello and Roux, 2011b). 
The conventional and atypical MAPK pathways both phosphorylate other 
protein kinases called mitogen activated protein kinase-activated protein 
kinase (MAPKAPKs) which consist of 11 serine and threonine kinases and 
contain five groups; ribosomal S6 kinases (RSKs), mitogen and stress 
activated kinases (MSKs), MAPK-interacting kinases (MNKs), MAPK 
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activated protein kinases 2/3 (MK2/3) and MAPK activated protein kinase 5 
(MK5) (Cargnello and Roux, 2011b). Although the MAPKs are widely 
expressed in all mammalian cells, due to the differential expression in 
transcription factors in distinct cell types the function for each MAPK can be 
different between organisms and also between cell types in the same 
organism (Donovan et al., 2001). 
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Figure 1.7 Mitogen activated protein kinase (MAPK) signalling pathways in mammalian 
cells. There are four distinct MAPK cascades for mammalian cells termed; ERK1/2, p38 
MAPK (p38α, β, γ and δ), JNK 1/2/3 and ERK5. These cascades are arranged into a hierarchal 
three tier system. Mitogens such as growth factors, cytokines and environmental stress and 
extracellular stimuli, stimulate the activation of MAPK cascade by acting on specific 
receptors. Distinct extracellular stimuli phosphorylate one or more MAPKKK which 
sequentially activates MAPKK. The activated MAPKK phosphorylates MAPKs on T-X-Y motif 
in the activation loop of MAPKs. X corresponds to a glutamic acid in ERK1/2, a glycine in p38 
MAPKs, a proline in JNKs and a glutamic acid as well in ERK5. Phosphorylated MAPKs 
activate multiple downstream cytosolic or nuclear substrates including P90RSK and SGK 
which are protein kinases and MEF2 and Sap1a which are transcription factors. Activated 
substrates lead to specific cellular responses such as cell survival, differentiation, 
proliferation and apoptosis. Diagram adapted from (Nithianandarajah-Jones et al., 2012b).  
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1.3.2   Extracellular-signal-regulated kinase 1/2 (ERK1/2) 
ERK1/2 was the first mammalian protein kinase of MAPKs to be discovered 
and since then it has been extensively studied as the best characterised 
MAPK (Sturgill and Ray, 1986, Rubinfeld and Seger, 2005). ERK1 and 
ERK2 are individual kinases so ERK1 in humans has 379 amino acids 
whereas ERK2 consists of 360 amino acids, however they are usually 
referred to as ERK1/2 because they share about 84% sequence identity and 
most of the same signalling activity (Boulton et al., 1991). ERK1/2 is 
activated by numerous stimuli including growth factors such as PDGF, EGF 
and NRG in response to insulin and also they are activated by ligands for 
heterodimeric G protein coupled receptors, osmotic stress and cytokines 
(Raman et al., 2007). Receptor tyrosine kinases (RTKs) initiate the activation 
of ERK1/2 where the RAF kinases which are the primary MAPKKKs in the 
ERK1/2 module phosphorylate the dual specificity kinases MEK1/2 
(MAPKK). In turn, phosphorylation of ERK1/2 occurs within T-E-Y in the 
activation loop which allows ERK1/2 to activate its downstream substrates 
(Cargnello and Roux, 2011b). ERK1/2 has an important role in various 
pathologies such as cardiovascular diseases, cancers and diabetes as it is 
widely expressed and regulates various cellular and physiological events 
(Rose et al., 2010). 
Although ERK1 and ERK2 are approximately similar in amino acid 
sequence, they are distinctly different in expression pattern and biological 
functions during development when phenotypic studies in mice knock out the 
respective components of MEK/ERK cascade. When ERK2 is deleted, mice 
die early in development between E10.5 and E11.5 while in case of deleting 
ERK1, mice are viable and develop normally, suggesting that ERK1 cannot 
compensate for lack of ERK2 activity (Pages et al., 1999, Yao et al., 2003). 
Furthermore, deletion of both ERK1 and ERK2 in developing mice in 
endothelial cells prompted embryonic lethality at E10.5 as the angiogenesis 
became defective (Srinivasan et al., 2009). 
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1.3.3   p38 mitogen activated protein kinase 
The p38 MAPK family consists of four isoforms in mammalian cells; p38α 
(SAPK2a), p38β (stress activated protein kinase 2b, SAPK2b), p38γ 
(SAPK3) and p38δ (SAPK4). p38α is ubiquitously expressed in most cell 
types at a significant level while other isoforms are expressed in specific 
tissues. p38β is expressed in the brain, p38γ is expressed in skeletal and 
cardiac muscle and p38δ is expressed in endocrine glands (Cuadrado and 
Nebreda, 2010). Furthermore, p38β shares about 73% identities with p38α 
whereas p38γ and p38δ are 70% identical with p38α (Li et al., 1996, Denise 
Martin et al., 2012). The p38 MAPK cascade is activated by different 
environmental and cellular stress factors and inflammatory cytokines such as 
UV radiation, oxidative stress, hypoxia, chemical shock, interleukin 1 (IL-1) 
and tumour necrosis factor alpha (TNF-α) (Cuadrado and Nebreda, 2010).The 
p38 MAPK is important in the regulation of many biological functions 
including differentiation, cell migration, apoptosis and cell survival 
(Cargnello and Roux, 2011a). 
MKK3 and MKK6 activate and phosphorylate p38 MAPKs in the dual 
phosphorylation Thr-Gly-Tyr (T-G-Y) motif of the activation loop. MKK4 
can also phosphorylate p38 (Cuenda et al., 1995). The p38 family is present 
in the cytosol and nucleus. Once the p38s are activated, they phosphorylate 
their various substrates. The substrates in the cytoplasm as targets for p38s 
include cytosolic phospholipase A2 (c-PLA2), MAPK interacting 
serine/threonine kinase 1 (MNK 1/2), MK2, MK3, MK5, Bcl-2 and Bax. The 
nuclear targets of p38s comprise activation transcription factor-1 -2 -3 (ATF-
1/2/3), ETS domain containing protein like transcription factor (Elk-1), MEF-
2, GADD153, p53 and MSK1/2 (Cargnello and Roux, 2011b, Denise Martin 
et al., 2012). 
The functional redundancy of the p38 MAPK family has been demonstrated 
(Sabio et al., 2005). However, genetic ablation of p38α in mice leads to 
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embryonic lethality at E11.5 due to angiogenesis defects in the placenta while 
deletion of p38β, p38γ and p38δ MAPK isoforms did not result in any 
phenotypic abnormalities in mice which suggest that p38α is important for 
normal embryonic development and has a role in vascular development 
(Mudgett et al., 2000).  
1.3.4   C-Jun-N-terminal kinases (JNKs) 
In the early 1990s, the first c-Jun-N-terminal kinase was identified as a 
cycloheximide activated microtubule associated protein-2 (MAP-2) kinase 
(Kyriakis and Avruch, 1990). Three isoforms of JNK have been discovered, 
termed; JNK1 (SAPKβ), JNK2 (SAPKα) and JNK3 (SAPKγ), also named 
MAPK8, MAPK9 and MAPK10 respectively (Cargnello and Roux, 2011b, 
Kyriakis and Avruch, 2012). The JNKs family are over 85% identical in 
sequence and are encoded by 3 different genes which lead to more than 10 
spliced variants (Gupta et al., 1996). JNK3 is expressed only in neuronal, 
testis and cardiomyocytes while JNK1 and JNK2 are ubiquitously expressed. 
JNK1 is the major c-Jun kinase after stimulation in response to environmental 
stresses, inflammatory cytokines and growth factors while JNK2 plays a role 
in c-Jun degradation after binding to c-Jun in unstimulated cells, suggesting 
that they have functional differences (Raman et al., 2007). The JNK family 
has been implicated in various biological processes including cell survival, 
cell proliferation, apoptosis and differentiation and has a physiological role in 
immune responses and inflammation (Nakamura and Johnson, 2007). Besides 
the physiological role, JNKs have pathological roles in arthritis, neurological 
disorders, liver diseases, cardiac diseases and cancer (Rose et al., 2010). 
The JNKs are activated by various stress stimuli such as heat shock, ionizing 
radiation, oxidants, UV radiation and to a lesser extent are activated in 
response to growth factors (Kyriakis and Avruch, 2012, Bode and Dong, 
2007). MKK4 and MKK7 phosphorylate JNKs by dual phosphorylation of 
Thr and Tyr residues within Thr-Pro-Tyr motif in the activation loop. 
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Furthermore, JNKs are localized from the cytoplasm to the nucleus where 
they interact with different transcriptional factors such as c-Jun, ATF-2, p53, 
Elk-1 and activator protein-1 (AP-1) (Rose et al., 2010). The JNKs have a 
critical role in an intrinsic apoptosis pathway; deletion of both JNK1 and 
JNK2 from mice resulted in a defect in the mitochondrial death signal 
pathway and failure to release cytochrome c (Tournier et al., 2000). However, 
genetic ablation of JNK1, JNK2 or JNK3 individually in mice has been 
shown that mice are still viable and develop normally (Dong et al., 1998). 
 
1.4   Extracellular signal regulated kinase 5 (ERK5) 
Extracellular regulated signal protein kinase 5 (ERK5) is the most recently 
identified member of the MAPK family. ERK5 is the largest member of the 
MAPK family and is twice as large as other members. The specific function 
of ERK5 is not clear, despite studies showing that ERK5-deficient mice die at 
around E10.5 because of cardiovascular defects and angiogenesis failure in 
embryonic and extra-embryonic tissue (Hayashi et al., 2004a).  
1.4.1   Identification of ERK5 
Two research groups originally cloned ERK5 (Zhou et al., 1995, Lee et al., 
1995). Dixon and co-workers first identified MEK5, the catalyst of ERK5; 
they isolated MEK5 cDNA and found around 40% identity to known MEKs. 
Subsequently, they identified ERK5 as a binding partner by specific 
interactions with MEK5 in a yeast two-hybrid assay (Zhou et al., 1995). In a 
separate study, Lee et al. used a PCR assay of placental cDNA and identified 
the complete cDNA of a new human MAPK termed Big MAP kinase 
(BMK1). This was found to be different to ERK1 and ERK2 due to its unique 
C-terminal structure. Both groups stated that BMK1 and ERK5 were derived 
from the same gene, which ultimately meant that both were the same protein 
(Lee et al., 1995). In mammals, ERK5 is expressed in various tissues and is 
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abundant in heart, skeletal muscle, placenta, lung and kidney (Zhou et al., 
1995, Lee et al., 1995). 
 1.4.2   Structure of ERK5 
The human ERK5 gene (MAPK7) is located on chromosome 17p11.2, 
spanning 5.6 kb, with an open reading frame of 2445 base pairs; the gene 
encodes 816 amino acids with a molecular mass of approximately 98 KDa 
(Figure 1.8) (Yan et al., 2001). ERK5 has an N-terminal domain that consists 
of two regions: cytoplasmic targeting (amino acids 1-77) and a kinase domain 
(amino acids 78-406). The N-terminal kinase domain shows the highest 
homology to ERK1 and ERK2, with a sequence identity of about 60%. It is 
important for upstream interactions with the kinase MEK5 (amino acids 78-
139) and for oligomerisation (amino acids 140-406) and also includes the 
MEK5 dual phosphorylation sites (T
218
 and Y
220
) (Yan et al., 2001). Adjacent 
to the kinase domain, ERK5 has a common docking (CD) domain which 
involved in the interaction of ERK5 with its substrates (Tanoue and Nishida, 
2003). In addition, ERK5 has a unique C-terminal domain in comparison 
with other MAPKs (400 amino acids) which gives it a relatively large size, 
more than twice that of conventional MAPKs (Buschbeck and Ullrich, 2005). 
The C-terminal tail contains nuclear localisation signals (NLS) which are key 
for nuclear import; it also has a nuclear export signal (NES) which plays a 
significant role in the cytoplasmic retention of ERK5 (Kondoh et al., 2006). 
The N-terminal tail of ERK5 binds to the C-terminal half to retain ERK5 in 
the cytoplasm and generate NES (close conformation). Dual phosphorylation 
of Thr
218
 and Tyr
220
 by MEK5 in the N-terminal domain causes the 
interruption of this binding and exposes NLS in the C terminal domain of 
ERK5 to import ERK5 into the nucleus (open conformation) (Kondoh et al., 
2006) (Figure 1.9). Furthermore, the C-terminal portion of ERK5 contains a 
Myocyte enhancer factor 2 (MEF2) interacting region (amino acids 440-501), 
which is regulated by an effective transcriptional activation domain (amino 
acids 664-789) via auto-phosphorylation (Kasler et al., 2000). Moreover, the 
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C-terminal truncation of ERK5 results in an increase in the kinase activity of 
ERK5, suggesting that the C-terminal half of ERK5 has an auto-inhibitory 
capacity (Buschbeck and Ullrich, 2005). The C-terminal portion of ERK5 
also has two proline-rich domains, called PR1 (amino acids 434-465) and 
PR2 (amino acids 578-701), which play an important role as binding sites for 
Src3 homology 3 (SH3) domain containing proteins (Borges et al., 
2007)(Figure 1.8).  
 
Figure 1.8 Structure of ERK5. ERK5 protein divided in to N-terminal domain and large C-
terminal domain. The N-terminal kinase domain contains cytoplasmic region and MEK5 
binding region in the kinase domain and oligomerisation site. ERK5 is phosphorylated via 
MEK5 on residues Thr218 and Tyr220 which are located in the kinase domain. C-terminal 
contains two prolin-rich domains (PR1 and PR2), nuclear localization signal and 
transcriptional activation domain. Diagram adapted from (Nithianandarajah-Jones et al., 
2012b). 
1.4.3   Activation of ERK5 
ERK5 is activated by serum and a range of growth factors such as VEGF, 
EGF, FGF-1 and PDGF and also by certain inflammatory cytokines like IL-6 
beside the osmotic and oxidative stresses that were originally identified as 
stimulators of ERK5 (Hayashi and Lee, 2004, Kato et al., 1998b, Abe et al., 
1996). Furthermore, trophic factors in neurons such as nerve growth factor 
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(NRG) and brain derived neurotrophic factor (BDNF) are also known to 
activate ERK5 (Finegan et al., 2009, Cavanaugh et al., 2001). Laminar shear 
stress, hypoxia and ischaemia as physiological and pathological stresses 
respectively, have the ability to phosphorylate ERK5 (Yan et al., 1999, Sohn 
et al., 2002). 
MEKK2 and MEKK3 are the two best characterised MAPKKKs that are 
activated by extracellular stimuli which in turn phosphorylate the 
MEK5/ERK5 signalling cascade by phosphorylating Ser
313
 and The
317 
of 
MEK5 (Chao et al., 1999, Sun et al., 2001). Hetero-dimerization adjusts the 
specificity of signal transduction between MEKK2/MEKK3 and MEK5 by 
phox and Bem1p (PB1) domains within the N-terminal of MEK5 and 
MEKK2/MEKK3 (Nakamura and Johnson, 2003). MEKK2 and MEKK3 
share 94% sequence identity and also contain PB1 domains in their N-
terminal tail (Blank et al., 1996). Furthermore, they are abundantly divergent 
in their N-terminal region to support the differential regulation of ERK5 
signalling pathway. Based on this, MEKK2 binds to the adaptor Src 
homology 2 (SH2) domain containing scaffold protein Lck associated adaptor 
(Lad) which establishes a mechanism by which EGF activates ERK5 by Src 
and also enhances ERK5 activation via complexes with MEK5 (Sun et al., 
2003). MEKK2 has a great affinity to MEK5 compared with MEKK3 and 
triggers the phosphorylation of ERK5 to a greater extent than MEKK3, 
demonstrating that MEKK2 is a more powerful activator of ERK5 than 
MEKK3 (Sun et al., 2001). Once MEK5 is activated by MEKK2 and 
MEKK3, it phosphorylates the Thr
218
 and Tyr
220
 residues within the T-E-Y 
dual phosphorylation motif in the activation loop of the ERK5 kinase domain 
(Mody et al., 2003). MEK5 is the only upstream MAPKK that activates 
ERK5 directly. The phosphorylation of ERK5 on Thr
218
 via MEK5 is not 
enough for full catalytic activity, thus phosphorylation of both Thr
218
 and 
Tyr
220
 is required for full activation of ERK5 (Mody et al., 2003). The 
activation of ERK5 is followed by phosphorylation of MEK5 and the auto-
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phosphorylation of various residues in the C-terminal of ERK5 resulting in 
increased transcriptional activity of ERK5 (Morimoto et al., 2007a).  
MEK5 shares 48% identity in sequence with MEK1 and contains a Raf-1 
phosphorylation motif S
311
XXXT
315
 analogous to the activation motif of 
MEK1 and the cascade Ras > Raf-1> MEK1/2> ERK1/2 suggesting that 
Ras/Raf-1 may be able to activate ERK5; there are no interactions or 
activation of protein in the MEK1/ERK1 cascade and MEK5/ERK5 cascades 
(Zhou et al., 1995, English et al., 1998). The small molecular weight GTPase 
protein Ras has been implicated in the regulation of ERK5 by EGF 
manifested by the ability of a dominant negative (DN) mode of Ras to inhibit 
ERK5 activation in response to EGF (Kamakura et al., 1999). However, the 
dominant active (DA) form of Ras induces the phosphorylation of ERK5 in 
human embryonic kidney 293 (HEK293) cells (English et al., 1998). The 
phosphorylation of ERK5 in HeLa cells in response to EGF is independent of 
Ras, suggesting that, Ras mediated activation of ERK5 is likely dependent on 
the cell type (Kato et al., 1998b, Kamakura et al., 1999) (Figure 1.9). 
1.4.4   Inactivation of ERK5 cascade 
A MAP Kinase phosphatase (MKP) subfamily of dual specificity 
phosphatases (DUSPs) dephosphorylates the T-X-Y motif of MAPKs to 
inactivate them (Dickinson and Keyse, 2006). However, the DUSP that 
dephosphorylates Thr
218
 and Tyr
220 
residues within the T-E-Y activation 
motif of ERK5 has not been identified. On the other hand, it has been stated 
that phosphor-tyrosine specific phosphatases PTP-SL (protein tyrosine 
phosphatase STEP-like) may able to dephosphorylate ERK5 at Tyr
220
 residue 
which interrupts its translocation to the nucleus (Buschbeck and Ullrich, 
2005). ERK5 can phosphorylate PTP-SL but this action compared to the 
increased phosphatase activity of PTP-SL binding to ERK5 is considered to 
be a minor interaction (Buschbeck and Ullrich, 2005). Moreover, post-
translational modifications have the ability to regulate the activation of 
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ERK5. A small ubiquitin-like modifier 3 (SUMO3) protein covalently binds 
to ERK5 on Lys6 and Ly22 following exposure to advanced glycation end-
stage products (AGE) or H2O2 in HUVEC (Woo et al., 2008). Consequently, 
SUMOylation of ERK5 inhibits the transcriptional activity induced via shear 
stress without affecting ERK5 phosphorylation in HUVEC (Woo et al., 2008) 
(Figure 1.9). 
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Figure 1.9 ERK5 intracellular localization. Under the basal condition (un-phosphorylated 
state) the N and C-terminal of ERK5 interact with each other leading to masked NLS and 
release of NES to export ERK5 from the nucleus. Upon phosphorylation of ERK5 by MEK5 in 
T-E-Y motif in the activation loop, the conformation is changed which results in the 
disruption of NES and unmasking NLS to trigger the translocation of ERK5 into the nucleus. 
Diagram adapted from (Nishimoto and Nishida, 2006). 
 
1.4.5   Substrates of ERK5 
Regulation of downstream transcription factors is considered the most 
important role of ERK5. Relatively few physiological substrates of ERK5 
have been identified; myocyte enhancer factor 2A, C, D (MEF2A, MEF2C 
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and MEF2D) are the best characterised ERK5 substrates (Kato et al., 1997). 
Once activated, ERK5 phosphorylates MEF2C on serine 387 which enhances 
the transcriptional activity of MEF2C and then increases c-Jun gene 
expression (Kato et al., 1997). MEF2A and MEF2C are regulated by both 
ERK5 and p38 MAPK, while MEF2D is a specific substrate for ERK5 
(Ornatsky et al., 1999, Kato et al., 2000). The MEF2 interacting region and a 
transcriptional activation domain in ERK5’s C-terminal region play an 
important role in the regulation of MEF2 activity (Kasler et al., 2000). The 
stimulation of MEF2 activity by ERK5 is affected by truncation of the C-
terminal tail of ERK5 mutant (Yan et al., 2001). 
Other substrate targets of ERK5 that are well-characterised include the MEF2 
family; serum response factor accessory protein 1a (Sap1a), c-Myc and pro-
apoptotic protein Bcl2 antagonist of cell death (Bad) (English et al., 1998, 
Kamakura et al., 1999, Pi et al., 2004). Like MEF2 substrates, ERK5 
activates Sap1a and subsequently improves transcriptional activity 
(Kamakura et al., 1999). However, unlike MEF2 and Sap1a, ERK5 
phosphorylates c-Myc at serine 62 and increases the stability of c-Myc 
protein (Sears et al., 2000). Furthermore, ERK5 activation results in the 
phosphorylation of c-Fos promotor on serine 387 and alternative sites in its 
C-terminal tail (Terasawa et al., 2003). ERK5 and all other MAPK members 
have the ability to phosphorylate substrates on Ser/Thr residues that precede a 
proline residue (Mody et al., 2003). However, residues Thr
28
 in the N-
terminal tail of ERK5 and residues Ser
421
, Ser
433
, Ser
496
, Ser
731
 and Thr
733
 in 
the C-terminal region of ERK5 undergo auto-phosphorylation of ERK5 but 
are not followed by proline residues, suggesting that the specificity of ERK5 
may differ from other MAPK family members (Mody et al., 2003) 
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Figure 1.10 Schematic representation of ERK5 signalling pathway. Cytokines, growth 
factors and environmental stresses are the main stimuli that activate the signalling cascade; 
MEKK2/MEKK3 phosphorylates MEK5 which in turn activates ERK5. The activated ERK5 
phosphorylates several downstream targets to regulate cell survival and proliferation. 
Diagram adapted from (Wang and Tournier, 2006). 
 
1.4.6   Cellular physiology of ERK5 
ERK5 is ubiquitously expressed in many cell types; however, some studies 
propose that ERK5 has particular roles in specific cell types (Regan et al., 
2002b, Hayashi et al., 2004a). ERK5 has been involved in the regulation of 
various cellular functions such as cell survival, cell adhesion and cell 
proliferation (Kato et al., 1998a). In addition, ERK5 has been implicated in 
progression of some diseases for example cancer, cardiac hypertrophy and 
ischaemia (Montero et al., 2009a). 
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1.4.6.1   ERK5 and cell survival 
ERK5 plays a role in the activation of the pro-apoptotic Bcl-2 interacting 
mediator of cell death (Bim), Bcl-2 homology (BH3)-only member of the 
Bcl-2 family (Girio et al., 2007). When ERK5 is inactivated, Bim becomes 
de-phosphorylated and segregated in the mitochondria which subsequently 
interacts with Bax (Bcl-2 associated X protein) to induce apoptosis pathway 
through mitochondria, resulting in caspase activation and cell death (Girio et 
al., 2007). During mitosis in HeLa cells, the phosphorylation and de-
phosphorylation of Bim is mediated by EGF stimulation of ERK5 activation 
(Girio et al., 2007) These findings suggest that ERK5 may able to regulate 
other Bcl-2 family proteins to promote cell survival.  
Many studies have shown that ERK5 plays a pivotal role in neuronal cell 
survival in response to various neurotrophic pro-survival stimuli (Wang and 
Tournier, 2006).Watson and colleagues revealed that ERK5 in rat dorsal root 
ganglia (DRG) mediates the activation of the transcriptional factor cAMP 
responsive element binding protein (CREB) in response to neurotrophins 
BDNF and NGF to help neuronal cell survival (Watson et al., 2001). ERK5 
mediates the protective effect of BDNF in newly-generated cerebellar granule 
neurones giving rise to MEF2 dependent transcription of the neurotrophin 3 
(NT3) to facilitate neuronal cell survival, suggesting that MEF2 is implicated 
in ERK5-mediated survival in neuronal cells (Shalizi et al., 2003). 
1.4.6.2   ERK5 and cell proliferation  
Various studies have shown that ERK5 is implicated in the regulation of cell 
proliferation in certain cell types. The activation of ERK5 mediates the 
proliferation of MCF10A cells in response to EGF stimulation (Kato et al., 
1998a). Hayashi and co-workers demonstrated that the activation of 
serine/threonine kinase SGK to S phase entry required ERK5 which 
subsequently facilitate cell proliferation following EGF stimulation in 
MCF10A cells (Hayashi et al., 2001). 
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On the other hand, the cell cycle progression and cell proliferation of CCI39 
fibroblasts in response to EGF stimulation were blocked when cells were 
treated with MEK1/2 inhibitor PD184252 to inhibit the activation of ERK1/2 
but not ERK5 activation (Squires et al., 2002). Furthermore, the cell 
proliferation of vascular smooth muscle cells in response to aldosterone is 
independent of the ERK5 pathway (Ishizawa et al., 2005). In addition, 
knockdown of ERK5 with shRNA in leukaemia T-cells had no effect on cell 
cycle progression and cell proliferation suggesting that ERK5 is not 
necessary for cell proliferation in response to growth factor induction in 
certain cell types (Garaude et al., 2006). 
1.4.6.3   ERK5 and cell migration and adhesion  
ERK5 mediates cell migration of renal epithelial cells in response to growth 
factor stimulation (Izawa et al., 2007). However, ERK5 mediates the 
phosphorylation of FAK to facilitate focal adhesion in hepatic stellate cells 
leading to shrink migration in these cells (Rovida et al., 2008). Several 
studies have been demonstrated that the relationship between ERK5 and FAK 
depends on the cell types; ERK5 seems to be an upstream activator for FAK 
in some cell types and downstream of FAK in other cell types (Villa-
Moruzzi, 2007, Rovida et al., 2008, Sawhney et al., 2009). In breast and 
prostate cancer, ERK5 forms a complex with FAK to regulate cell migration 
and adhesion in these cancerous cells (Sawhney et al., 2009). Furthermore, 
overexpression of MEK5 accelerates the phosphorylation of FAK (Sawhney 
et al., 2009). These data suggest that ERK5 is important in the regulation of 
cell migration and adhesion.  
1.4.7   ERK5 and endothelial cell function  
1.4.7.1   Inhibition of ERK5 signalling axis 
The physiological role of the ERK5 signalling pathway in vivo was 
established by using gene ablation of specific components of the pathway in 
mice (Hayashi et al., 2004a)(Table 1.1). ERK5 deficient-mice showed defects 
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in the development of the heart and maturation of vasculature and 
angiogenesis in embryonic tissues which lead to lethality around E10.5 
(Regan et al., 2002b, Sohn et al., 2002, Hayashi et al., 2004b, Kesavan et al., 
2004a). Furthermore, overexpression of VEGF in these mice led to normal 
development up to E12.5 with abnormalities in cardiovascular which 
subsequently resulted in observed lethality at E12.5-E14.5 (Miquerol et al., 
2000). Studies have shown that deregulation of hypoxia inducible factor-1 α 
(HIF-1α) may play a role in increased VEGF expression and preventing its 
ubiquitination and proteolysis which consequently causes aberrant 
angiogenesis (Pi et al., 2005). The phenotypic defects of erk5 gene deletion in 
mice include immature vasculature, disorganised and rounded endothelial 
cells resulting in increased vessel leakiness and loss of vascular integrity 
leading to embryonic death by haemorrhage (Regan et al., 2002b, Sohn et al., 
2002, Yan et al., 2003). Similar phenotypic abnormalities have been shown in 
MEKK3, MEK5 and MEF2 knockout mice, suggesting that the ERK5 
signalling pathway is significant in angiogenesis (Table 1.1) (Wang et al., 
2005).  
1.4.7.2   Inhibition of endothelial apoptosis 
To address the initial defects caused by ERK5 gene ablation, generation of 
endothelial-specific ERK5 knockout mice confirmed the primary defects 
occurred in the endothelium which subsequently caused cardiovascular 
abnormalities and death around E10, similar to the global ERK5 knockout 
mice (Hayashi et al., 2004a). Nevertheless, specific knockout of ERK5 in 
hepatocytes, neuronal and cardiomyocytes cells has no effect on the 
development (Hayashi and Lee, 2004, Hayashi et al., 2004a) (Table 1.1). 
Vascular integrity in adult mice is affected by knockout of ERK5 followed by 
death within 2-3 weeks due to leaky blood vessels resulting from endothelial 
cell apoptosis (Hayashi et al., 2004a). Together, these data suggest that ERK5 
is critical for endothelial cell function. 
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Table 1.1 Phenotypic results in mice after global ablation of specific components of 
ERK5 signalling pathway.   
Genotype Phenotype Reference 
Mekk2
-/-
 
Mice develop normally and are fertile and viable. 
 
Mice exhibit altered cytokine expression in thymocytes but 
develop normally and are viable. 
 
Mice are viable and develop normally, but exhibit reduced 
cytokine expression in embryonic stem cell-derived mast 
cells. 
(Kesavan et 
al., 2004b) 
(Guo et al., 
2002) 
 
 
(Garrington 
et al., 2000) 
Mekk3
-/-
 
Embryonic death at E11.0 due to severe abnormalities in 
early angiogenesis. 
Vasculogenesis was not affected.  
(Yang et al., 
2000) 
Mek5
-/-
 
Defects in cardiac development, decreased proliferation and 
increased apoptosis in heart, dorsal and head  lead to 
embryonic lethality at E10.5 
(Wang et al., 
2005) 
Erk5
-/-
 
Abnormalities in vascular maturation, angiogenesis, heart 
development and looping resulted in embryonic death at 
E9.5-E10.5  
 
Underdevelopment of vasculature within the yolk sac, 
embryonic death at E9.5-E10.5 
 
Defects angiogenesis in the embryo and placenta, embryonic 
death at  E10.5-E11 
 
Embryonic death at E10.5-11.5 with growth retardation in 
the head and impaired angiogenesis in the embryo and 
placenta.  
(Regan et al., 
2002b) 
 
 
(Hayashi et 
al., 2004a) 
 
(Yan et al., 
2003) 
 
(Sohn et al., 
2002) 
Erk5
-/-
 
Hepatocyte 
Mice develop normally and are viable (Hayashi and 
Lee, 2004) 
Erk5
-/- 
Cardiomyocytes 
Mice are viable and develop normally. (Hayashi et 
al., 2004b) 
Erk5
-/- 
Endothelial 
Cardiovascular defects lead to embryonic death at E9.5-10.5 (Hayashi and 
Lee, 2004) 
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The phenotype of Mef2c 
-/- 
is similar to that of Erk5
-/-
 in mice leading to 
cardiac and vascular defects which eventually results in embryonic lethality 
(Hayashi and Lee, 2004, Roberts et al., 2009). Furthermore, Erk5
-/-
 murine 
endothelial cells exposed to overexpression of a constitutively active form of 
MEF2C are partially protected from apoptosis (Hayashi et al., 2004b, Olson, 
2004). Recent in vitro studies revealed that ERK5 is required for VEGF 
induced phosphorylation of AKT in HDMECs to suppress apoptosis and 
support cell survival in tubular morphogenesis via VEGFR-2 (Roberts et al., 
2010c). 
1.4.7.3   Shear-stress and atheroprotection 
Fluid shear stress is important in modulating the structure and function of 
blood vessels and also plays a pivotal role in hemodynamic forces recognised 
and transduced via endothelial cells (Yan et al., 1999). The integrity of ECs is 
critical for maintenance of blood vessels function. Various factors can 
contribute to impairment of endothelial cells such as high cholesterol, 
smoking, hypertension and diabetes which subsequently lead to dysfunction 
of endothelial cells, low lamina shear stress, endothelial apoptosis and finally 
atherosclerosis (Traub and Berk, 1998). Laminar shear stress induces ERK5 
activation in endothelial cells (Yan et al., 1999). Fluid shear stress and 
peroxisome proliferator activated receptor (PPARγ) have atheroprotective 
effects, since ERK5 is activated by shear stress; phosphorylation of PPARγ is 
induced via activated ERK5 in endothelial cells (Akaike et al., 2004). 
Furthermore, ERK5 activation via fluid shear stress has the ability to confer 
an atheroprotective effects by negatively regulating the inflammatory 
cytokines such as tumour necrosis factor-α (TNF-α) mediated activation of 
nuclear factor κB (NF-κB) and adhesion molecule expression including 
vascular cellular adhesion molecule-1 (VCAM-1) and E-selectin in 
endothelial cells (Akaike et al., 2004).  
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The atheroprotective role of activated ERK5 by steady laminar shear stress is 
demonstrated by inhibiting bovine lung microvascular endothelial cells 
(BLMECs) apoptosis by activation of Bad (Pi et al, 2005). In addition, 
activation of ERK5 by constitutively active-MEK5 (CA-MEK5) in these cells 
increased the cell viability and reduced the apoptotic cells, while inhibiting 
the activation of ERK5 via overexpression of dominant negative ERK5 (DN-
ERK5) increased cell apoptosis and reduced the protective effect (Pi et al., 
2005). Using a novel MEK5 inhibitor, BIX02188, showed that in BLMECs, 
the MEK5/ERK5 pathway mediates flow dependent blocking of TNF-α 
signalling (Li et al., 2008). Studies of transcriptional profiles in human 
umbilical vein endothelial cells (HUVECs) identified Kruppel like factor 2 
(KLF2) which is induced by laminar shear stress (SenBanerjee et al., 2004). 
KLF2 has been involved in negatively regulating inflammation and 
angiogenesis which improved vascular stability (Dekker et al., 2002, 
SenBanerjee et al., 2004). Moreover, activation of ERK5 is required for flow 
induced expression of KLF2 in HUVECs (Parmar et al., 2006). Beside the 
activation of KLF2, phosphorylation of KLF4-dependent gene expression has 
been shown to be provoked by ERK5 and this complex MEK5/ERK5/KLF4 
plays an important role in flow-dependent protective functions in endothelial 
cells (Ohnesorge et al., 2010). ERK5 activation increased transcriptional 
activity of Nrf2 (Kim et al., 2012). In contrast, depletion of ERK5 by siRNA 
or chemical compounds such as the MEK5 inhibitor, BIX 01289, inhibit 
laminar flow-induced the activation of Nrf2 dependent gene expression (Kim 
et al., 2012). More recently, it has been shown that the transcriptional activity 
of ERK5 in HUVECs is inhibited via MAP-activated protein kinase-1 
(MAPAPK-1 also known p90RSK) which in turn induces the inflammatory 
response in the endothelial cells and promotes vascular dysfunction (Le et al., 
2013). 
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1.4.7.4   Hypoxic responses  
The levels of hypoxia inducible transcription factor HIF-1α in BLMECs is 
regulated via ERK5 by promoting HIF-1α ubiquitination and proteolysis 
resulting in a reduction in hypoxia induced gene expression of VEGF (Pi et 
al., 2005). Hypoxic conditions induce ERK5 activation, which in turn 
negatively regulate VEGF expression in murine fibroblasts (Sohn et al., 
2002).  In addition, it has been shown that increased VEGF production leads 
to recognised angiogenic defects in ERK5 ¯/¯ embryo (Sohn et al., 2002). 
Analysis of gene expression profiles found that several hypoxic responsive 
genes were activated in the absence of ERK5, Sohn and co-workers suggest 
that the absence of ERK5 plays a repressor role increasing the hypoxic 
inducible responsiveness of some genes and also increases expression of 
genes that are normally unresponsive to hypoxia (Sohn et al., 2005). 
 
1.5   ERK5 and cancer  
Cancer is the cellular progression from normal homeostasis to neoplastic 
status with acquisition of a number of hallmark traits; evading suppressors, 
enabling replicative immortality, resisting cell death, sustained proliferative 
signalling, activating invasion and metastasis, inducing angiogenesis, 
reprogramming energy metabolism and evading immune destruction 
(Hanahan and Weinberg, 2011). Activation of the MEK5/ERK5 pathway is 
implicated in cancer development and disease progression through its role in 
angiogenesis and blood vessel homeostasis (Lochhead et al., 2012). Increased 
attention to the potential role of ERK5 in cancer has resulted from the 
discovery that the inhibitors used to demonstrate a potential role for ERK1/2 
in cancer also targeted ERK5 (Kamakura et al., 1999, Mody et al., 2001a). 
The activation of ERK5 is implicated in proliferation of the cervical cancer 
cell line HeLa and non-tumourigenic breast epithelial cell line MCF10A in 
response to EGF sttimulation (Kato et al., 1998b). In neuroblastoma, ERK5 is 
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phosphorylated by anaplastic lymphoma kinase (ALK), a molecular target in 
neuroblastoma, which induced the transcription factor MYCN and induced 
cell proliferation, suggesting that ERK5 with ALK are important targets in 
neuroblastoma (Umapathy et al., 2014). 
In addition to EGF, various oncogenes have the ability to phosphorylate 
ERK5, suggesting that ERK5 is a key downstream effector of these cascades 
(Lochhead et al., 2012). Anlaysis of cancer tissues or cancer cell lines has 
revealed that the MEK5/ERK5 pathway is overexpreed in many human 
cancers including breast cancer, prostate cancer, hepatocellular carcinoma, 
melanoma and ovarian cancer correlates with poor prognosis (Mehta et al., 
2003a, Song et al., 2004, Ostrander et al., 2007, Sticht et al., 2008, Montero 
et al., 2009b). 
The ability of ERK5 to promote cell proliferation and survival contributes to 
cancer progression, thereby facilitating metastasis via promoting cell 
migration and invasion (Figure 1.11). The ERK5 pathway promotes 
metastasis by transcriptional upregulation of the matrix metalloproteinase-9 
(MMP-9) via AP-1 transcription factor (Mehta et al., 2003a). As MMPs 
degrade extracellular matrix proteins (ECM), they play a sigificant role in 
metastasis (Foda and Zucker, 2001). 
 
The Ras oncogene is mutated in a number of cancer types, such as thyroid 
(50%), colon (50%), lung (30%), ovarian (15%), breast, skin and liver. The 
ERK5 cascade is suspected to be implicated in mediating the oncogenic 
effect of RAS. In PC12 cells and C2C12 cells, the activation of ERK5 
requires RAS activation (Kamakura et al., 1999). Ras exists in dependent and 
independent pathways for the activation of ERK5; for example, the inhibition 
of EGF-induced ERK5 in PC12 cells by RAS was complete, while in COS17 
cells it was about 50%, indicating that the results depend on the cell type 
(Kamakura et al., 1999). In addition to RAS, there are many other oncogenes 
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that can activate ERK5, such as Cancer Osaka Thyroid (Cot), which requires 
JNK, p38 and ERK5 to induce the c-Jun promoter to subsequently stimulate 
neoplastic transformation (Chiariello et al., 2000). Src is another oncogene 
that mediates ERK5 activation in response to H2O2 (Abe et al., 1997). Similar 
to RAS, activated Src tyrosine kinase activates the ERK5 pathway, which in 
turn contributes to transformation via Src; this suggests that ERK5 plays an 
important role in neoplastic transformation (Barros and Marshall, 2005). 
1.5.1   Tumour angiogenesis 
ERK5 is implicated in tumour-associated angiogenesis; this was suggested by 
analysis of the deletion of the erk5 gene in mice, resulting in embryonic 
lethality at E9.5-10.5, and the histological and immune histological analysis 
of mutant embryos, which revealed serious defects in cardiac development 
and angiogenesis (Regan et al., 2002a). Furthermore, ablation of ERK5 in a 
human tumour xenograft model resulted in regression of tumour vasculature 
and reduction in tumour growth in mice (Hayashi et al., 2005b). In addition, 
it is known that pro-angiogenic factors such as VEGF, FGF-2 and EGF have 
the ability to stimulate ERK5 activation in HUVECs (Hayashi et al., 2004a). 
Roberts and co-workers have shown that ERK5 is required to mediate VEGF 
stimulated tubular angiogenesis in HDMECs (Roberts et al., 2010b). 
Together, these data indicate that ERK5 could be a potential anti-angiogenic 
drug target. 
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Figure 1.11 ERK5 promotes cancer progression. ERK5 regulates tumour growth by 
triggering un-controlled cell proliferation and survival. In addition, ERK5 induces 
angiogenesis to control tumour development and also it increases the mobility and the 
invasiveness of cancer cells to facilitate the metastasis. The abundance of ERK5 functions 
makes this cascade attractive as a therapeutic target for cancer.  
 
1.5.2   Breast and Prostate cancers 
Studies have examined MEK5 in breast cancer and found that the constitutive 
activation of signal transducer and activator of transcription (STAT3) induces 
and up-regulates MEK5. STAT3 is commonly detected in breast cancer cell 
lines but not in breast epithelial cells (Song et al., 2004). STAT3 is regulated 
by ErbB/HER, which suggests that, as MEK5 is up-regulated by STAT3, the 
phosphorylation of downstream ERK5 is, induced as well (Song et al., 2004). 
Furthermore, ERK5 is a cellular mediator of EGF-induced proliferation in an 
immortalised breast epithelial cell line showing the growth of breast cancer 
cells (Esparis-Ogando et al., 2002a). The second member of the epidermal 
growth factor (EGF) family, Neuregulin (NRG), binds to ErbB3/HER3 and 
ErbB4/HER4 and induces the ERK5 pathway, which in turn participates in 
responses of proliferation that are induced by NRG receptors (Esparis-
Ogando et al., 2002a). Mutations or increased activation of these receptors 
(ErbBs) is associated with poor prognosis, a high risk of metastases and 
potentially chemotherapy-resistant cancers (Esparis-Ogando et al., 2002a). In 
addition, the expression of a dominant-negative form of ERK5 represses the 
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proliferation of breast cancer cells through a noticeable decrease in NRG-
induced proliferation. Overexpression of HER2/ErbB2 constitutively 
activates the dual phosphorylation site of ERK5 in breast cancer cell lines 
such as SKBR3 and BT474 (Esparis-Ogando et al., 2002a). ERK5 has been 
assessed in 84 samples of primary breast cancer tumours; the results indicate 
that 17 samples (20%) had an overexpression of ERK5 (Montero et al., 
2009b). MEK5 is implicated in survival signalling and apoptotic regulation in 
breast cancer and inhibition of MEK5 signalling sensitised breast cancer cells 
to chemotherapy (Weldon et al., 2002). 
Based on the observation of phosphorylation of ERK5 induced by the EGFR 
family in breast cancer cells and the constitutively activated form of MEK5, a 
study has assessed the role of the abnormal activation of the MEK5/ERK5 
pathway in prostate cancer. The results indicate that ERK5 protein expression 
is up-regulated in high grade prostate cancer (Mehta et al., 2003a). 
Overexpression of MEK5 in prostate cancer is correlated with an 
unfavourable prognosis and tumour metastases (Mehta et al., 2003a). ERK5 
activation induces the transcriptional activation of c-Jun via MEF2, which in 
turn increases the activator protein AP-1; this up-regulates the matrix 
metallopeptidase-9 (MMP-9) resulting in degradation of the extracellular 
matrix (ECM) surrounding the cancer cell and allows them to invade and 
metastasise as mentioned (section 5.1) (Mehta et al., 2003a). The expression 
of MMP-9 plays a role in metastasis in various tumours including breast 
cancer, prostate cancer and ovarian cancer (Scorilas et al., 2001, Sehgal et al., 
1998). In addition, overexpression of ERK5 in PC3 cells increases the levels 
of proliferation, invasion and motility which in turn accelerate tumour 
formation, confirming the role of ERK5 in the aggression of prostate cancer 
(McCracken et al., 2008a). 
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1.5.3   Ovarian carcinoma 
Folic adhesion kinase (FAK) plays a functional role in cell motility and cell 
survival, as well as recruiting signalling molecules to focal adhesions (Hanks 
et al., 2003). The overexpression of FAK has been found in many different 
types of tumours and its over-activity is associated with invasion and 
metastasis (Parsons et al., 2008). Protein tyrosine phosphatase (PTP) and dual 
specificity phosphatase (DUSP) are known to have a role in cellular motility 
that is maintained by HER2; also, PTPN12 is a regulator of adhesion, 
migration and FAK (Villa-Moruzzi, 2011). ERK5 is a downstream target for 
FAK and the receptor tyrosine kinase HER2 (Esparis-Ogando et al., 2002a, 
Sawhney et al., 2009). Based on these facts, Villa-Moruzzi assessed the role 
of the ERK5 target FAK in the HER2-dependent pathway; the results 
indicated that HER2-driven motility is mediated by ERK5 and PTPN12 in an 
ovarian cancer cell line (SKOV-3) (Villa-Moruzzi, 2011).  
1.5.4   Skin cancer 
The knockdown of ERK5 in human malignant melanoma cells A375 
abolished their ability to form invadopodia (Ramsay et al., 2011). 
Furthermore, the deletion of ERK5 in B16F10 melanoma and LL/2 Lewis 
xenograft models affected tumour angiogenesis and reduced tumour volumes 
in these xenograft models (Hayashi et al., 2005b). Inactivation of ERK5 in 
epidermal keratinocytes blocked inflammation driven tumourigenesis 
(Finegan et al., 2015). Furthermore, the ablation of epidermal ERK5 
weakened the migration of neutrophils and mast cells to the skin in response 
to tetradecanoylphorbol acetate (TPA) (Finegan et al., 2015). Recent data has 
shown that in contrast to ERK1/2, ERK5 does not drive proliferation in 
melanoma cells with KRAS or BRAF mutations (Lochhead et al., 2016). 
1.5.5   Pharmacological inhibitors of ERK5 
Two pharmacological inhibitors of the MEK5/ERK5 pathway have been 
discovered, BIX02188 and BIX02189 (Figure 1.12) (developed by the 
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Boehringer Ingelheim), which belong to indoline kinase inhibitors series and 
selectively inhibit MEK5 without affecting MEK1/2 (Tatake et al., 2008). 
BIX02188 and BIX02189 have been shown to prevent sorbitol induced 
ERK5 activation and increase the transcriptional activity of MEF2C in co-
transfected cells with MEK5 DA and ERK5 (Tatake et al., 2008). Osmotic 
stress-induced ERK5 and MEF2C activation in HeLa and HEK293 cells were 
inhibited by these inhibitors (Tatake et al., 2008). Utilising these inhibitors to 
block ERK5 activation in response to NRG stimulation in PC12 cells, inhibits 
the differentiation of these cells (Obara et al., 2009). Based on reports 
indicating that CDK1 is proposed to be the kinase responsible for ERK5 
activation during mitosis, using BIX02188 and BIX02189 is pivotal to 
distinguish whether the phosphorylation of ERK5 is MEK5-dependent or-
independent (Inesta-Vaquera et al., 2010). These findings suggest that the 
inhibition of MEK5 via BIX inhibitors is not sufficient to block ERK5 
activation in mitotic tumour cells (Inesta-Vaquera et al., 2010). 
The modification of adenosine triphosphate (ATP)-competitive polo kinase 
inhibitor (BI-2536) that led to loss of polo kinase inhibitor activity, resulted 
in a XMD8-92, a highly selective inhibitor for ERK5 phosphorylation (Figure 
1.12) (Yang et al., 2010b). XMD8-92 inhibits ERK5 activation in response to 
EGF stimulation in HeLa cells without an inhibitory effect on ERK1/2 (Yang 
et al., 2010b). The treatment of mouse lung and cervical xenograft tumours 
with XMD8-92 reduced the tumour growth by 95% by a reduction of tumour 
cell proliferation by suppression of the promyelocytic leukaemia protein 
(PML) and by inhibition of the contribution of ERK5 in tumour associated 
angiogenesis (Yang et al., 2010b). In contrast with the loss of vascular 
integrity after deletion of erk5 in endothelial cells of adult mice, it has been 
noted that the stability of blood vessels of mice did not appear to be 
detrimentally affected by XMD8-92 treatment (Yang et al., 2010b).  
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Figure 1.12 Chemical structure of BIX02189 and XMD8-92 
 
1.5.6 Anti-cancer drugs 
The anti-cancer treatments that used in this project are doxorubicin and 
cisplatin in ovarian cancer cell lines and vemurafenib in malignant melanoma 
cell lines. 
1.5.6.1 Doxorubicin 
In 1957, the first isolated anthracycline antibiotics was daunorubicin from the 
actinobacterium Streptomyces peucetius (Dimarco et al., 1981). In 1969, 
doxorubicin, analogue daunorubicin, was discovered from Streptomyces 
peucetius var. caesius, a mutagenic Streptomyces peucetius, and since then 
many research reports relating to pharmacodynamics and pharmacokinetics of 
doxorubicin have been published (Arcamone et al., 1969). 
Doxorubicin consists of an amino sugar called daunosamine which is linked to 
the tetracyclic aglycone structure and this amino sugar produces a hydrophilic 
centre for doxorubicin (Figure 1.1). A short chain with a carbonyl group at C-
13 and a hydroxyl group at C-14 attaches to ring A at C-9 and a quinine group 
presents in ring C and a hydroquinone group presents in ring B (Arcamone et 
al., 1969, Minotti et al., 2004). The structural difference between daunorubicin 
and doxorubicin is that it is a methyl group at C-14 in daunorubicin, while in 
doxorubicin it is a hydroxyl group at C-14 (Figure 1.1). The complex structure 
of doxorubicin is closely related to its main mechanisms of action and its 
metabolism. Since doxorubicin was introduced into clinical practice in the 
BIX02189 XMD8-92 
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1970s, it has become one of the most effective chemotherapy treatments for 
several tumours, such as breast cancer, ovarian cancer and mesothelioma 
(Ogura, 2001). The various mechanisms of action of doxorubicin-induced 
cytotoxicity have been discovered include inhibition of topoisomerase II 
triggered via DNA intercalation, apoptosis induced by p53 
dependent/independent pathway, oxidative damage mediated by free radicles 
and transport doxorubicin into the nucleus via interactions with proteasome 
(Minotti et al., 2004). 
 
 
 
 
Figure 1.1 The molecular structure of doxorubicin 
1.5.6.2 Cisplatin 
The inorganic platinum complex, cis-diamminedichloroplatinum (II), 
commonly known as cisplatin, was the first platinum compound to be 
discovered. It was first described by Peyrone in 1845, but its antitumor activity 
was only noticed after 121 years (Peyrone, 1844). The physicist Barnett 
Rosenberg and colleagues accidentally observed that Escherichia coli when 
grown in an electrical chamber with platinum electrodes stopped dividing and 
started to elongate. This  inhibition  of  cell  division  without  an  apparent  
reduction  in  growth  was  attributed to the elution of platinum compounds 
from the platinum electrodes used in the chamber (Rosenberg et al., 1965). 
Further experiments with platinum compounds led to the determination of 
cisplatin as the compound that exerted the anti-proliferative actions. It is 
composed of a doubly charged platinum ion surrounded by four ligands, two 
amine ligands and two chloride ligands (Figure 1.12). Cisplatin was approved 
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by the US Food and Drug Administration (FDA) for treatment of testicular and 
bladder cancer in 1978 (Kelland, 2007). Cisplatin  is  now  a  widely  used  
chemotherapeutic  drug  in  the  treatment  of  a variety  of  cancers, including 
lung, bladder, testicular, ovarian and gastric cancers (Schiller et al., 2002, von 
der Maase et al., 2000, Einhorn, 2002, Hennessy et al., 2009, Cunningham et 
al., 2006). In spite of the extensive clinical experience with cisplatin, the  exact  
molecular  mechanism of  the  cytotoxicity  induced  by  cisplatin  is  not 
clearly understood, but it is generally accepted that the main target for the drug 
is DNA (Kelland, 2007). Once inside cytoplasm, cisplatin undergoes 
hydrolysis, the chloride atoms are replaced by water molecules and cisplatin 
becomes a potent electrophile which allows the platinum atom to bind to DNA 
and form cisplatin-DNA adducts inducing intra-strand and inter-strand cross-
linking. The interaction of cisplatin with DNA to form DNA adducts mediates 
its cytotoxic effects by inhibiting DNA replication and transcription by 
inducing programmed cell death (Trimmer and Essigmann, 1999). 
 
 
 
 
Figure 1.12 Structure of cisplatin Cis-diamminedichloroplatinum (II) 
 
1.5.6.3 Vemurafenib 
The vemurafenib was approved by the US Food and Drug Administration 
(FDA) in 2011 and by Health Canada and the European Commission in 2012 
for the treatment of adult patients with metastatic melanoma harbouring 
BRAF
V600E
 mutations, gets its name from V600E mutated BRAF inhibition 
and is also known under the names PLX4032 and Zelboraf®. It is developed 
by Plexxikon Inc. and commercialised by Hoffmann-La Roche (Sharma et al., 
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2012). Vemurafenib is a novel and highly selective serine/threonine kinase 
inhibitor with the ability to block proliferation in tumours carrying the mutant 
BRAF gene (Figure 1.13) (Nijenhuis et al., 2014). 
Vemurafenib inhibits the protein synthesised by the mutant BRAF
V600E
 and 
prevents the constitutively activation of the MAPK signalling pathway 
(Sharma et al., 2012). Vemurafenib binds reversibly to BRAF
V600E
 and reduces 
the activity of the kinase by blocking the activating domain, which results in 
decreased activation of MEK and ERK, which in turn slows down the cell 
growth and proliferation (Flaherty et al., 2011). Despite the strong initial 
response, patients almost always experience tumour relapse within one year of 
treatment and become resistant to vemurafenib and this suggests the existence 
of intrinsic BRAF inhibitor resistance. Also, an acquired resistance after initial 
response to the drug was observed (Kudchadkar et al., 2012). 
PLX4720 is a structurally related progenitor of vemurafenib/PLX4032 that 
displays similar inhibition of mutant BRAF protein in biochemical assays and 
it differs only in one phenyl ring from PLX4032 (Tsai et al., 2008, Michaelis et 
al., 2014). Vemurafenib was selected for further clinical development over 
PLX4720, due to a more favourable pharmacokinetic profile, with greater 
bioavailability in beagle dogs and monkeys (Bollag et al., 2010). However, 
PLX4720 is the preferred compound for use in pre-clinical mouse models, due 
to better pharmacokinetics in rodents (Bollag et al., 2012). PLX4720 was 
found to inhibit BRAF
V600E
 at low nanomolar concentrations, and was 10-fold 
more selective for B-Raf (V600E) than for the wild-type B-Raf. It was even 
more selective for BRAF
V600E
 than for other kinases (Bollag et al., 2010). 
 
 
 
Figure 1.13 The molecular structure of vemurafenib. 
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1.5.6.4 Oncogene addiction  
Cancer cells are known to contain multiple genetic and epigenetics 
abnormalities and are notorious for harbouring several mutations. Despite this, 
they often display dependence on a single oncogene or pathway for their 
growth and survival, a phenomenon called oncogene addiction (Weinstein, 
2002; Weinstein and Joe, 2006). As a consequence of this addiction, 
inactivation of the oncogene which tumour cells are dependent on results in 
regression of the tumour. 
The oncogene addiction phenomenon has been verified in many mouse 
models. Switching on the c-myc oncogene in hematopoietic cells resulted in 
the development of myeloid leukemia and T-cell; however, switching off this 
gene the leukemia cells stopped dividing and showed differentiation and 
apoptosis (Felsher and Bishop, 1999). Furthermore, oncogene addiction has 
also been shown to occur in conditional mouse models of h-ras in melanoma 
(Chin et al., 1999), bcr-abl induced leukemia (Huettner et al., 2000) and k-ras 
induced lung adenocarcinoma (Fisher et al., 2001). 
Oncogene addiction is also relevant to tumour-stromal interaction, tumour 
metastasis and tumour invasion. Therefore, activation of EGFR or RAS leads to 
stimulation of signalling pathways in cancer cells which promote the 
expression of MMPs and VEGF (Wittekind and Neid, 2005). Inactivation of 
these genes in cancer cells inhibits tumour invasion, angiogenesis (Weinstein 
and Joe, 2006). RAS mutations can drive ERK1/2 pathway addiction; in 
tumour cells with KRAS mutations, inhibition of MEK1/2 is still a viable 
strategy (Little et al., 2013). The ERK1/2 signalling pathway is often de-
regulated in human cancer attributable to mutations in BRAF or KRAS and also 
NRAS and HRAS and activating mutations in RTKs such as EGFR and FGFR1. 
As a consequence of the addiction of tumour cells to these oncogenic drivers to 
maintain their cancer specific traits, mutant oncoprotiens and their signalling 
pathway are important in drug targets. The ERK1/2 cascade has attracted more 
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interest in new cancer therapeutics research and some inhibitors are currently 
undergoing clinical evaluation, such as the RAF inhibitor, vemurafenib, which 
selectively inhibits BRAF
V600E
 and the MEK1/2 inhibitor, selumetinib (Ji et al., 
2012; Joseph et al., 2010). Cell lines derived from melanoma, thyroid and 
colorectal cancer that have BRAF mutations exhibit high activation of ERK1/2 
and these cell lines are frequently addicted to the ERK1/2 signalling pathway. 
A s a consequence of this addiction, inhibition of ERK1/2 signalling pathway 
sensitises tumour cells to insults they are relatively resistant to (Balmanno and 
Cook, 2009). 
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1.6   Projects aims 
The objective of this project was to elucidate the role of ERK5 in drug-
induced resistance in cancer cells and tumour angiogenesis. 
In order to achieve this objective, this study aimed to: 
1- Characterise the activation and phosphorylation of ERK5 in endothelial 
cells and tumour cells (HeLa) in response to pro-angiogenic factors and 
small molecule inhibitors of the ERK5 signalling axis XMD8-92 and 
BIX02189. Assess the role of these inhibitors on VEGF induced 
angiogenesis using a 3-D collagen gel model and co-culture in vitro 
angiogenesis assay. 
2- Assessment of the activation of ERK5 in vemurafenib-resistant melanoma 
cells and the effect of inhibitors of the MEK5/ERK5 signalling pathway. 
Determine the role of ERK5 in aberrant angiogenesis via inhibition of 
melanoma cell-mediated angiogenesis by targeting the MEK5/ERK5 
cascade in HDMEC/NHDF/melanoma cell co-culture in vitro 
angiogenesis assay. 
3- Investigate the ERK5 activation status in doxorubicin and cisplatin-
resistant ovarian cancer cells and the effect of inhibitors of the 
MEK5/ERK5 signalling pathway in potentially restoring chemo 
sensitivity in resistant cells. Assessment the effect of targeting the ERK5 
signalling axis to prevent tumour cell-induced angiogenesis by using 
HDMEC/NHDF/ovarian cancer cell co-culture in vitro angiogenesis 
assay. 
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2.1    Materials 
2.1.1    Reagents 
Recombinant  human  vascular  endothelial  growth  factor  VEGF-A165 and 
basic fibroblast growth  factor  (FGF-2)  were  purchased  from  R&D  
Systems  Inc. (Minneapolis, MN,  USA). Recombinant  human  hepatocyte  
growth  factor  (HGF), epidermal growth factor  (EGF), dimeric platelet-
derived growth factor (PDGF)-BB and insulin like growth factor (IGF) were  
bought  from  Peprotech  EC  (Rocky  Hill,  NJ,  USA). 
Aprotinin, leupeptin, pepstatin, phenylmethylsulphonyl fluoride (PMSF), 
agar, agarose (electrophoresis grade), glycerol, 3-(N-morpholino)-
propanesulphonic acid (MOPS), polyoxyethylenesorbitan monolaurate 
(Tween-20) and sodium dodecyl sulphate (SDS) 20% (w/v) solution, were 
purchased from Melford (Ipswich, UK). Prestained protein marker (broad 
range 10-230 kDa) was purchased from New England Biolabs (UK) Ltd, 
(Hitchin, UK). 
Ammonium chloride, ammonium peroxodisulphate (APS), ampicillin 
solution, bicinchoninic acid solution, copper (II) sulphate solution, dimethyl 
sulphoxide (DMSO), sterile DNase- and RNase-free dH2O, ethidium bromide 
(EtBr), ethylenediaminetetraacetic acid (EDTA), gelatin from porcine skin, 
kanamycin solution, Luria Bertani (LB) broth powder, manganese (II)  
chloride tetrahydrate, sodium orthovanadate (Na3VO4), N,N,N’,N’-
tetramethylethylenediamine (TEMED), Tris-EDTA (TE) buffer solution (pH 
8.0) and Triton X-100 were purchased from Sigma-Aldrich (Poole, UK). 
Enhanced chemiluminescence (ECL from Pierce) western blotting detection 
reagents, glycine, sodium chloride (NaCl), Tris-Base were bought from 
Thermo Fisher Scientific
™
 (Loughborough, UK).) Bovine serum albumin 
(BSA) was purchased from Boehringer. Full-range (12-225 kDa) rainbow 
molecular weight markers and Hybond ECL nitrocellulose membrane were 
purchased from GE Healthcare (Amersham, UK).  Ultrapure ProtoGel
® 
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solution was bought from Geneflow Ltd. (National Diagnostics, 
Staffordshire, UK). NuPAGE
®
 4-12% Bis-Tris gels, LDS sample buffer [4X] 
were purchased from Novex
®
, Life Technologies™ (Paisley, UK). BIX 
02189 was purchased from Selleck Chemicals (Stratech Scientific Ltd., 
Suffolk, UK). XMD 8-92 was bought from Tocris Bioscience (Bristol, UK). 
RNeasy mini RNA extraction kit, QIAshredder kit, RNase-Free DNase set 
and QIAprep Spin Miniprep/Maxiprep kits were purchased from Qiagen 
(Crawley, UK). Oligonucleotide primers and 2x Power SYBR ® Green 
mastermix were purchased from Life Technologies™ (Paisley, UK). 
Moloney murine leukemia virus (M-MLV) reverse transcriptase, 0.1 M 
dithiothreitol (DTT), 5 x first strand buffer, 10 mM PCR grade dNTP mix, 
RNaseOUT™ recombinant ribonuclease inhibitor. GoTaq® Flexi DNA 
polymerase, MgCl 2 (25 mM), 5X colourless GoTaq® Flexi Buffer; ultra-
pure deoxynucleotide triphosphates (dNTPs) (100 mM of each dNTP in 
ddH2O) and CellTiter-Glo™ luminescent cell viability assay were from 
Promega. Optical-grade sealing film for 96-well qRT-PCR plates was 
purchased from Bioline (London, U.K.). 
Paraformaldehyde, Triton X-100, 2-mercaptoethanol for electrophoresis, and 
SIGMA FAST TM BCIP/NBT (5-bromo-4-chloro-3-indolyl phosphate/nitro 
blue tetrazolium) tablets were purchased from Sigma-Aldrich (Poole, U.K.). 
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2.1.2    Antibodies  
Table 2.1 Primary antibodies used in this study 
 
Antibody 
 
Source 
 
Cat. No. 
 
Dilution 
 
Host Species 
 
Appl. 
Actin 
(I-19) 
Santa Cruz Biotechnology 
(CA, USA) 
 
sc-1616-R 
 
1:2000 
 
Rabbit 
 
WB 
AKT New England Biolabs 
(Hitchin, UK) 
 
#9271 
 
1:1000 
 
 
Rabbit 
 
WB  
 
EGF-R1 New England BioLabs 
(Hitchin, UK) 
 
#2232 
 
1:1000 
 
Rabbit 
 
WB 
ERK5 New England Biolabs 
(Hitchin, UK) 
 
#3372 
1:1000 
1:100 
1:50 
 
Rabbit 
WB 
 IF 
 IP 
GAPDH XP New England Biolabs 
(Hitchin, UK) 
 
#5174 
 
1:2000 
 
Rabbit 
 
WB 
p44/42 MAPK 
(ERK1/2) 
New England Biolabs 
(Hitchin, UK) 
 
#9102 
1:1000 
1:100 
 
Rabbit 
WB 
IF 
VEGF 
Receptor 2 (55B11) 
New England Biolabs 
(Hitchin, UK) 
 
#2479 
1:1000 
1:200 
 
Rabbit 
WB 
IF 
Phospho- AKT 
(S473) XP 
New England Biolabs 
(Hitchin, UK) 
 
#4060 
 
1:2000 
 
Rabbit 
 
WB 
Phospho- EGFR1 New England Biolabs 
(Hitchin, UK) 
 
#2234 
 
1:1000 
 
Rabbit 
 
WB 
Phospho- ERK5 
(T218/Y220) 
New England Biolabs 
(Hitchin, UK) 
 
#3371 
 
1:1000 
 
Mouse 
 
WB 
Phospho- p44/42 
MAPK 
(T202/Y204) XP 
New England Biolabs 
(Hitchin, UK) 
 
#4370 
 
1:2000 
 
Rabbit 
 
WB 
Phospho-
SAPK/JNK 
(Thr
183
/Tyr
185
) 
Antibody 
New England Biolabs 
(Hitchin, U.K.) 
 
#9251 
 
1:1000 
 
Rabbit 
 
WB 
Cleaved Caspase-3 
(Asp
175
) 
Antibody 
New England Biolabs 
(Hitchin, U.K.) 
 
#9661 
 
1:1000 
 
Rabbit 
 
WB 
Monoclonal Mouse 
Anti-Human CD31, 
Endothelial Cell 
Clone JC70A 
Dako Cytomation (Glostrup, 
Denmark) 
 
M 0823 
 
1:750 
 
Mouse 
 
IHC 
WB, Western blotting; IF, immunofluorescence; Immunohistochemistry (IHC) 
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Table 2.2 Secondary antibodies used in this study 
 
Antibody 
 
Source 
 
Cat. No. 
 
Dilution 
 
Appl. 
Alexa Fluor® 488 Donkey 
Anti-Rabbit IgG (H+L) 
Molecular Probes® (Life 
Technologies™; Paisley, UK) 
 
#A21206 
 
1:1000 
 
IF 
Alexa Fluor® 568 Donkey 
Anti-Rabbit IgG (H+L) 
Molecular Probes® (Life 
Technologies™; Paisley, UK) 
 
#A10042 
 
1:1000 
 
IF 
Hoechst 33342 Molecular Probes
® (Life 
Technologies™; Paisley, UK) 
 
#H1399 
 
1:5000 
 
IF 
HRP-conjugated 
AffiniPure Donkey Anti-
Goat IgG (H+L) 
Jackson ImmunoResearch 
Laboratories, Inc. (PA, USA) 
#705-035- 
147 
 
1:10000 
 
WB 
HRP-conjugated 
AffiniPure Goat Anti-
Mouse IgG (H+L) 
Jackson ImmunoResearch 
Laboratories, Inc. (PA, USA) 
#115-035- 
166 
 
1:5000 
 
WB 
HRP-conjugated 
AffiniPure Goat Anti-
Rabbit IgG (H+L) 
Jackson ImmunoResearch 
Laboratories, Inc. (PA, USA) 
#111-035- 
144 
 
1:5000 
 
WB 
Anti-mouse IgG (whole 
molecule) alkaline 
phosphatase conjugate 
antibody 
Sigma-Aldrich (Poole, U.K.) #250 A3688 IHC 
WB, Western blotting; IF, immunofluorescence; Immunohistochemistry (IHC) 
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2.1.3    Cell lines 
Table 2.3 Cell lines used in this study 
Abbr. Name Cell type and details Source 
A375 Malignant melanoma cancer cell 
line 
From Prof. Richard Marais (Manchester Cancer 
Institute) 
A375-R Malignant  melanoma cancer 
cell line resistant to PLX4027 
From Prof. Richard Marais (Manchester Cancer 
Institute) 
SKMel 5 Malignant  melanoma cancer 
cell line 
From Prof. Richard Marais (Manchester Cancer 
Institute) 
SKMel 5-R Malignant  melanoma cancer 
cell line resistant to PLX4027 
From Prof. Richard Marais (Manchester Cancer 
Institute) 
HeLa Human epithelial cervical cancer 
cell line Isolated from adult, 
African-American female 
European Collection of Cell Cultures supplied by 
Sigma- Aldrich (Poole, UK) 
A2780 Malignant  ovarian cancer cell 
line 
From Prof. Robert Brown and Carol McCormik 
(Institute of Cancer Science, Glasgow University) 
A2780-Cis Malignant ovarian cancer cell 
line resistant to cisplatin 
From Prof. Robert Brown and Carol McCormik 
(Institute of Cancer Science, Glasgow University) 
A2780-ADR Malignant ovarian cancer cell 
line resistant to doxorubicin 
From Prof. Robert Brown and Carol McCormik 
(Institute of Cancer Science, Glasgow University) 
NHDF Normal Human Dermal 
Fibroblasts 
PromoCell (Heidelberg, Germany). 
HDMEC Human Dermal Microvascular 
Endothelial cells (Lot No. 
6060707.1) 
Isolated from juvenile, 
Caucasian male 
           PromoCell (Heidelberg, Germany) 
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2.1.4    Cell culture media and solutions 
Table 2.4 Cell culture media and solutions used in this study 
Name Composition Source 
EBM MV2 basal 
medium containing 
1% (v/v) FCS 
EBM MV2 basal medium supplemented with 1% (v/v) 
fetal calf serum (FCS), (Cat. No. C-22221). 
PromoCell 
(Heidelberg, 
Germany). 
Fibroblast growth 
medium 
Fibroblast growth medium supplemented with 1.0 ng/ml 
bFGF and 5.0 µg/ml insulin, (Cat. No.: C-23110). 
PromoCell 
(Heidelberg, 
Germany). 
EBM MV2 growth 
medium 
EBM MV2 basal medium supplemented with 5% (v/v) 
fetal calf serum (FCS), EGF (5.0 ng/ml), hydrocortisone 
(0.2 μg/ml), VEGF (0.5 ng/ml), FGF-2 (10.0 ng/ml), insulin-
like growth factor-1 (20.0 ng/ml) and ascorbic acid (1.0 
μg/ml), (Cat. No. C-22121). 
PromoCell 
(Heidelberg, 
Germany). 
DMEM Dulbecco’s Modified Eagle Medium (DMEM) (Cat. No. 
D6429) containing 4500 mg/L glucose, L-glutamine, 
sodium pyruvate and sodium bicarbonate Supplemented 
with 10% (v/v) 
Gibco® (Life 
Technologies™; 
Paisley, UK) 
RPMI 1640 RPMI medium 1640 (1X) + GlutaMAX™ -I 
 
Gibco® (Life 
Technologies™; 
Paisley, UK) 
Serum-free medium EBM MV2 basal medium with no added growth factors or 
serum, (Cat. No. C-22221). 
PromoCell 
(Heidelberg, 
Germany) 
Trypsin 0.05% Trypsin-EDTA (1X), Phenol Red (Cat. No. 25300- 
054) 
Gibco® (Life 
Technologies™; 
Paisley, UK) 
Gelatin 0.5% (w/v) gelatin from porcine skin in ddH2O, 
autoclaved 
Sigma-Aldrich® 
(Poole, UK) 
Versene Dulbecco’s phosphate buffered saline without Ca
2+/Mg2+ 
supplemented with 0.5 mM EDTA 
Lonza (Basel, 
Switzerland) 
PBS Cell Wash Dulbecco’s phosphate buffered saline with Ca
2+/Mg2+ Lonza (Basel, 
Switzerland) 
Ice-cold PBS Lysis 
Wash 
Dulbecco’s phosphate buffered saline without Ca2+/Mg2+ 
stored at 4ºC 
Lonza (Basel, 
Switzerland) 
HEPES buffer 
solution (1M) 
4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid in 
distilled water (pH 7.2 to 7.5). 
Gibco® (Life 
Technologies™; 
Paisley, UK) 
PureCol collagen 97% type I collagen (3 mg/ml), 3% type III collagen from 
bovine hide in 0.01 M HCl, pH 2.0. 
Inamed 
Biomaterials 
(Leimuiden, The 
Netherlands) 
Sodium bicarbonate 
solution 7.5% (w/v) 
Sodium bicarbonate in ddH2O, 7.5% (w/v). Gibco® (Life 
Technologies™; 
Paisley, UK) 
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2.1.5    Cell culture materials 
The 10 centimetre diameter polystyrene tissue-culture dishes, 6-, 12-, 24- 
and 96-well cell-culture plates, white-walled 96-well cell culture plates, 96-
well polypropylene PCR microplates, centrifuge tubes, cell scrapers, 
cryovials, microfuge tubes, filter pipette tips and serological pipettes were 
bought from Greiner Bio-One (Stonehouse, U.K.). Glass coverslips (16 mm 
diameter) were bought from Agar Scientific (Stansted, U.K.). 
2.1.6    Oligonucleotide primers  
The oligonucleotide primer pairs used in this study are provided in Appendix 
I. Primers were purchased from Invitrogen (Paisley, U.K.) and designed via 
Invitrogen OligoPerfect™ designer facility using the following parameters: 
Primer size (bases): min 18, opt 20, max 27.  Primer melting temperature (T 
m (°C)): min 57, opt 60, max 63.  Primer GC content (%GC): min 40, opt 50, 
max 60.  Product size (bp): min 100, max 150.  Salt conc.: 50 mM Primer 
conc.: 50 nM.  
Oligonucleotide primers were reconstituted to 100 µM using Tris-EDTA 
(TE) buffer solution (pH 8.0). Qiagen primers were reconstituted to 100 µM 
by adding 55 µl of TE buffer solution. Primers were incubated at room 
temperature (r.t.) for 2 min to allow re-hydration to occur, vortexed for 15s 
and stored at -80°C. Aliquots of the reconstituted primers were diluted 40-
fold in sterile, RNase-free ddH2O (Sigma-Aldrich), to a final concentration of 
2.5 µM prior to use in qRT-PCR reactions. 
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2.2   Methods 
2.2.1    Cell Culture 
2.2.1.1    Cell Culture technique 
Sterile conditions were maintained by wearing a Howie coat and nitrile 
gloves, using sterile cell culture equipment and working a TriMAT2 Class II 
microbiological safety cabinet. Culture media were warmed in a water bath to 
37°C prior to use. All work surfaces were disinfected using 70% (v/v) ethanol 
before and after cell culture work. 
2.2.1.2    Gelatine coating of cell culture dishes and plates 
NHDF and HDMEC were seeded and cultured on sterile 10 cm diameter 
polystyrene cell culture dishes, plates and cover slips coated with 0.5% (w/v) 
gelatine and incubated at 37 °C in a humidified, 5% (v/v) CO2, atmosphere in 
a Sanyo MCO-17AC incubator (SANYO E&E Europe BV, Loughborough, 
U.K.) for at least 10 min before use. Prior to plating out NHDF and HDMEC, 
gelatine was aspirated off from the dishes or/and plates. 
2.2.1.3    Thawing of cryopreserved cell stocks 
Cryopreserved cells stored in liquid nitrogen at -196 °C were thawed in a 37 
°C water bath for 2-3 min and the cryovials were disinfected with 70% (v/v) 
ethanol before transferring the cells to a 15 ml capped tube containing 9 ml 
culture medium. The cells were centrifuged at 1500 rpm for 5 min and the 
supernatant was aspirated off and the pelleted cells resuspended in 10 ml 
culture medium. After that, NHDF and/or HDMEC were transferred into 10 
cm gelatin coated dish whereas the cancer cell types (A375, SKMel5 and 
A2780) were transferred to a non-gelatinized T75 cm2 flask.  
2.2.1.4    Routine cell culture 
Cells were grown at 37 °C for 2-3 days until the confluence reached 80-90%, 
the cells were then split to the next passage. Medium was aspirated and cells 
were washed with 10 ml Versene (DPBS without Ca
2+
/Mg
2+
) before adding 
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1 ml of 0.05% Trypsin-EDTA. Cells were incubated at 37 °C for 3-5 
minutes, after which, dishes/flasks were tapped gently to aid cell detachment. 
90-100% of cells will have detached, which can be viewed under an inverted 
light microscope. Cells were re-suspended with appropriate cell culture 
medium and re-seeded in the splitting ratio as described in Table 2.5. Finally, 
the resistant cancer cell lines (A2780-Cis, A2780-ADR, A375 R and SKMel5 
R) were treated cisplatin, doxorubicin and vemurafenib (PLX4720) 
respectively at an appropriate concentration to maintain their phenotypic 
resistance. 
Table 2.5 Cell splitting ratio 
Cell type Culture medium Splitti
ng 
ratio 
HDMEC EBM MV2 growth medium. 1:5 
NHDF Fibroblast growth medium 1:5 
HeLa 
D-MEM containing 10% (v/v) 
FBS. 
1:5 
A2780 RPMI containing 10% (v/v) FBS 1:18 
A2780-
CP70 
RPMI containing 10% (v/v) FBS 1:10 
A278 -
ADR 
RPMI containing 10% (v/v) FBS 1:8 
375 RPMI containing 10% (v/v) FBS 1:8 
A375-R RPMI containing 10% (v/v) FBS 1:10 
SKMel 5 RPMI containing 10% (v/v) FBS 1:5 
SKMel 5-
R 
RPMI containing 10% (v/v) FBS 1:6 
 
2.2.1.5    Cell Counting 
Cells were counted to ensure an accurate number of cells for each 
experiment. As described in section 2.2.1.4, cells were trypsinised in 1 ml 
trypsin to detach from the dish/flask and re-suspended in 7 ml of appropriate 
cell culture medium after incubated the trypsinised cells for 3 min. 
Approximately 100 µL of cells were pipetted onto a Neubauer Improved 
haemocytometer (Hecht-Assistant, Sondheim/Rhon, Germany) for counting 
under a light microscope. 
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2.2.2    Cell treatment 
2.2.2.1    Growth factor stimulation of cells 
Prior to stimulation with growth factors, all the cells (HDMEC, NHDF, 
A2780s, A375s and SKMel5) were serum-starved in appropriate low serum 
medium overnight at 37 °C.  The growth factors used can be found in section 
2.1.1. Vascular endothelial growth factor (VEGF) and epidermal growth 
factor (EGF) were the main growth factors utilised in this study to stimulate 
HDMEC and cancer cell lines respectively. Sterile filtered PBS containing 
0.1% (w/v) BSA was used to dilute the growth factors making 100 mg/ml 
stock concentrations which were stored in aliquots at -80 °C. For 
experimental use, growth factors were diluted with low serum medium to 50 
ng/ml final concentrations and incubated for different periods of time. 
2.2.2.2    Intracellular kinase inhibition using small-molecule inhibitors 
The small molecule kinase inhibitors used in the experiments, BIX 02189, 
XMD8-92, TRAMETINIB and lapatinib, were diluted in sterile dimethyl 
sulphoxide (DMSO) to stock solutions of 50 mM, 30 mM, 10 mM and 30 
mM respectively and stored in aliquots at -80 °C. The inhibitors were diluted 
in appropriate low-serum media to give 0.1% (v/v) final concentration of 
DMSO in each condition. In control experiments, 0.1% (v/v) DMSO in 
appropriate low serum was added as a vehicle control. Prior to stimulation of 
cells with growth factors (section 2.2.2.1) and cell lysis (section 2.2.2.4), cells 
were incubated with inhibitors for one hour at 37 °C.  
2.2.2.3    Anti-cancer drugs 
The anti-cancer drugs used in this study, cisplatin, adriamycin (doxorubicin) 
and PLX4720, were diluted in DMSO into stock solutions of 1 mM, 30 mM 
and 50 mM respectively and stored in aliquots at -80 °C. For experimental 
use, the drugs were diluted in appropriate cell culture medium containing 
10% FCS to result in 0.1% (v/v) final concentration of DMSO in each case. 
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Cells were incubated with different concentrations of anti-cancer drugs for 
24h or 48h prior to cell lysis (section 2.2.2.4). 
2.2.2.4    Cell lysis 
Unless otherwise stated in the text, cell lysates were prepared by placing cell 
culture plates on ice and then washing cells with ice-cold PBS (Table 2.4). 
After that, modified radio immunoprecipitation assay (RIPA) buffer, 20 mM 
Tris-HCl; pH 7.5, 150 mM NaCl, 2.5 mM EDTA, 10% (v/v) glycerol, 1% 
Triton-X-100, 1 mM Na3VO4, 10 µg/mL Aprotinin, 10 µg/mL leupeptin, 
10 µg/mL pepstatin, 1 mM PMSF, 0.1% (w/v) SDS and 0.5% (w/v) sodium 
deoxycholate, was added to generate the lysates for Western immunoblotting 
and then the lysed cells were scraped and transferred into centrifuge tubes 
and the cell debris cleared by centrifugation at 14000 rpm for 20 min. The 
supernatant was transferred to fresh centrifuge tubes and mixed with 1/3 
volume of 4x LDS. Protein samples were then boiled at 90 °C for 5 min and 
vortexed and finally frozen at -80 °C prior to use in Western immunoblotting. 
2.2.3    RNA extraction 
The RNA extraction process was carried out on a clean bench using RNase 
free filter tips and RNase free water. To minimize RNA degradation, RNA 
samples were kept on ice all the time. The RNA was extracted from the cells 
using an RNeasy mini kit (Qiagen. UK).  
The cells were washed with PBS (without Ca
2+
/Mg
2+
) and 600 µl of RLT 
buffer containing 1% (v/v) 2-mercaptoethanol was added to each 10 cm dish. 
Cells were collected by scraping in RLT buffer and the lysates were 
transferred to QIAshredder spin column and centrifuged for 2 min at 15000 
rpm. Samples were transferred into RNeasy mini column and spun at 15000 
rpm for 30 seconds and then the flow through was discarded. RNeasy mini 
columns were washed with 350 µl of RW1 and centrifuged at 15000 rpm for 
30 sec, the flow-through was discarded. To eliminate genomic DNA 
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contamination, on-column DNase digestion was applied by adding 80 µl of 
DNase 1 solution to the column membrane of each RNeasy mini column and 
incubated for 15 min at room temperature to ensure complete digestion of any 
contaminating genomic DNA. Each membrane was washed by adding 350 µl 
of RW1, spun at 15000 rpm for 30 sec and flow through discarded. Each 
RNeasy mini column was washed with 500 µl of RPE and centrifuged for 2 
min at 15000 rpm. The RNeasy columns were transferred to new centrifuge 
tubes and 30 µl of RNase free water was added to each column membrane to 
elute total RNA. The RNA quality was assessed using a Nano drop ND-1000 
spectrophotometer (Laptech international, Lewes, UK). A 260/280 ratio > 2.0 
was required to confirm RNA purity. 
2.2.4    Reverse transcription of mRNA (cDNA synthesis) 
The reverse transcription reaction procedure was carried out in sterile, RNase 
and DNase free PCR tubes. In each tube, 1 µl of total RNA was mixed with 1 
µl oligo d (T)18 (Invitrogen Custom primer, 500 µg/ml), 1 µl dNTP mix 
(10mM, Invitrogen) and nuclease free water to give a final reaction volume 
of 12 µl. The reaction was mixed by pipetting gently, tubes were heated to 65 
ºC for five minutes using a PCH-1 heating unit and placed on ice to cool. A 
master mix containing 4 µl of 5x first strand buffer, 2 µl 0.1 M DTT, 1 µl 
RNaseOUT and 1 µl M-MLV Reverse Transcriptase (Invitrogen) was 
prepared and 8 µl of this master mix was added to each tube and incubated at 
25 ºC for 5 min followed by a further 37 ºC for 60 min and finally by 15 min 
at 70 ºC to inactive the reaction. At the end, samples were diluted with 130 µl 
of ddH2O to give a cDNA concentration of 6.7ng/µl. 
2.2.5    Real Time PCR 
RT-PCR reaction mixtures contained 1.5 µl (10 ng) cDNA template, 6.7ng/μl 
sterile nuclease free ddH2O, 10 µl 2x Power SYBR Green Mastermix 
(Applied Biosystem), a highly specific dye SYBR Green that fluoresces when 
bound to dsDNA, and 2 µl of each of the forward and reverse primers at 250 
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nM in a final volume of 20 µl for each reaction. All the RT-PCR reactions 
were mixed by vortexing and then loaded into a 96-well PCR plate, which 
was then sealed with optically clear sealing film. Thereafter, the plate was run 
on an ABI 7000 PCR system (Applied Biosystem, CA, USA) with the 
following parameters; 50˚C for two minutes and 95˚C for 10 minutes, 
followed by 40 cycles of 95˚C for 15 seconds and 60˚C for one minute. 
2.2.5.1    Interpreting RT-PCR results 
The relative expression of the gene of interest was determined by using the 
comparative cycle threshold (Ct) method. The mean and the standard 
deviation (SD) of three replicate samples were calculated for the first stage.  
Secondly, the Ct value of the target gene was subtracted from the Ct value of 
the reference gene, a housekeeping gene such as GAPDH or β-Actin, to 
calculate the ∆Ct for each sample as shown in the equation below: 
∆Ct= Ct target gene – Ct reference gene 
Thirdly, the standard deviation of ∆Ct value was calculated from the 
standard deviation for the target and reference gene Ct values, as shown 
below: 
(s=standard deviation) 
s1= standard deviation of reference gene Ct values s2= standard deviation of 
target gene Ct values s(∆Ct)=(s1
2
+s2
2
)
1/2
 
In the fourth stage, the ∆∆Ct value was calculated by subtracting ∆Ct of the 
stimulated samples from the ∆Ct of the basal samples as shown below: 
∆∆Ct=∆Ct stimulated samples - ∆Ct basal samples. 
Finally the range in fold increase was calculated as follows using this 
equation: 
2-(∆∆Ct+2) to 2-(∆∆Ct-s) 
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2.2.6    Cell viability assay 
As mentioned in 2.2.6, a Cell-Titre Glo® luminescent cell viability kit 
(Promega, UK) was used to determine the viable cells in culture based on the 
quantification of ATP. Cells were seeded at 5000 per well in a 96-well plate 
in appropriate cell culture medium and incubated at 37 ºC for 24 hours. After 
incubation, the cells were treated with inhibitors, growth factors and/or anti-
cancer drugs in an appropriate cell culture medium and incubated for 72 
hours at 37 ºC. Cells were washed twice with PBS and 100 µl of PBS was 
added to each well followed by 25 µl Cell-Titre Glo mix and incubated for 10 
minutes at room temperature on the shaker. After that, 100 µl of lysate was 
transferred to a white 96-well plate and luminescence was measured using a 
Varioskan plate reader. Finally Graph Pad Prism 5 software (Graph Pad 
Prism software, Inc. San Diego, CA) was used to determine and analyze an 
IC50 for each cell type and condition.  
 
2.2.7    Western Blotting 
2.2.7.1    Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
SDS-PAGE was accomplished using two methods, the first was pre-cast 15-
well NuPAGE® Novex® 4-12% Bis-Tris polyacrylamide gels in the XCell 
SureLock™ Mini-cell electrophoresis system, with 800 ml 1x MOPS running 
buffer (0.05 M MOPS, 0.05 M Tris, 1 mM EDTA, 0.1% (v/v) SDS). The 
second type was self-cast, made in XCell SureLock™ Mini-Cell, XCell II™ 
Blot Module, 1.5 mm (Invitrogen, UK). The desired acrylamide gel 
percentage was prepared as shown in Table 2.6 with 800 ml 1x SDS running 
buffer (25 mM Tris base, 0.192 M glycine, 0.1% (w/v) SDS, pH 8.3 was 
prepared as a 10X stock solution and diluted 1:10 in ddH2O prior to use. To 
ensure an even edge to the top of the gel and remove air bubbles, 1 ml of 
isopropanol was overlaid on top of the gel and allowed to polymerise for 45 
min at room temperature. After 45 min, the isopropanol was poured off and 
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the stacking gel (Table 2.6) was added to a 15-well plate. A 1.5 mm comb 
was inserted into the top cassette and the stacking gel allowed polymerising 
for 45 min. 
One or two gels (pre-cast or self-cast) were loaded in the Mini-Cell running 
unit and placed into the tank and secured by locking the tension wedge. The 
combs were removed and rinsed with running buffer to eliminate any un-
polymerised acrylamide. Up to 25µl of protein lysates in LDS was loaded 
into each well with 2 µl of full range rainbow marker that added to 23 µl 1X 
LDS sample buffer and loaded into the first well of each SDS-PAGE gel. 
Then, the running buffer was poured into the tank and the lid was placed on 
to the running unit. Finally, the apparatus was connected to power supply to 
run the gels at constant current of 50 mA, 250 V, 15 W for MOPS and 35 
mA, 125 V, 15 W for Tris-Glycine for up to 2 hours. 
Thereafter, the plastic cassettes containing the electrophoresed gels were 
opened after disassembling the Mini-Cell. The stacking gel was removed and 
the resolving gel soaked in 25 ml 1X Tris-Glycine transfer buffer (12 mM 
Tris, 96 mM Glycine, 20% (v/v) Methanol) before transfer.  
Table 2.6 Composition of SDS-PAGE gels 
 
Mini Gel 
 
Units 
 
Stacker 
Running Gel 
   5% 6% 7% 8% 10% 12% 15% 
30% acrylamide/0.8%Bis ml 0.7 1.7 2.0 2.3 2.7 3.3 4.0 5.0 
2.0M Tris/HCl pH8.8 ml - 2.0 2.0 2.0 2.0 2.0 2.0 2.0 
0.5M Tris/HCl pH6.8 ml 0.7        
87% Glycerol ml - 0.7 0.7 0.7 0.7 0.7 0.7 0.7 
dH2O ml 3.6 5.6 5.3 5.0 4.6 4.0 3.3 2.3 
Total Volume ml 5 10 10 10 10 10 10 10 
10%APS µl 2.5 22.9 22.9 22.9 22.9 22.9 22.9 22.9 
TEMED µl 5 5 5 5 5 5 5 5 
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2.2.7.2   Western Blot analysis  
Proteins resolved by SDS-PAGE or Phos-tag™ SDS-PAGE were transferred 
onto Hybond-ECL nitrocellulose membrane in 1X transfer buffer. In the 
transfer unit, the electrophoresed gel along with nitrocellulose membrane, 
measuring 7.5 cm x 8.5 cm, was sandwiched between two pre-soaked 
sponges and filter papers, measuring 7.5 cm x 8.5 cm. The blotting chamber 
was filled with 1X transfer buffer and the rest of tank with cold dH2O and 
then the lid was placed on top. Finally, the apparatus was connected to power 
supply to run at constant current of 140 mA, 250 V, 15 W for MOPS and 125 
mA, 300 V, 15 W for Tris-Glycine for up to 2 hours. 
After protein transfer, the nitrocellulose membrane was washed with 1X 
TBS-T to remove methanol. The membrane was blocked in 5% (w/v) Bovine 
Serum Albumin (BSA) in TBS-T and incubated at room temperature for 1 
hour to block non-specific binding sites. After that, the membrane was 
incubated with appropriate primary antibody diluted in 2% (w/v) BSA in 
TBS-T at 4 ºC overnight. The membrane was then washed six times with 1X 
TBS-T prior to incubation with appropriate horseradish peroxidase (HRP) - 
linked secondary antibody diluted in 2% (w/v) BSA in TBS-T at 4 ºC for 90 
minutes. Following incubation with secondary antibody, the membrane was 
washed 5 times with 1X TBS-T followed by a wash with TBS before 
incubating the membrane with a 1:1 solution of enhanced chemiluminescence 
(ECL) reagent 1 and reagent 2 at room temperature for 2-4 minutes. The 
membrane was then sealed in a plastic wallet within an X-ray film cassette 
before transfer to a dark room to expose the membrane to X-rays for different 
times. Films were soaked in developing and fixing solution for 1 minute 
before drying. 
2.2.7.3   Quantification of protein expression by densitometry 
The relative amount of specific proteins was determined by quantifying the 
immune reactive bands detected on X-ray film. The X-ray films were scanned 
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using an Epson® 4490 photo scanner and the Densitometric analysis was 
accomplished using ImageJ (National Institute of Health (NIH), Version 
1.47n). Actin or GAPDH were used as a loading control. 
2.2.8   3-D collagen matrix tube formation assay 
This assay was utilised to induce the tubular morphogenesis process by 
placing endothelial cells between two layers of collagen gels and exposing 
these cells to appropriate growth factors. 
Under sterile conditions and on ice, the lower layer of collagen mixture, 8 
parts PureCol™ type I collagen (final concentration 2.4 mg/ml), 1 part 
sterile-filtered 0.1 M NaOH (final concentration 10 mM), 1 part X10 conc. 
Ham's F-12 medium without L-glutamine or sodium bicarbonate, 1:50 
dilution of HEPES buffer solution (1 M) (final concentration 20 mM), 1:64 
dilution of sodium bicarbonate (7.5%) liquid (final concentration 0.117%), 
1:100 dilution of GlutaMAX™-I supplement (200 mM) (final concentration 2 
mM) was prepared and mixed gently prior adding 300 µl of collagen mix to 
each well of 24-well plate and incubating at 37 ºC for overnight allowing 
collagen to set. After incubation, 0.5 ml of EBM MV2 basal medium was 
added to each well to facilitate HDMEC adhesion to the collagen layer. 
HDMECs which had been placed in EBM MV2 basal medium containing 1% 
FCS overnight prior to seeding, were added to each well of 24-well plate at 
90,000 cells/well in EBM MV2 basal medium containing 1% FCS and 
incubated at 37 ºC for 2 hours to allow cellular attachment. The cells were 
investigated under an inverted light microscope to confirm cell adhesion to 
the lower layer. Once the cells had adhered, media was aspirated off and 2
nd
 
collagen layer added (200 μl) and the plate incubated at 37 ºC for 1.5-2 hours 
allowing the upper collagen layer to set. After incubation, 0.5 ml of EBM 
MV2 basal medium with 1% FCS containing 2X appropriate growth factors 
and/or inhibitors was added gently without disturbing the upper collagen 
layer to each well and incubated at 37 ºC for 16-24 hours. Following the 
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tubular morphogenesis assay, media was aspirated and the cells were fixed by 
adding 0.5 ml of 4% (w/v) paraformaldehyde in PBS to each well. 
2.2.8.1    Visualisation and quantification of tubes within 3D-collagen gels 
 The tubular morphogenesis assay was imaged using an inverted light 
microscope attached to a Nikon DS-Fil-L2 digital camera (Nikon, UK). 
Tubes were defined as structures containing a number of fused cells counted 
in three randomly chosen fields to each well from triplicate condition. For 
image quantification, AngioQuant image analysis software was used.  
2.2.9    NHDF/HDMEC co-culture in vitro angiogenesis assay 
2.2.9.1    Normal NHDF/HDMEC -/+ cancer cells co-culture 
On day 1, NHDFs were seeded at 20,000 cells per well in a gelatine-coated 
24-well plate in 1 ml fibroblast growth medium and incubated at 37 ºC for 3 
days. On day 4 after ensuring that the NHDF had grown to confluence, the 
NHDF layer was washed once with PBS and then HDMECs were seeded at 
45,000 cells per well in 0.5 ml of EBM MV2 growth medium and incubated 
for 24 hours. After incubation for 24 hours, cells were washed with PBS and 
0.5 ml of EBM MV2 basal medium with 1% FCS containing growth factors 
and/or inhibitors were added to each well and the plate was returned to the 
incubator for 72 hours. On day 8, media was aspirated off and replaced with 
fresh EBM MV2 basal media containing 1% FCS and growth factors -/+ 
inhibitors and returned to the incubator for a further two days. On day 10, 
media was removed from the wells and the co-culture was washed twice with 
PBS and then fixed in 1 ml of ice-cold 70% (v/v) ethanol per well and 
incubated at room temperature for 30 minutes. 
In the case of cancer cell co-culture, appropriate densities of cancer cells 
(Table 2.7) were seeded in 0.5 ml of appropriate cell culture medium on top 
of the NHDF layer and mixed gently on day three and incubated for 24 hours. 
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2.2.9.2    Inhibition of co-culture assay with MEK5 and ERK5 inhibitors 
at different times 
To assess the functional effects of BIX02189 and XMD8-92 in angiogenesis, 
the NHDF/HDMEC -/+ cancer cells co-culture assay was treated with these 
inhibitors and fixed at different times. As described above (2.2.9.1), NHDFs 
were plated on the first day and incubated for 3 days. On day 3, cancer cells 
were added to the NHDF monolayer and incubated for 24 hours. One day 
prior to seeding HDMECs on the co-culture, HDMECs growing on 10 cm 
gelatine-coated dishes were treated with BIX02189 and XMD8-92 and 
incubated for 24 hours at 37 ºC. On day 4 of the assay, HDMECs treated with 
inhibitors were seeded at 45,000 cells per well in 0.5 ml EBM MV2 growth 
medium and incubated for 24 hours. On the fifth day, the NDHF/HDMEC -/+ 
cancer cells co-culture was treated with inhibitors -/+ VEGF (50 ng/ml) in 0.5 
ml EBM MV2 growth medium containing 1% FCS after the cells were 
washed with PBS and incubated for two days. On day 7, cells were fixed as 
described above (2.2.9.1). In certain experiments, the treated HDMECs with 
Table 2.7 Cell density for co-culture of cancer cells 
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BIX02189 and XMD8-92 were seeded on the co-culture on day 7 and 
incubated for 24 hours in EBM MV2 growth medium. After that, the co-
culture was treated with BIX02189 and XMD8-92 -/+ VEGF in EBM MV2 
containing 1% FCS and incubated for 24 hours on day 8. Cells were fixed in 
1 ml of ice-cold 70% (v/v) ethanol per well and incubated at room 
temperature for 30 minutes on day 10. 
2.2.9.3    Staining of HDMECs in NHDF/HDMEC -/+ cancer cells co-
culture 
After fixing the co-culture for 30 min in ice-cold ethanol 70%, the ethanol 
was tipped off and the plate was blotted on blue roll to remove residual 
ethanol. One millilitre of blocking buffer (1% BSA in PBS w/v) was added to 
each well and incubated at 37 ºC for 30 min. After incubation, the blocking 
buffer was poured off and the plate was blotted on the blue roll and then 200 
µl of Monoclonal Mouse Anti-Human CD31, Endothelial Cell Clone JC70A 
Antibody (Dako Cytomation, Glostrup, Denmark) antibody diluted in 
blocking buffer (1:750) was added to each well and incubated at 37 ºC for 60 
minutes. The primary antibody solutions were tipped off and the plate was 
washed with 1 ml blocking buffer three times. For colorimetric assay, 250 µl 
of Anti-mouse IgG (whole molecule) alkaline phosphatase conjugate 
antibody was added in blocking buffer (diluted 1:200) to each well and 
incubated for 1 hour. After secondary antibody incubation, the plate was 
washed 3 times with distilled water after aspirating the secondary antibody 
from the plate. 250 µl of substrate (1 SIGMA Fast BCIP/NBT tablet per 10 
ml dH2O) was added to each well and incubated for 10 min at 37 ºC to form 
a purple colour precipitate in tubule-containing wells. The substrate solution 
was removed and dH2O added to each well for 5 minutes. The dH2O was 
aspirated and this procedure repeated 3 times. 
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2.2.9.4    Immunofluorescence staining of HDMEC/NHDF/HeLa co-
culture assay 
Cell culture was fixed in 2% paraformaldehyde (PFA)/PBS for minutes at RT 
on day 10. 500 microliters of DPBS containing 0.2% (v/v) Triton-X-100 was 
added per well and the plates were incubated at room temperature for 10 min. 
After that, the plates were blocked in TBS containing 0.1% Tween-20 and 
1% BSA and 5% serum (from animal source of 2° antibody) for 1 hour at 
room temperature. A 1:750 dilution of monoclonal mouse anti-human CD31, 
endothelial cell clone JC70A antibody, 1:100 Rabbit anti-human collagen-1 
antibody and 1:50 mouse anti-human muc16 antibody in 1% BSA in TBST 
for 1 hour at RT. Alexa  Fluor®   488  conjugate, 568 and 680  were  
prepared  in antibody  dilution  buffer  1%  BSA  in  TBST.  50 microliters of 
the antibody dilution was added to each well, and plates were incubated at RT 
for 1 hour in the dark. 20μl of Hoechst was added to each well in dilution 
1:5000 in 1% BSA in TBST and incubated for 10 min at RT. After that, each 
well was washed twice in TBST. Then plates were analysed using an inverted 
Zeiss Axio Observer microscope and the associated Zen software. 
2.2.9.5    Image analysis and quantification of tube formation in 
NHDF/HDMEC -/+ co-culture  
Tube formation in co-culture was analysed by taking three random images in 
different fields from triplicate wells per condition. The co-culture assay was 
examined by using an inverted light microscope attached to a Nikon DS-Fil-
L2 digital camera and the low magnification (X4 objective). For image 
quantification, AngioQuant image analysis software was used.  
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2.2.10    Statistical analysis 
Data are presented as means ± SD. IC50s and densitometric values from cell 
viability assays and western blot experiments respectively that had been 
repeated 3 times or more were subjected to statistical analysis. Data analysis 
for IC50s was performed using GraphPad Prism (GraphPad software Inc. San 
Diego, CA) while ImageJ software was utilised to analyse for densitometry to 
quantify the level of signal from western blotting images. Two-tailed 
unpaired Student’s t-test was used to compare the means of two independent 
groups. In all cases, differences with p values less than 0.05 were considered 
as significantly different. 
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3.1    Introduction 
MEK5 and ERK5 proteins are expressed in different tissues and cell lines 
(Zhou et al., 1995, Buschbeck and Ullrich, 2005). ERK5 is involved in 
various cellular functions including cell proliferation, differentiation, 
adhesion, migration and survival (Kato et al., 1998a, Wang and Tournier, 
2006, Sawhney et al., 2009). Furthermore, ERK5 has been implicated in 
progression of some diseases such as cancer, ischemia and cardiac 
hypertrophy (Wang and Tournier, 2006, Takeishi et al., 2002, Montero et al., 
2009b). Targeted deletion of erk5 (Regan et al., 2002b, Yan et al., 2003), 
mek5 (Wang et al., 2005) or mekk3 (Yang et al., 2000) in mice results in 
death around E9.5-11.5 due to severe defects in vasculature revealed the 
importance of the ERK5 signalling pathway. Notably, developmental defects 
due to global erk5 knockout in mice was also revealed in endothelial-specific 
deleted erk5 in mice, but not in other cell types such as cardiomyocytes and 
hepatocytes revealing the significant role of ERK5 in endothelial cell 
function (Hayashi et al., 2004b, Hayashi and Lee, 2004, Roberts et al., 2009). 
However, the heterogeneity of endothelial cells rising from different vascular 
beds resulted in a little useful information regarding study the role of 
interesting protein in angiogenesis by using large-vessel endothelial cells 
such as HUVEC (Conway and Carmeliet, 2004). Angiogenesis is a process 
confined to microvasculature. Thus, in vitro study of microvascular 
endothelial cells gives appropriate representation of physiological events 
during angiogenesis in vivo (Cines et al., 1998, Hewett, 2009).  
ERK5 is activated in response to pro-angiogenic growth factors VEGF, EGF 
and FGF-2 in HUVEC and has a potential role in mediating growth factor-
stimulated angiogenesis (Hayashi et al., 2004a). Previous work in the group 
has shown that ERK5 plays an important role in HDMEC via regulating 
VEGF-mediated AKT phosphorylation and inhibiting apoptosis to facilitate 
tubular morphogenesis in cells (Roberts et al., 2010c). In the context of 
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tumour development, ERK5 has been implicated in tumour angiogenesis and 
integrity of vascularisation during development (Hayashi et al., 2005a). Over 
expression of ERK5 has implicated in tumourigenesis in many cancers, 
increased activation of ERK5 in oral squamous cell carcinoma is associated 
with advanced tumour stage (Sticht et al., 2008). ERK5 over-expression 
correlated with decreased disease-free survival in breast cancer and 
furthermore, MEK5 over-expression in prostate cancer is associated with 
bone metastases, poor survival and invasion (Montero et al., 2009a, Mehta et 
al., 2003b). In addition, high levels of ERK5 are involved in the development 
and progression of hepatocellular carcinoma (HCC) (Zen et al., 2009). 
This chapter describes experiments performed in order to characterise ERK5 
activation in both HDMEC and HeLa cells to analyse the role of ERK5 in 
tumour angiogenesis by utilising an in vitro model that is more representative 
of in vivo angiogenesis. Small molecule inhibitors of the MEK5/ERK5 
signalling pathway (BIX02189 and XMD8-92) and other intracellular 
signalling molecules were used to define potential regulators and effectors of 
ERK5. Specifically, the effect of these inhibitors on angiogenesis in 
NHDF/HDMEC/HeLa co-culture was assessed to determine whether ERK5 
represents a potential therapeutic target for tumour angiogenesis. 
 
3.2    Characterisation of ERK5 activation 
3.2.1    ERK5 protein expression in HDMEC and HeLa cells  
Since the discovery of ERK5 in 1995, detection of ERK5 activation mostly 
involved protein separation by SDS-PAGE on an 8% acrylamide gel followed 
by western blotting using a polyclonal anti-BMK1/ERK5 antibody. During 
SDS-PAGE, phosphorylated ERK5 displays reduced electrophoretic 
mobility, thus migrating slower than the non-phosphorylated form of ERK5 
resulting in a bandshift with the appearance of a separated band above the 
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main ERK5 protein band (Abe et al., 1996, Abe et al., 1997, Duff et al., 
1995). This bandshift assay was used to confirm ERK5 activation. Since 
VEGF had been reported to induce ERK5 activation in HUVECs and 
MLCECs and EGF triggered ERK5 activation in HeLa cells, these agonists 
were used to determine the activation of ERK5 in HDMEC and HeLa cells 
(Hayashi et al., 2004a, Kato et al., 1998a, Esparis-Ogando et al., 2002b). 
Furthermore, the activation of ERK1/2 by VEGF in various endothelial cells 
and EGF in HeLa cells were known, thus ERK1/2 phosphorylation was 
assessed to determine whether these growth factors were biologically active 
(Dangelo et al., 1995, Mody et al., 2001b). HDMECs were stimulated or not 
with 50 ng/ml of pro-angiogenic growth factor, vascular endothelial growth 
factor (VEGF) and HeLa cells were also stimulated or not with 50 ng/ml of 
epidermal growth factor (EGF) for 10 min and then cells were lysed with 
RIPA lysis buffer. The total cell lysates were separated on 8% acrylamide 
SDS-PAGE gel. Western blot analysis using anti-ERK5 in EGF-stimulated 
HeLa cells revealed a slower migrating band above the main band at 
approximately 130 kDa suggesting that ERK5 is activated in HeLa cells by 
EGF (Figure 3.1). In contrast, VEGF stimulation of HDMECs did not show a 
mobility bandshift of ERK5 phosphorylation. To analyse this further, 
phosphorylation of Thr
218
/Tyr
220
 residues of the T-E-Y motif located on the 
activation loop of ERK5 was probed with phospho-ERK5 antibody in order 
to detect ERK5 activation. The phosphorylation of ERK5 in HDMECs was 
detected by p-ERK5 antibody and clearly induced upon stimulation via 
VEGF (Figure 3.1). Furthermore, the use of p-ERK5 antibody on HeLa 
lysates confirmed the ERK5 activation results obtained from the mobility 
bandshift assay. VEGF and EGF stimulation resulted in ERK1/2 activation in 
HDMECs and HeLa cells suggesting that these growth factors are 
biologically active in these cells (Figure 3.1). Individual quantification of the 
stimulated upper p-ERK5 mobility bands were compared to an arbitrary value 
of 1.0 set for p-ERK5 bands in the basal condition. 
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Western blotting showed that ERK5 is activated in HDMECs and HeLa cells 
in response to VEGF and EGF respectively. In order to analyse this further 
the mRNA expression of VEGFR-2, EGFR-1, MEK5 and ERK5 in HDMECs 
and HeLa was also analysed by qRT-PCR. The VEGFR2 mRNA was highly 
expressed in HDMECs by 8000-fold increase compared to HeLa cells while 
in contrast; EGFR-1 expression was highly increased in cancer cells (HeLa) 
by a 45-fold increase. The expression of MEK5 and ERK5 genes in cancer 
cells, represented here by HeLa cells was higher in comparison with 
HDMECs (Figure 3.2). 
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Figure 3.1 Characterisation of ERK5 activation in HDMECs and HeLa cells. HDMECs 
and HeLa cells were seeded on 12-well plates for 24 h, prior to overnight serum starvation. 
Cells were stimulated with 50ng/mL of VEGF and EGF for 10 min, followed by RIPA lysis. 
Protein lysates from HDMECs and HeLa cells were resolved on an 8% acrylamide gel, 
followed by Western blotting (WB) with antibodies against ERK5, p-ERK1/2, p-VEGFR, p-
EGFR and actin as a loading control. Densitometric analysis of protein phosphorylation is 
relative to the basal control condition. The basal control condition was set arbitrarily as 1.0. 
This result is representative of three independent experiments (*p<0.05). 
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Figure 3.2 Analysis of gene expressions by qRT-PCR. The bar charts show RT-PCR 
analysis for VEGFR-2, EGFR-1, MEK5 and ERK5 mRNA level in HDMECs and HeLa 
cells. RNA of these cells was extracted and cDNA prepared. Data were analysed by the ∆∆Ct 
value method and the expression was normalized to β-actin expression and illustrated as fold 
change. 
 
3.3    Small-molecule kinase inhibitors  
BIX02189 (Tatake et al., 2008) and XMD8-92 (Yang et al., 2010c) are two 
small-molecule kinase inhibitors used for blocking the activation of MEK5 
and ERK5 respectively. BIX02189 selectively inhibits MEK5 over MEK1/2 
whereas XMD8-92 inhibits EGF stimulated ERK5 activation (Tatake et al., 
2008, Yang et al., 2010b). These two inhibitors were validated by dose 
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response experiments conducted in HDMECs and HeLa cells to assess the 
effect on intracellular signalling pathways.  
3.3.1    ERK5 activation was inhibited in response to XMD8-92 
In HeLa cells, EGF-stimulation resulted in increased ERK5 activation 
compared to non-stimulated cells (Figure 3.3). Adding 0.1 μM XMD8-92 and 
subsequent doses 0.3 μM, 1 μM and 3 μM appeared to gradually decrease the 
phosphorylation of ERK5 in comparison with basal or 0.1% DMSO control. 
In addition 10 μM and 30 μM concentrations were able to reduce the 
activation of ERK5 to the level of the unstimulated control condition (Figure 
3.3). The phosphorylation of AKT and ERK1/2 appeared unaffected by any 
concentration of XMD8-92. Also, EGF-mediated ERK5phosphorylation was 
not inhibited by XMD8-92 even at higher concentration 30 μM.  
In HDMECs, stimulation with VEGF increased ERK5 activation in 
comparison with unstimulated cells (Figure 3.4). The addition of XMD8-92 
displayed marginal reduction at 0.3 μM and 1 μM increasing from 3 μM up to 
30 μM which nearly reached the level of ERK5 phosphorylation in basal or 
0.1% DMSO untreated controls (Figure 3.4). The activation of AKT was 
slightly increased from the untreated condition to XMD8-92-treated condition 
at a concentration of 3 μM and then decreased with high concentrations back 
to control levels. The addition of XMD8-92 to HDMECs did not affect the 
phosphorylation of ERK1/2 whereas VEGF-mediated ERK5 phosphorylation 
was slightly inhibited at 30 μM compared to basal control (Figure 3.4). 
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Figure 3.3 XMD8-92 dose responses in HeLa cells. HeLa cells were plated on 12-well 
plates for 48 h prior to overnight serum starvation. Cells were then pre-incubated with 0.1 
µM, 0.3 µM, 1 µM, 3 µM, 10 µM and 30 µM XMD8-92 or 0.1% DMSO for 1 h, prior to 
EGF stimulation (50ng/mL) for 10 min and RIPA lysis. Proteins were separated on an 8% 
acrylamide gel followed by incubating with antibodies against p-EGFR, ERK5, p-AKT, p-
ERK1/2 and Actin for western blotting (WB). Densitometric analysis of protein 
phosphorylation or protein expression relative to the basal control condition (set arbitrarily as 
1.0).This result is representative of three independent experiments (*p<0.05) related to 
untreated cells. 
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Figure 3.4 XMD8-92 dose responses in HDMECs. HDMECs were plated on 12-well plates 
for 48 h prior to overnight serum starvation. Cells were then pre-incubated with 0.1 µM, 0.3 
µM, 1 µM, 3 µM, 10 µM and 30 µM XMD8-92 or 0.1% DMSO for 1 h, prior to VEGF 
stimulation (50ng/mL) for 10 min and RIPA lysis. Proteins were separated on an 8% 
acrylamide gel followed by incubating with antibodies against p-VEGFR2, ERK5, p-AKT, 
p-ERK1/2 and Actin for western blotting (WB). Densitometric analysis of protein 
phosphorylation or protein expression relative to the basal control condition (set arbitrarily as 
1.0).This result is representative of three independent experiments. 
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3.3.2    BIX02189 inhibits ERK5 activation 
In HeLa cells, stimulation with 50ng/ml EGF resulted in more than a 3-fold 
increase in ERK5 phosphorylation compared to unstimulated basal and 0.1% 
DMSO controls (Figure 3.5). The addition of 0.1 μM, 0.3 μM and 1 μM 
BIX02189 appeared to decrease the activation of ERK5 in comparison with 
EGF-stimulated basal or 0.1% DMSO controls while 3 μM, 10 μM and 30 
μM concentrations of BIX02189 reduced the phosphorylation of ERK5 to the 
unstimulated basal level (Figure 3.5). Phosphorylation of EGFR and ERK1/2 
did not appear to be effected at any concentration of BIX02189, while 
activation of AKT appeared to be slightly increased at 3 μM and reached 7-
fold increase at 30 μM compared to EGF-stimulated basal (Figure 3.5).  
In HDMECs, VEGF-stimulation produced an increase in ERK5 activation 
compared to unstimulated cells (Figure 3.6). Treatment with BIX02189 
decreased the phosphorylation of ERK5 in comparison with stimulated basal 
or 0.1% DMSO controls detected by Thr
218
/Tyr
220
 specific p-ERK5 antibody 
(Figure 3.6). Phosphorylation of VEGFR2 was reduced at 0.1 μM BIX02189 
and started to gradually increase at 1 μM until it reached 3-fold increase at 30 
μM compared to the stimulated control suggesting that MEK5 may play a 
negative regulation role in VEGFR2 signalling. ERK1/2 activation was not 
affected by BIX02189 concentrations up to 10 μM; however activation of 
ERK1/2 was inhibited at 30 μM reducing the level to that in the unstimulated 
BIX02189-treated control and that could relate to the potential non-specific 
and toxic effect of this inhibitor at this concentration. BIX02189 did not 
appear to have an effect on the activation of AKT up to 3 μM. However the 
higher concentrations 10 μM and 30 μM decreased the phosphorylation of 
AKT to 1.5 and 2-fold respectively in comparison with stimulated control and 
that could suggest that VEGF-mediated ERK5 activation is required for 
activation of AKT and ERK1/2 (Figure 3.6). 
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These data suggested that 3 μM BIX0218 is sufficient to inhibit the 
MEK5/ERK5 signalling pathway without affecting the parallel ERK1/2 
pathway in HDMEC and HeLa cells. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 3.5 BIX02189 dose responses in HeLa cells. HeLa cells were plated on 12-well 
plates for 48 h prior to overnight serum starvation. Cells were then pre-incubated with 0.1 
µM, 0.3 µM, 1 µM, 3 µM, 10 µM and 30 µM BIX02189 or 0.1% DMSO for 1 h, prior to 
EGF stimulation (50ng/mL) for 10 min and RIPA lysis. Proteins were separated on an 8% 
acrylamide gel followed by incubating with antibodies against p-EGFR, ERK5, p-AKT, p-
ERK1/2 and Actin for western blotting (WB). Densitometric analysis of protein 
phosphorylation or protein expression relative to the basal control condition (set arbitrarily as 
1.0).This result is representative of three independent experiments (*p<0.05, **p<0.01) 
related to untreated cells. 
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Figure 3.6 BIX02189 dose responses in HDMECs. HDMECs were plated on 12-well plates 
for 48 h prior to overnight serum starvation. Cells were then pre-incubated with 0.1 µM, 0.3 
µM, 1 µM, 3 µM, 10 µM and 30 µM BIX02189 or 0.1% DMSO for 1 h, prior to VEGF 
stimulation (50ng/mL) for 10 min and RIPA lysis. Proteins were separated on an 8% 
acrylamide gel followed by incubating with antibodies against p-VEGFR2, ERK5, p-AKT, 
p-ERK1/2 and Actin for western blotting (WB). Densitometric analysis of protein 
phosphorylation or protein expression relative to the basal control condition (set arbitrarily as 
1.0).This result is representative of three independent experiments (*p<0.05) related to 
untreated cells 
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3.4   Assessment of the effect of MEK5 inhibitor BIX02189 
and ERK5 inhibitor XMD8-92 on VEGF-stimulated 
tubular morphogenesis in HDMECs 
Stimulation of endothelial cells with pro-angiogenic growth factors such as 
VEGF and FGF-2, results in tubular morphogenesis to make capillary-like 
structures in a 3-D collagen gel (Montesano et al., 1983, Bohman et al., 
2005). To determine wither growth factor stimulation could trigger tubular 
morphogenesis in HDMECs; endothelial cells were seeded between two 
layers of collagen (section 2.2.9.1) and stimulated with vascular endothelial 
growth factor (VEGF) for 24 hours. HDMECs without stimulation with 
VEGF, failed to form tube-like structure. However, stimulation with VEGF 
induced HDMECs to undergo tubular morphogenesis (Figure 3.7).  
 
The importance of the MEK5/ERK5 signalling pathway in VEGF-mediated 
tubular morphogenesis in endothelial cells was assessed by using different 
concentrations of the kinase inhibitors BIX02189 and XMD8-92 to inhibit 
MEK5 and ERK5 expression respectively. Treatment of HDMECs with 3μM 
XMD8-92 had a profound effect upon VEGF-stimulated tubular 
morphogenesis by decreasing the tubes to the level of unstimulated control. 
Furthermore, even the 1μM, 0.1μM and 0.01μM concentrations produced a 
clear effect on VEGF-induced tubular morphogenesis in HDMECs in 
comparison with the stimulated control (Figure 3.7). Similarly, HDMEC 
treatment with 3μM MEK5 inhibitor (BIX02189) also abolished VEGF-
induced HDMEC tube-like structures over 24 h. Moreover, adding 1μM 
BIX02189 to HDMECs suppressed the formation of tubular morphogenesis 
while 0.1μM and 0.01μM had a marginal effect in comparison with 
stimulated control (Figure 3.7).  
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This data suggested that 3μM of MEK5 and ERK5 inhibitors (BIX02189 and 
XMD8-92 respectively) is able to abolish VEGF-induced tubular 
morphogenesis in HDMECs in 3D collagen gel. Furthermore, these results 
show that ERK5 is required for VEGF-induced HDMEC tubular 
morphogenesis in agreement with previous data by using MEK5 and ERK5 
siRNA (Roberts et al., 2010c). 
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Figure 3.7 MEK5 and ERK5 inhibitors prevent VEGF-stimulated HDMEC tubular 
morphogenesis within 3-D collagen matrix. (A) HDMECs were seeded at 8.25 x 10
5
  cells 
per dish in 10 cm  dishes  in  10  ml  of  EBM  MV2  growth  medium,  and  grown  for  24  
h. Cells  were  serum-starved  in  EBM  MV2  basal  medium containing 1% (v/v) FCS for 
20 h prior to seeding between two layers of collagen I gel at 90,000 cells per well in 24-well 
cell-culture dishes (section 2.2.9.1).  Cells seeded within the collagen I gels were treated with 
the MEK5 inhibitor BIX02189 and the ERK5 inhibitor XMD8-92 at different concentrations 
and incubated for 30 minutes. Cells were then stimulated with EBM MV2 basal medium 
containing 1% (v/v) FCS supplemented with 50ng/ml VEGF and incubated for 16-24 h at 37 
°C. After that time, cells were fixed in 4% paraformaldehyde and visualised by inverted light 
microscope (section 2.2.9.2). (B)The total length of tubular structures was quantified from 
three fields (X 10 objective) per well using AngioQuant image analysis software. *p<0.05; 
**p<0.01; ***p>0.005 
 
3.5    Assessment of the effects of MEK5/ERK5 signalling 
pathway inhibitors (BIX02189, XMD8-92) on tumour 
angiogenesis by using an in vitro endothelial / fibroblast/ 
tumour cell co-culture assay. 
Angiogenesis involves the coordinated proliferation, migration and 
differentiation of endothelial cells to form a lumen containing vessel. This 
process is regulated by a balance between pro- and anti-angiogenic factors 
and when the balance is disrupted, pathological conditions can appear such as 
cancer (Folkman, 1995). Pro-angiogenic factors such as VEGF and bFGF 
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induce the formation of tumour blood vessels (Ferrara et al., 1992, Galzie et 
al., 1997). These growth factors directly bind to the receptor tyrosine kinases 
on the endothelial cell surface and stimulate endothelial cells to release 
proteolytic enzymes that degrade the extracellular proteins, allowing cell 
invasion and metastasis. Thus, inhibiting angiogenesis provided a promising 
strategy for the treatment of solid tumours (Folkman et al., 1971). 
Although the 3-D collagen gel in vitro angiogenesis assay represents the early 
stage of in vivo angiogenesis, a disadvantage of this model is that tubular 
structures usually regress within 48 hours of formation (Montesano et al., 
1983, Bohman et al., 2005, Matsumoto et al., 2002). However, endothelial 
cells in co-culture with fibroblasts undergo differentiation over several days 
to form well-established tube-like structures that remain stable for many days 
after formation and represent the capillary structure in vivo (Montesano et al., 
1993, Bishop et al., 1999, Donovan et al., 2001, Roberts et al., 2010b, 
Richards and Mellor, 2016). Furthermore, endothelial/fibroblast co-culture 
assay is more easily quantified by automated computer analysis than a 3-D 
collagen assay.  
In this experiment, endothelial cells represent key cells involved in 
angiogenesis which are dependent on the interaction with mural cells such as 
fibroblasts. Fibroblasts produce extracellular matrix proteins which provide a 
base to promote endothelial cell migration and facilitate vessel remodelling 
(Staton et al., 2009). The pro-angiogenic growth factors that are released 
from tumour cells, bind to fibroblast and endothelial cells to assist the 
progress of 3-D organisation and tubulogenesis of endothelial cells (Sorrell et 
al., 2007). Therefore, endothelial cells co-cultured with fibroblasts provide a 
more realistic concept to the collagen tubular morphogenesis assay in vitro 
representation of in vivo angiogenesis (Donovan et al., 2001). Optimisation of 
the number of endothelial cells, HDMEC, seeded on the confluent fibroblast, 
NHDF, layers and the length of HDMEC/NHDF assay was conducted 
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previously in our lab. In this study, the image analysis software termed 
‘AngioQuant’ was used for quantification of tubule formation in 
HDMEC/NHDF/HeLa cells. 
3.5.1    BIX02189 and XMD8-92 inhibit tumour cell-induced tube 
formation in a HDMEC/NHDF/HeLa co-culture assay 
To determine the effect of MEK5 and ERK5 inhibitor treatment upon 
angiogenesis of HeLa cells in a HDMECs/NHDF/HeLa co-culture assay, 
HeLa cells were plated on a confluent monolayer of fibroblast cells prior to 
plating endothelial cells (HDMECs) on these layers on day 4 and the co-
culture then treated with 3μM BIX02189 and/or XMD8-92 on day 5 and 8 
and finally fixed on day 10 (as illustrated in Figure 3.8 b). Analysis of 
HDMECs co-cultured with NHDFs revealed that l VEGF stimulated tube-like 
networks compared to unstimulated basal control (Figure 3.8). The addition 
of tumour cells (represented by HeLa cells) to this co-culture induced tube 
formation by increasing the total tube length in comparison with unstimulated 
basal control which supports the ability of tumour cells to trigger networked 
vessels (Figure 3.8). Treatment of the HDMECs/NHDF/HeLa co-culture 
assay with 3μM XMD8-92 on day 5 and 8 of this assay had a notable effect 
upon tube formation by decreasing tube length compared to the untreated 
basal control. Similarly, treatment of this co-culture with a MEK5 inhibitor 
(BIX02189) impaired angiogenesis in this assay by shortening the tube length 
about 2-fold compared to the untreated basal control (Figure 3.8).  
This data revealed that the HeLa cervical carcinoma cells are able to induce 
the tube formation. However, treatment with ERK5 inhibitor (XMD8-92) or 
its upstream MEK5 inhibitor (BIX02189) is able to inhibit the tumour 
angiogenesis. 
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Figure 3.8 Effect of ERK5 and MEK5 inhibitors on tumour angiogenesis in 
HDMECs/NHDF/HeLa co-culture assay. (A) NHDF were seeded in in fibroblast growth 
medium at 20,000 cells per well on gelatine-coated 24-well plates and incubated for 48 
hours. On day 3 HeLa cells were plated at 10,000 cells per well on NHDF layer and 
incubated for 24 hours. On day 4 of the assay, HDMECs were plated at 45,000 cells per well 
onto the confluent NHDF and HeLa layers. On day 5 and 8, co-cultures were treated with 
EBM MV2 basal medium containing 1% (v/v) FCS alone or with indicated amount of 
BIX02189 and XMD8-92, as shown in the treatment schedule (B). On day 10, cells were 
fixed and stained with anti-CD31 to detect endothelial cells (green) or anti-collagen-1 to 
detect fibroblast (red) or anti-muc16 to detect HeLa cells (grey) (as described (section 
2.2.9.4) , and total tube length was quantified using AngioQuant image analysis software. (C) 
Data is presented as total tube length from triplicate (n=3, mean ±SD) compared to basal. 
The result shown is representative of three independent experiments (*p< 0.05, **p<0.01). 
 
3.5.2    The effect of MEK5/ERK5 signalling cascade inhibition on early 
vessels development of normal and tumour angiogenesis in 
HDMECs/NHDF -/+ HeLa co-culture assay 
3-D collagen gel assay results revealed that ERK5 is critical for tubular 
morphogenesis below 24 hours which suggests that ERK5 may be required 
for early angiogenesis in response to pro-angiogenic factors such as VEGF. 
However, deletion of erk5 in adult mice induced lethality due to endothelial 
apoptosis leading to cardiovascular defects (Hayashi et al., 2004b) suggesting 
C 
CHAPTER THREE: Characterisation of the role of ERK5 in tumour angiogenesis in 
vitro 
 
100 
 
that ERK5 is also important for endothelial cell physiology in established 
vasculature. To compare the effect of XMD8-92 and BIX02189 at early 
neovascularisation and on established vessels, HDMECs were treated with an 
ERK5 inhibitor (XMD8-92) or MEK5 inhibitor (BIX02189) prior to plating 
onto a confluent NHDF or NHDF/HeLa layer on day 4 and the co-culture 
treated with these inhibitors prior to stimulation of the HDMEC/NHDF co-
culture with VEGF on day 6 (Figure 3.9b). To analyse effects on established 
vessels, the co-culture was stimulated with VEGF on day 6 and treated with 
XMD8-92 and BIX02189 on day 7 and 9 before fixing on day ten. Treatment 
of HDMECs with 3μM XMD8-92 prior to plating onto NHDF notably 
decreased VEGF stimulated tube formation by 3-4 times compared to 
stimulated cells (Figure 3.9a). Similar to XMD8-92, treatment of HDMECs 
and co-culture with BIX02189 prior to stimulation with VEGF reduced tube 
formation by 3-4 fold in comparison with stimulated basal control (Figure 
3.9a). By contrast, treatment of the co-culture with XMD8-92 or BIX02189 
on day 7 and 9 of the assay only reduced VEGF stimulated tube formation 2 
and 1 fold respectively in comparison to stimulated basal control. In the 
HDMEC/NHDF/HeLa co-culture there was a clear induction of tube 
formation from tumour cells by increasing the tubes two folds compared to 
unstimulated cells (Figure 3.9a and c). Treatment of HDMEC prior to plating 
onto NHDF/HeLa on day 3 and HDMEC/NHDF/HeLa co-culture on day 5 of 
the assay with 3μM of ERK5 inhibitor had a noticeable effect upon tumour-
stimulated tubule formation compared to untreated basal control. However, 
treatment of HDMEC/NHDF/HeLa co-culture with XMD8-92 on day 7 and 9 
of the assay had less effect upon network formation compared to untreated 
cells (Figure 3.9a). Quantification of total tube length showed that treatment 
of ERK5 inhibitor at early time points reduced tumour-induced tube 
formation by 4-fold while treatment the established vessels decreased tube-
like network by 3-folds in comparison with untreated basal control (Figure 
3.9c). Similar to XMD8-92, treatment of the co-culture with BIX02189 on 
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day 3 and 5 of the assay diminished tumour-stimulated tubule formation 4-
times compared to the untreated basal control (Figure 3.9a and c). By 
contrast, treatment HDMEC/NHDF/HeLa co-culture with MEK5 inhibitor on 
day 7 and 9 on the assay reduced only about a single fold in comparison with 
the untreated basal control. Also this experiment was repeated and confirmed 
by using immunofluorescence staining of HDMEC/NHDF/HeLa co-culture 
which gave the same findings (Figure 3.10). 
This data suggest that tubule formation in a HDMEC/NHDF or 
HDMEC/NHDF/HeLa co-culture assay is most sensitive to ERK5 and/or 
MEK5 inhibitor (XMD8-92 and BIX02189 respectively) treatment during 
early vessel development. 
 
 
 
 
 
 
 
 
 
 
 
 
A 
9 
CHAPTER THREE: Characterisation of the role of ERK5 in tumour angiogenesis in 
vitro 
 
102 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 The effect of MEK5/ERK5 inhibitors, BIX02189 and XMD8-92, on tumour 
angiogenesis in a HDMEC/NHDF/HeLa co-culture assay (A) NHDF were seeded in 
fibroblast growth medium at 20,000 cells per well on gelatine-coated 24-well plates and 
incubated for 48 hours. On day 3, HDMECs were treated with 3μM MXD8-92 and 
BIX02189; HeLa cells were plated at 5,000 cells per well on NHDF layer and incubated for 
24 hours. On day 4, HDMECs were plated at 45,000 cells per well onto the confluent NHDF 
and HeLa layers with EBM MV2 basal medium FGM. On day 5, co-culture media were 
changed to EBM MV2 basal medium containing 1% (v/v) FCS and the co-culture was 
treated with inhibitors.  Day 7 and 9, co-cultures were treated with the indicated amount of 
BIX02189 and XMD8-92, as shown in the treatment schedule (B). On day 10, cells were 
fixed and stained as described (section 2.2.9.3.3), and total tube length was quantified using 
AngioQuant image analysis software. (C) Data is presented as total tube length from 
compared to basal. The result shown is representative of three independent experiments (*p< 
0.05, **p<0.01). 
3μM 
XMD8-92 
3μM 
BIX02189 
3μM 
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Figure 3.10 The effect of MEK5/ERK5 inhibitors, BIX02189 and XMD8-92, on tumour 
angiogenesis in a HDMEC/NHDF/HeLa co-culture assay. (A) NHDF were seeded in 
fibroblast growth medium at 20,000 cells per well on gelatine-coated 24-well plates and 
incubated for 48 hours. On day 3, HDMECs were treated with 3μM MXD8-92 and 
BIX02189; HeLa cells were plated at 5,000 cells per well on NHDF layer and incubated for 
24 hours. On day 4, HDMECs were plated at 45,000 cells per well onto the confluent NHDF 
and HeLa layers with EBM MV2 basal medium FGM. On day 5, co-culture media were 
changed to EBM MV2 basal medium containing 1% (v/v) FCS and the co-culture was 
treated with inhibitors.  Day 7 and 9, co-cultures were treated with the indicated amount of 
BIX02189 and XMD8-92, as shown in the treatment schedule (B). On day 10, cells were 
fixed and stained with anti-CD31 to detect endothelial cells (green) or anti-collagen-1 to 
detect fibroblast (red) or anti-muc16 to detect HeLa cells (grey) (as described section 2.2.9.4) 
and total tube length was quantified using AngioQuant image analysis software. (C) Data is 
presented as total tube length from compared to basal. The result shown is representative of 
three independent experiments (*p< 0.05, **p<0.01). 
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3.6    Discussion 
The clear activation of ERK5 upon EGF stimulation in HeLa cells (Figure 
3.1) confirms data from previous studies on ERK5 in these cells (Kato et al., 
1998a, Kondoh et al., 2006, Yang et al., 2010c). In HeLa cells, the ERK5 
protein underwent a mobility bandshift with conventional SDS-PAGE as a 
consequence of phosphorylation. ERK5 is known to undergo phosphorylation 
on the Thr
218
 / Tyr
220
 residues in the activation loop of the kinase domain 
which then facilitates C-terminal phosphorylation (Figure 3.1). In contrast, it 
was difficult to detect VEGF-mediated ERK5 activation in HDMECs via 
mobility bandshift with conventional SDS-PAGE (Figure 3.1). However, 
using p-Thr
218
 / Tyr
220
 antibody facilitated the detection of ERK5 
phosphorylation in HDMECs upon VEGF stimulation (Figure 3.1).  
The use of small molecule kinase inhibitors targeting MEK5 and ERK5 upon 
VEGF and EGF stimulation of ERK5 phosphorylation revealed that XMD8-
92, which is an ATP-competitive inhibitor, prevented the phosphorylation of 
ERK5 in C-terminal residues in HeLa cells (Figure 3.3) while the dual 
phosphorylation of ERK5 in HDMECs was not affected (Figure 3.4) which 
means that XMD8-92 could affect the kinase activity of ERK5 which activate 
the transcriptional activation of C-terminal tail by auto-phosphorylation 
(Morimoto et al., 2007a). Furthermore, the inhibition of MEK5 with 
BIX02189 decreased the phosphorylation of ERK5 on Thr
218
 / Tyr
220
 in 
VEGF-stimulated HDMECs (Figure 3.6). In addition, the phosphorylation of 
C-terminal residues of ERK5 in HeLa cells was inhibited by BIX02189 
(Figure 3.5). Thus, pharmaceutical inhibition of ERK5 only targets kinase 
activity in comparison with ERK5 knockout which leads to unfavourable 
effects on vascular integrity (Yang et al., 2010c). The siRNA mediated 
silencing of ERK5 expression has been previously shown to inhibit VEGF-
stimulation tube formation in HDMECs (Roberts et al. 2010). Similar results 
were obtained using a small molecule ERK5 inhibitor. 
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To analyse the effect of small molecule kinase inhibitors XMD8-92 and 
BIX02189 upon VEGF stimulated tube formation in human dermal 
microvascular endothelial cells, a 3-D collagen angiogenesis assay which is 
highly representative of angiogenesis in vivo was applied. As is well 
established, VEGF is able to induce tubular morphogenesis, migration and 
survival of HDMECs in various angiogenic assays. In this chapter, VEGF 
induced HDMEC tube formation in a 3-D collagen gel (Figure 3.7). Treated 
HDMEC with different concentrations of XMD8-92 or BIX02189 decreased 
VEGF-induced tube formation in HDMEC in especially with 3μM and 1μM 
in comparison with untreated HDMEC with inhibitors (Figure 3.7) and thus 
could support the observation that the knockout of ERK5 in mice declined the 
blood vessels significantly in a Matrigel implant (Hayashi et al., 2005a). Also 
these findings confirmed that MEK5/ERK5 is required for VEGF-induced 
tubular morphogenesis in endothelial cells (Roberts et al., 2010c). 
The ability of the MEK5/ERK5 inhibitors to prevent VEGF-stimulated 
angiogenesis may have therapeutic value in the treatment of aberrant 
angiogenesis. The 3-D collagen in vitro angiogenesis assay showed that 
XMD8-92 and BIX02189 MEK5/ERK5 inhibition prevented VEGF-
stimulated HDMEC tube formation. To investigate the role of ERK5 inhibitor 
in VEGF-induced capillary like structure in NHDF/HDMEC -/+ tumour cell 
co-culture in vitro angiogenesis assay was applied, which more highly 
represented in vivo angiogenesis. Treatment of the HDMEC/NHDF/HeLa 
cells co-culture with dose response of MEK5/ERK5 pharmaceutical 
inhibitors (BIX02189 and XMD8-92) prevented tube-like structure formation 
at a concentration of 3 μM and demonstrating the potent anti-tumour effect of 
XMD8-92 and BIX02189 in tumour angiogenesis which support data that 
revealed that XMD8-92 blocks angiogenesis in vivo (Figure 3.8) (Yang et al., 
2010c). Treatment of HDMECs with XMD8-92 or BIX02189 at an early 
stage of tubule formation (day 3 and 5) and at established capillary like-
structures (day 7 and 9) provided an opportunity to study the role of ERK5 in 
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both early and established tubule formation. Treatment of HDMEC with 
XMD8-92 and BIX02189 on day 3 before plating on NHDF/HeLa and then 
treatment of NHDF/HDMEC/HeLa co-culture with XMD8-92 and BIX02189 
on day 5 led to more potent inhibition of endothelial capillary formation 
which suggests that tube formation in HDMEC/NHDF/HeLa co-culture is 
most sensitive to MEK5/ERK5 signalling pathway inhibitor treatment during 
early angiogenesis (Figure 3.9).  
Whilst there has been extensive study of the role of MEK5/ERK5 signalling 
pathway in tumour in the last decade, the current study is the first to 
investigate the inhibitory effect of the pharmaceutical inhibitors (BIX02189 
and XMD8-92) on inhibition of the MEK5/ERK5 signalling cascade in 
NHDF/HDMEC/tumour cell co-culture.  
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4.1   Introduction 
Melanoma is the most deadly skin cancer which originates from the 
melanocytes. Melanoma is known for its high metastatic potential, enhanced 
heterogeneity and also the ability to resist chemotherapy. It is the least 
common form of skin cancer (less than 5% of cases) but is considered the 
most deadly. Skin cancer is ranked the fifth most common cancer among men 
and sixth among women (National Cancer Institute, 2015). In 2015, an 
estimated 73,870 people will be diagnosed with melanoma in the USA and an 
estimated 9,940 of those diagnosed will die as a result of this malignancy 
(National Cancer Institute, 2015). In the UK, 100,000 new cases are 
diagnosed each year and this disease kills over 2500 patients each year 
(British Skin Foundation, 2015). Furthermore, Caucasian white populations 
are at high risk and are more likely to develop melanoma than black 
populations (Boyle, 2011).  
The risk factors correlated with increased development of melanoma include 
environmental factors such as UV light and increased exposure to the sun. 
Family history as a genetic factor also plays an important role in the 
development of melanoma (Gray-Schopfer et al., 2005). Genetic mutations in 
melanocytes such as the p53 tumour suppressor gene and BRAF, NRAS and 
oncogenes, increase the risk of melanoma (Tran et al., 2008, Zaidi et al., 
2012). BRAF plays a central role in the development of melanoma. 
Approximately 60% of melanoma cases have the BRAF mutation in the gene 
encoding the serine–threonine protein kinase B-RAF and about 20% have 
undergone an activating mutation in one of the RAS genes while the 
remaining 20% of melanomas are unknown (Flaherty et al., 2010, Davies et 
al., 2002). BRAF mutations are also found in about 55% of papillary thyroid 
and 18% of colorectal cancers as well as about 14% of ovarian cancers 
(Flaherty et al., 2010, Davies et al., 2002, Downward, 2003) . More  than 75 
mutations have been described in BRAF but the BRAF gene with valine to 
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glutamic acid substitution (V600E) is considered the most common mutation 
in BRAF (90%) which leads to constitutive activation of BRAF and the 
downstream MAPK signalling cascade (Davies et al., 2002). The RAS-RAF-
MEK-ERK MAPK pathway plays a pivotal role in the progression of 
melanoma and is considered a therapeutic target for melanoma treatment 
(McCubrey et al., 2006). In August 2011, the FDA approved 
vemurafenib/PLX4032 (Zelboraf
®
) and PLX4720 (preclinical analog of 
PLX4032) which are selective BRAF V600E inhibitors for treatment of 
metastatic melanoma. This agent benefits as many as 80% of patients and 
improves overall survival compared to other chemotherapy agents such as 
dacarbazine (Chapman et al., 2011). Although these patients’ responses to 
vemurafenib were encouraging, unfortunately virtually all patients acquired 
resistance to the agent within about 7 months and the disease relapsed 
(Chapman et al., 2011). Therefore, acquired resistance to BRAF inhibition is 
considered a challenge to long term survival for melanoma patients.  
The melanoma cells acquire resistance to vemurafenib due to reactivation of 
the MAPK pathway. Alternative spliced forms of BRAF V600E and also 
activation of RTK (PDGFRβ) have been shown to play a role in acquired 
resistance to vemurafenib (Su et al., 2012).  
This chapter describes the experiments performed in an effort to characterise 
the activation of ERK5 in BRAF V600E melanoma cancer cell lines and 
vemurafenib resistant counterparts. In addition, by utilising the 
pharmacologic inhibitors of the MEK5/ERK5 signalling pathway in 
combination with PLX4720 in a cell viability assay, the ability to reverse 
resistance in melanoma cells for these inhibitors has been defined. 
Furthermore, the effect of XMD8-92 and BIX02189 in combination with 
vemurafenib in tumour angiogenesis was analysed by using a tumour 
cell/endothelial/fibroblast co-culture assay. 
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4.2    Characterisation of ERK5 activation in A375 and A375R 
melanoma cancer cell lines 
4.2.1    MAPKs signalling pathways in A375 and A375R 
In mammals, mitogen-activated protein kinases (MAKPs) play a role in cell 
responses to growth factors and stress leading to proliferation, survival, 
motility and differentiation of cells (Cargnello and Roux, 2011b). MAPKs 
include ERK1/2, p38 (α, β, γ, and δ), JNK1 to -3 and ERK5. 
In order to assess the profile of MAPK activity in A375 and A375R in 
response to 1µM PLX4720 and test whether these kinases in addition to AKT 
interfered with ERK5 activation in the melanoma resistant cell line, protein 
expression using western blot was conducted. A375 and A375R were 
incubated with 1µM PLX4720 for 24 hours and then lysed with RIPA lysis 
buffer prior to resolution on 8% SDS-PAGE acrylamide gel and western blot 
analysis with phospho antibodies directed against p-AKT, p-SAPK/JNK, p-
p38 and p-ERK1/2. 
Treatment with vemurafenib totally abrogated the phosphorylation of 
ERK1/2 in A375 cells whereas the same concentration, 1µM, of the drug in 
vemurafenib-resistant A375R cells incompletely decreased the 
phosphorylation of ERK1/2, in agreement with a previous report (Su et al., 
2012). The p-JNK level was increased in the vemurafenib-resistant cells 
compared with vemurafenib-sensitive cells whereas activation of p38 MAPK 
and p-AKT were observed in both cell types (Figure 4.1). The receptor 
tyrosine kinase EGFR was activated in the vemurafenib-resistant cells but not 
in vemurafenib-sensitive cells (Figure 4.1). These results revealed that ERK5, 
SAPK/JNK and EGFR showed increased phosphorylation in A375R 
compared to A375. 
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4.2.2    ERK5 activation is increased in the PLX4720 resistant melanoma 
cell line (A375 R) 
ERK5 is involved in many cellular functions including cell survival, cell 
proliferation and differentiation and has been implicated in the pathogenesis 
of many types of cancer (Lochhead et al., 2012). ERK5 is activated by a 
variety of growth factors and it has been reported that EGF and NGF activate 
ERK5 in many cell types (Kato et al., 1998b). All growth factors in Figure 
4.3 especially EGF stimulated ERK5 phosphorylation in the A375 cell lines. 
ERK5 up-regulation was investigated in A375 and A375R cells in presence 
or not of PLX4720 to study the role of ERK5 in the resistant A375R cells. 
The A375 and A375R cells were incubated with 1µM of PLX4720 or with 
0.1% (v/v) DMSO vehicle control for 24 hours and then lysed with RIPA 
prior to SDS-PAGE using an 8% gel, followed by immunoblotting with anti-
ERK5 (New England BioLab, Hitchin, UK). It was shown that ERK5 was 
activated in A375R in the absence of PLX4720 compared to A375 at the 
same state (Figure 4.1). In the present of 1µM of PLX4720, ERK5 was 
phosphorylated in the A375R resistant cell line two fold higher compared 
with A375 (Figure 4.1). Furthermore, EGFR was observed to be activated in 
A375R without any stimulation with EGF suggesting that EGFR could be 
implicated in the resistance of A375 cells to vemurafenib. 
 RT-PCR was also used to analyse the expression of MEK5 and ERK5 in 
A375 and A375R. The expression of MEK5 mRNA in A375R was increased 
slightly above A375 (Figure 4.2). In case of the expression of ERK5 mRNA, 
the A375R cells showed that ERK5 was more expressed in these cells 
compared to the basal (Figure 4.2). These data suggest that activation of 
ERK5 may play a role in vemurafenib resistant in melanoma cells. 
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Figure 4.1 Intracellular signalling in vemurafenib-sensitive and resistant A375 cells. 
A375 and A375R were seeded in 12-well plate for 24 hours and then incubated with 1µM 
PLX4720 or 0.1% DMSO vehicle control prior to lysis of the cells with RIPA lysis buffer. 
Protein lysates from A375 and A375R were resolved on 8% acrylamide gel and analysed 
with western blot by using antibodies against ERK5, p-EGFR, p-AKT, p-SAPK/JNK, p-p38 
MAPK, p-ERK1/2 and Actin. Analysis of densitometry of protein phosphorylation or protein 
expression is relative to basal control condition of each cell type. This experiment is 
representative of three independent experiments (*p< 0.05, **p<0.001). 
 
 
CHAPTER FOUR: The role of ERK5 in tumour angiogenesis and drug-resistance in 
metastatic melanoma cell 
 
114 
 
 
 
 
 
 
 
 
 
Figure 4.2 MEK5 and ERK5 mRNA expression in A375 and A375R. The bar chart shows 
RT-PCR analysis for MEK5 and ERK5 mRNA level in A375 and A375R. The melanoma 
cells RNA were extracted and cDNA prepared. Data were analysed by the ∆∆Ct value method 
and the expression was normalized to β-actin expression and illustrated as fold change. Both 
experiments is representative of four individual experiments (*p<0.05). 
 
4.2.3    ERK5 is activated in A375 and A375R in response to growth 
factors 
A375 are human malignant melanoma cells derived from the skin of a 54 
year old female patient with malignant melanoma (Yang et al., 2010a). These 
cells were kindly provided by Prof Richard Marais, CRUK Manchester 
Cancer Institute. A375 cells express the BRAF (V600E) mutation. The 
A375R cells are vemurafenib resistance and were generated by chronic 
exposure of A375 cells to increasing levels of PLX-4720 (0.01M-0.1M 
over 8 weeks). 
As mentioned in Chapter Three, phosphorylated ERK5 on an 8% SDS-PAGE 
gel exhibited reduced electrophoretic mobility, migrating slower than the 
non-phosphorylated form of ERK5, a phenomenon called bandshift.  
Various growth factors, VEGF, FGF-2, HGF, EGF, NRG-1 and PDGF-BB 
were applied to evaluate the profile of ERK5 activation in A375 and A375R, 
by means of a mobility bandshift. The cells were stimulated or not (basal) 
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with growth factors for 10 minutes and then lysed with RIPA lysis buffer. 
The total cell lysates were separated on 8% acrylamide SDS-PAGE gel and 
analysed by western blot using a commercially available ERK5 antibody 
(New England BioLab, Hitchin, UK) (Figure 4.3). 
It was found that in A375 and A375R cells, all the utilised growth factors 
stimulated ERK5 activation compared to the control basal condition as their 
stimulation resulted in an ERK5 mobility bandshift. In A375 cells, both HGF 
and EGF were the agonists that most increased the activation of ERK5 
compared to the other agonists (Figure 4.3a). EGF stimulation of ERK5 
activation in A375R was greater than the other agonists (Figure 4.3b). 
Quantification of the stimulated lower ERK5 and upper ERK5 mobility bands 
were compared to an arbitrary value of 1.0 set for both ERK5 and p-ERK5 
bands in the basal condition.  
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Figure 4.3 Characterisation of ERK5 activation in A375 and A375R in response to 
growth factors using electrophoretic mobility band shift. (A) A375 cells were seeded in 
12-well plate for 24 hours and then serum starved overnight. Cells were stimulated with 
50ng/ml of VEGF, FGF-2, HGF, EGF, NRG-1 and PDGF-BB followed by RIPA lysis. (B) 
A375R cells were seeded in 12-well plate for 24 hours and then serum starved overnight. 
Cells were stimulated with 50ng/ml of VEGF, FGF-2, HGF, EGF, NRG-1 and PDGF-BB 
followed by RIPA lysis. Protein lysates from A375 and A375R were resolved on 8% 
acrylamide gel and analysed with western blot by using antibodies against ERK5 and Actin. 
Analysis of densitometry of protein phosphorylation or protein expression was relative to 
basal control condition of each cell type which was set arbitrarily as 1.0. This experiment is 
representative of three independent experiments (*p< 0.05) compared to basal control. 
 
4.3    Small molecule kinase inhibitors 
BIX02189 and XMD8-92 are two small-molecule kinase inhibitors used for 
blocking the activation of MEK5 and ERK5 respectively. BIX02189 
selectively inhibits MEK5 over MEK1/2 whereas XMD8-92 inhibits EGF 
stimulated ERK5 activation (Tatake et al., 2008, Yang et al., 2010b). 
TRAMETINIB (trametinib) inhibits MEK1/2 kinase activity and blocks 
RAF-dependent MEK1/2 phosphorylation (Gilmartin et al., 2011). Lapatinib 
A 
B 
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is a dual EGFR-1/HER2 TK inhibitor which has the ability to act as an ATP 
competitor and targets the kinase domain of HER2 and EGFR-1 (D'Amato et 
al., 2015).  
4.3.1    PLX4720 combined with XMD8-92 or BIX02189 but not 
trametinib or lapatinib inhibits ERK5 activation in A375 R 
In the vemurafenib-sensitive A375 cells, the addition of 1µM PLX4720 
combined with small molecule kinase inhibitors (BIX02189, XMD8-92 or 
lapatinib) appeared to inhibit ERK5 activation (Figure 4.4). In contrast, the 
combined treatment of PLX4720 with trametinib increased the 
phosphorylation of ERK5 in the parental cell line. 
As A375 cells are a vemurafenib-sensitive cell line, the treatment of these 
cells with PLX4720 abolished the phosphorylation level of ERK1/2 due to 
the inhibition of its upstream BRAF activity (Figure 4.4). The combination of 
a B-RAF inhibitor (PLX4720) with XMD8-92, BIX02189 or lapatinib but not 
trametinib induced the activation of ERK1/2 in the A375 cells (Figure 4.4). In 
addition, PLX4720 combined with these kinase inhibitors did not appear to 
affect the phosphorylation of AKT which is important in cell survival and 
apoptosis (Figure 4.4). BIX02189 and XMD8-92 combined with PLX4720 
blocked the phosphorylation of EGFR-1 compared to the 0.1% DMSO 
vehicle control (Figure 4.4).    
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Figure 4.4 Small-molecule kinase inhibitors in A375. A375 cells were seeded in a 12-well 
plate for 24 hours and then incubated with 1µM PLX4720 for 24 hours and 0.1% DMSO 
vehicle control, 3µM XMD8-92, 3µM BIX02189, 1µM lapatinib or 1µM trametinib were 
added to the drugged cells and incubated for 1 hour prior to lyse of the cells with RIPA lysis 
buffer. Protein lysates from A375 cells were resolved on 8% acrylamide gel and analysed 
with western blot by using antibodies against ERK5, p-EGFR, p-AKT, p-ERK1/2 and Actin 
which was used as a loading control. Analysis of densitometry of protein phosphorylation or 
protein expression is relative to basal control condition of each cell type which was set 
arbitrarily as 1.0. This experiment is representative of three independent experiments (*p< 
0.05). 
 
In the vemurafenib-resistant A375R cells, the combination of 1µM PLX4720 
with 3µM XMD8-92 and BIX02189 inhibited p-ERK compared with the 
0.1% DMSO vehicle control (Figure 4.5). The high sequence identity and 
significant similarity between MEK1/2 and MEK5 suggested that the first 
generation of MEK1/2 inhibitors such as PD98059 could inhibit MEK5 and 
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ERK5 MAPK activity (Fremin and Meloche, 2010), however 1µM trametinib 
combined with PLX4720 did not appear to suppress ERK5 activation in 
A375R as the slower electrophoretic band (p-ERK5) on the 8% SDS-PAGE 
acrylamide gel was detected (Figure 4.5). Furthermore, ERK5 
phosphorylation in vemurafenib-resistant A375R cells increased even in the 
presence of lapatinib and PLX4720, suggesting that ERK5 is not dependent 
upon EGF for activation in PLX4720-resistant melanoma cells. 
The phosphorylation of ERK1/2 and AKT did not have an effect by the 
combination of PLX4720 and kinase inhibitors except trametinib which 
blocked p-ERK1/2 as an inhibitor for this kinase (Figure 4.5).  
XMD8-92 and BIX02189 with PLX4720 appeared to induce the activation of 
EGFR with an increase in XMD8-92/PLX4720 compared to the 0.1% DMSO 
vehicle control (Figure 4.5). Trametinib/PLX4720 inhibited p-EGFR 
compared to 0.1% DMSO/PLX4720. These data together suggest that the 
ERK1/2 signalling pathway and EGFR do not play a role in MEK5/ERK5 
signalling activation in the PLX4720-resistant melanoma cells. 
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Figure 4.5 Small-molecule kinase inhibitors in A375R. A375R cells were seeded in a 12-
well plate for 24 hours and then incubated with 1µM PLX4720 for 24 hours and 0.1% 
DMSO vehicle control, 3µM XMD8-92, 3µM BIX02189, 1µM lapatinib or 1µM trametinib 
were added to the drugged cells and incubated for 1 hour prior to lyse of the cells with RIPA 
lysis buffer. Protein lysates from A375R cells were resolved on 8% acrylamide gel and 
analysed with western blot by using antibodies against ERK5, p-EGFR, p-AKT, p-ERK1/2 
and Actin which was used as a loading control. Analysis of densitometry of protein 
phosphorylation or protein expression is relative to basal control condition of each cell type 
which was set arbitrarily as 1.0. This experiment is representative of three independent 
experiments (*p< 0.05, **p<0.01). 
 
4.4   Increased ERK5 activation in vemurafenib-resistant 
melanoma cells. 
In order to confirm the role of the MEK5/ERK5 signalling axis in 
vemurafenib-resistant BRAF V600E mutated melanoma cancer cells, 
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investigations of the activation of ERK5 in different cell lines were 
conducted. Pairs of vemurafenib-sensitive and resistant cells from SKMel5 
and SKMel5R cell were used for this study. All these cells express mutant 
BRAF V600E and they are melanoma cell lines established from patient-
derived tumour samples.  
4.4.1   ERK5 is activated in SKMel5-WT and SKMel5R cells 
SKMel5 is a melanoma cell line harbouring the BRAF V600E mutation, and 
was established in 1974 from a 24-old Caucasian female with malignant 
melanoma (Memorial Sloan Kettering Cancer Center, 2015). SKMel5 and 
SKMel5R were treated with 1μM PLX4720 or 0.1% DMSO as vehicle 
control for 24 hours and lysed with RIPA prior to resolution on 8% SDS-
PAGE acrylamide gel followed by immunoblotting with anti ERK5. Western 
blot showed that a mobility bandshift of ERK5 appeared in vemurafenib-
resistant melanoma cells SKMel5R (Figure 4.6). The quantification of 
stimulated upper p-ERK5 mobility bands in SKMel5R compared to SKMel5 
showed that ERK5 is more phosphorylated in PLX4720-resistant cells than 
PLX4720-sensistive cells (Figure 4.6).  
The analysis of RTK and MAPK activity in SKMel5-WT and SKMel5R in 
response to PLX4720 revealed that EGFR-1 was up-regulated in 
vemurafenib-resistant cells compared with vemurafenib-sensitive cells 
(Figure 4.6). Treatment of SKMel5 and SKMel5R with 1μM PLX4720 
showed that the phosphorylation of ERK1/2 was decreased in both cell lines 
compared to the DMSO vehicle control. The activation of AKT in the 
resistant cell line appeared to be lower compared with sensitive cells. The 
incubation of SKMel5 and SKMel5R with 0.1% DMSO vehicle control or 
1μM PLX4720 had a negligible effect on the phosphorylation of JNK and 
p38 MAPK (Figure 4.6). 
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Figure 4.6 Intracellular signalling in vemurafenib-sensitive and resistant SKMel5 cells. 
SKMel5-WT and SKMel5R were seeded in a 12 well plates for 24 hours and then incubated 
with 1µM PLX4720 or 0.1% DMSO vehicle control prior to lysis of the cells with RIPA 
lysis buffer. Protein lysates from SKMEL5 and SKMel5R were resolved on 8% acrylamide 
gel and analysed with western blot by using antibodies against ERK5, p-EGFR, p-AKT, p-
SAPK/JNK, p-p38 MAPK, p-ERK1/2 and Actin. Analysis of densitometry of protein 
phosphorylation or protein expression is relative to basal control condition of each cell type. 
This experiment is representative of three independent experiments (*p< 0.05). 
 
The analysis of MEK5 and ERK5 mRNA in vemurafenib-sensitive and 
resistant cells in A375 and SKMel5 in response to 0.1% DMSO vehicle 
control or 1μM PLX4720 revealed that, the erk5 gene expression data in 
resistant cell lines was approximately compatible with the ERK5 protein 
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expression data which indicated that ERK5 was activated in resistant cell 
lines compared with parental cells (Figure 4.7). Treatment with PLX4720 
induced gene expression of MEK5 in both sensitive and resistant cell 
conditions in A375 and SKMel5 whereas cells incubated with the 0.1% 
DMSO vehicle control expressed MEK5 about one-fold in SKMel5R and 
slightly less in A375R compared to the PLX4720-sensitive cells A375 and 
SKMel5 (Figure 4.7). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 MEK5 and ERK5 mRNA expression in A375 and SKMel5 cells. The bar chart 
shows RT-PCR analysis for (A) MEK5 and (B) ERK5 mRNA level in A375 & A375R and 
SKMel5 & SKMel5R. The melanoma cells RNA were extracted and cDNA prepared. Data 
were analysed by the ∆∆Ct value method and the expression was normalized to β-actin 
expression and illustrated as fold change. The result shown is representative of three 
independent experiments. 
Parental Resistant 
Resistant Parental cells 
B 
A 
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4.5  Inhibition of ERK5 signalling cascade prevents 
vemurafenib resistance  
The increased activation of ERK1/2 in vemurafenib melanoma has led to 
rational use of MEK1/2 inhibitor treatments in combination with vemurafenib 
to treat melanoma patients. Data showing increased ERK5 activation in 
vemurafenib resistant cells suggests that inhibition of the ERK5 signalling 
cascade may also potentially inhibit drug resistance in these cells. The effect 
of BIX02189 and XMD8-92 on cell viability in A375 and A375R cells was 
analysed. 
4.5.1   Vemurafenib-sensitive and resistant melanoma cells do not show 
difference in response to the small-molecule kinase inhibitors 
In order to analyse the effect of the small-molecule kinase inhibitors of the 
MEK5/ERK5 axis in combination with vemurafenib on the resistant 
melanoma cells, validation and determination of the concentration of these 
inhibitors and PLX4720 in A375 and A375R is required to chose a 
concentration of drug that is not toxic to cells. The examination of the effect 
of the single-agent PLX4720 and the small-molecule kinase inhibitors, 
BIX02189, XMD8-92, lapatinib and trametinib against A375 and A375R was 
conducted by using an in vitro CellTiter-Glo® Luminescent Cell Viability 
Assay, which indirectly determines the number of viable cells by quantifying 
the amount of ATP present in a metabolically active cell, after 72 hours of 
treatment. The PLX4720, BIX02189, XMD8-92, lapatinib and trametinib 
dose response curves in vemurafenib-sensitive A375 cells and vemurafenib-
resistance A375R cells are shown in figure 4.8. The parental cells showed 
increased sensitivity to PLX4720 with an IC50 at 1.084 μM compared to the 
resistant cells A375R with an IC50 at 10.17 μM which gave 9.38-fold more 
resistance than parental cell line A375 (Table 4.1). Treating the vemurafenib-
sensitive and resistant melanoma cell lines with dose-response of four small-
CHAPTER FOUR: The role of ERK5 in tumour angiogenesis and drug-resistance in 
metastatic melanoma cell 
 
125 
 
molecule kinase inhibitors alone for 72 hours showed no changes between the 
two cell lines (Figure 4.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Dose response curves of PLX4720 and four small-molecule kinase inhibitors 
in A375 and A375R. (A) A375 and (B) A375R cells seeded in a 96-well plate for 24 hours 
and then treated with different concentrations of PLX4720, BIX02189, XMD8-92, lapatinib 
and trametinib and incubated for 72 hours. Cells were then analysed by using a CellTiter-
Glo® Luminescent Cell Viability Assay. This result is representative of three independent 
experiments. 
 
 
 
 
Table 4.1 The sensitivity of A375 and A375R to PLX4720, BIX02189, XMD8-92,  
lapatinib and trametinib  
 
A 
B 
Fold resistance is defined as the IC50 of the resistant cell line / IC50 of the parental cell line  
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4.5.2 Combination treatment of PLX4720 with BIX02189 reverses the 
PLX4720 resistance 
The parental cell lines, A375 and SKMel5-WT, and their acquired 
vemurafenib-resistant sublines, A375R and SKMel5R, were examined for 
their sensitivity to PLX4720 alone and the combination of PLX4720 with 
BIX02189 or XMD8-92.  
The results shown in Figure 4.9 show that, as expected, in contrast to the 
parental cell lines, the PLX4720-resistant cell lines are significantly resistant 
to PLX4720. The parental cell lines A375 and SKMel-WT were sensitive to 
PLX4720 with an IC50 of 0.784 and 1.075 μM respectively, while the 
resistant cells A375R and SKMel5R were more resistant to PLX4720 with an 
IC50 of 10.02 and 9.960 μM respectively which gave a 12.87-fold increase in 
A375 and 9.26-fold increase in SKMel5 in IC50 (Figure 4.9 and table 4.2). 
The combination of PLX4720 with 3µM BIX02189 or XMD8-92 in the A375 
cells did not show a change in IC50 values compared with PLX4720 alone, 
whereas the SKMel5-WT cells were sensitive to BIX02189 or XMD8-92 
with PLX4720 compared to PLX4720 alone (Figure 4.9 and Table 4.2). In 
the resistant cells A375R, incubation of 3µM BIX02189 or XMD8-92 with in 
the presence of PLX4720, increased sensitivity to PLX4720 and shifted the 
dose response curves to the left compared to PLX4720 alone. In addition, 
SKMel5R cells were more sensitive to PLX4720 when treated with 3µM 
BIX02189 or XMD8-92 in combination with PLX4720 and the resistance to 
PLX4720 were reversed (Figure 4.9). 
This result suggests that the combination of PLX4720 with BIX02189 or 
XMD8-92 could potentially reverse the resistance of A375 or SKMel5 to 
vemurafenib. 
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Figure 4.9 Dose response curves of PLX4720 combined with/without MEK5 inhibitor 
BIX02189 or ERK5 inhibitor XMD8-92 in A375, A375R, SKMel5-WT and SKMel5R. 
(A) A375, (B) A375R (C) SKMel5-WT and (D) SKMel5R cells seeded in a 96-well plate for 
24 hours and then treated with different concentrations of PLX4720 on its own and with 
3µM BIX02189 or XMD8-92 and incubated for 72 hours. Cells were then analysed by using 
a CellTiter-Glo® Luminescent Cell Viability Assay. This result is representative of three 
independent experiments. 
 
 
 
 
 
A 
Table 4.2 The sensitivity of A375 and A375R to PLX4720, combined with BIX02189, or 
XMD8-92 
 
Fold resistance is defined as the IC50 of the resistant cell line / IC50 of the parental cell line (Lidsky et al., 2014) 
 
B 
C D 
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4.6   Development of an in vitro endothelial 
cell/fibroblast/melanoma cancer cell co-culture assay to 
assess the effect of BIX02189 and XMD8-92 inhibition of 
ERK5 on tumour angiogenesis 
Tumour angiogenesis is characterized by an imbalance of pro-angiogenic and 
anti-angiogenic factors, endothelial cell proliferation, migration and 
differentiation and also the remodelling of extracellular matrix which 
eventually results in sprouting of new blood vessels. This process is triggered 
by the tumour cells which release pro-angiogenic factors such VEGF and 
bFGF which directly bind to the receptor tyrosine kinases on the surface of 
endothelial cells to support invasive sprouting to the tumour. Thus, inhibiting 
tumour angiogenesis provides a promising strategy for treatment of solid 
tumours (Folkman et al., 1971). 
In this experiment, endothelial cells represent key cells involved in 
angiogenesis which depend on the interaction with mural cells such as 
fibroblasts. Fibroblasts produce extracellular matrix (ECM) proteins which 
provide a base to promote endothelial cell migration and facilitate vessel 
remodelling (Staton et al., 2009). The pro-angiogenic growth factors that are 
released from tumour cells, bind to fibroblast derived ECM to assist the 
progress of 3D organisation and tubulogenesis of endothelial cells (Sorrell et 
al., 2007). Therefore, endothelial cells co-cultured with fibroblasts provide a 
precise in vitro representation of in vivo angiogenesis (Donovan et al., 2001).  
Optimisation of the number of endothelial cells, HDMEC, seeded on the 
confluent fibroblast, NHDF, layers and the length of HDMEC/NHDF assay 
has been conducted previously in our lab. In this study, the image analysis 
software termed ‘AngioQuant’ was used for quantification of tubule 
formation in HDMEC/NHDF/A375s. 
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4.6.1   Combination of PLX4720 with BIX02189 or XMD8-92 inhibits 
tube- formation in a HDMEC/fibroblast/A375s co-culture assay  
It was reported that ERK5 is required for VEGF stimulated tubular 
morphogenesis in a HDMEC/NHDF assay (Roberts et al., 2010a). 
Furthermore, deletion of erk5 in adult mice induces lethality due to 
endothelial apoptosis resulting in cardiovascular degeneration (Hayashi et al., 
2004a), which means that ERK5 is critical to endothelial cell survival in 
established vessels. To determine the effect of MEK5/ERK5 inhibitors upon 
tumour cell stimulated angiogenesis in human microvascular endothelial cells 
in co-culture assay, normal human dermal fibroblasts (NHDFs) were plated 
on day one to obtain a confluent monolayer followed by plating of A375 and 
A375R cells on day 3. On day 4, HDMECs were plated on the NHDF/A375s 
layers and incubated overnight. Co-cultures were treated with the selective 
BRAF inhibitor, PLX4720, MEK5 inhibitor, BIX02189, and ERK5 inhibitor, 
XMD8-92. Single-dose treatment with 1μM PLX4720, 3μM BIX02189 and 
3μM XMD8-92 and combined PLX4720 with BIX02189 or XMD8-92 was 
performed on day 5 and day 8. Co-cultures were later fixed and stained for 
expression of endothelial cell specific marker CD31 and visualised by 
immunohistochemistry (section 2.2.9.2 and 2.2.9.3). 
Quantification of total tube length revealed that tumour cells in 
HDMEC/NHDF/A375s induced more tube-like structures than 
HDMEC/NHDF. The ability of resistant cells A375R to increase tube 
formation compared to sensitive cells A375 relates to their secretion of more 
VEGF-A and VEGF-C to induce endothelial cells to increase tubule 
formation (Figure 4.11). In addition, VEGFR-2 expressed in HDMEC but not 
A375 or A375R cells. 
Single-dose treatment with 1μM PLX4720 or 3μM BIX02189, XMD8-93 
alone marginally lowered melanoma cell-stimulated endothelial capillary 
morphogenesis in PLX4720-sensitive and -resistant cells, compared to basal 
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control (Figure 4.10). Treatment of a HDMEC/NHDF/A375R co-culture with 
1μM PLX4720 in combination with 3μM BIX02189 resulted in a significant 
decrease in A375R-induced tube formation compared to basal control and 
treatment with PLX4720 alone (Figure 4.10). Similarly, combination 
treatment with low dose PLX4720 and BIX02189 in vemurafenib-sensitive 
cells co-cultured with HDMEC and NHDF has given approximately the same 
effect. 3μM XMD8-92 in combination with a low single dose of PLX4720 on 
day 5 and day 8 profoundly inhibited A375R-driven angiogenesis compared 
to basal control and PLX4720 or XMD8-92 alone (Figure 4.10). 
Vemurafenib-sensitive cells co-cultured with HDMEC/NHDF displayed a 
great reduction in tumour angiogenesis when treated with PLX4720 
combined with XMD8-92. This data suggested that continuous inhibition of 
the MEK5/ERK5 signalling axis reduced tumour cell-stimulated endothelial 
capillary network formation in HDMEC/NHDF/A375s co-cultures. Also, 
these data imply that, melanoma cancer cell-induced tube formation is more 
susceptible to PLX4720 combined with BIX02189 or XMD8-92 treatment 
than PLX4720 or BIX02189, XMD8-92 alone. 
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Figure 4.10 The effect of MEK5/ERK5 inhibitors, BIX02189 and XMD8-92, on tumour 
angiogenesis in a HDMEC/NHDF/A375s co-culture assay. (A) NHDF were seeded in 
fibroblast growth medium at 20,000 cells per well on gelatine-coated 24-well plates and 
incubated for 48 hours. On day 3, A375 and A375R cells were plated at 10,000 cells per well 
on NHDF layer and incubated for 24 hours. On day 4 of the assay, HDMECs were plated at 
45,000 cells per well onto the confluent NHDF and A375 layers. On day 5 and 8, co-cultures 
were treated with EBM MV2 basal medium containing 1% (v/v) FCS alone or with indicated 
amount of PLX4720, BIX02189 and XMD8-92, as shown in the treatment schedule (B). On 
day 10, cells were fixed and stained as described (section 2.2.9.3.3), and total tube length was 
quantified using AngioQuant image analysis software. (C) Data is presented as total tube 
length from triplicate (n=3, mean ±SD) compared to basal. The result shown is representative 
of three independent experiments (*p< 0.05, **p<0.01). 
A 
B 
C 
C 
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Figure 4.11 mRNA expression of VEGFs and VEGFR-2 in malignant melanoma A375 
and A375R cells. The bar chart shows RT-PCR analysis of vegf-a, vegf-b, vegf-c, vegf-d and 
vegfr-2 mRNA expression in A375 and A375R cells. The malignant melanoma cancer cells 
RNA were extracted and cDNA prepared. Data were analysed by the ∆∆Ct value method and 
the expression was normalized to GAPDH expression and illustrated as fold change. 
 
4.6.2   Tumour angiogenesis in a HDMEC/fibroblast/SKMel5 co-culture 
assay is abolished by treatment of the combination of PLX4720 with 
BIX02189 or XMD8-92 
To further investigate the role of the MEK5/ERK5 signalling axis in tumour 
angiogenesis by using MEK5 and ERK5 inhibitors combined with BRAF 
inhibitor, PLX4720,  in a HDMEC/NHDF/SKMel5 co-culture assay, NHDFs 
were plated on 24-well plates on day 1 to produce a confluent monolayer. On 
day three, SKMel5 and SKMel5R were plated on the NHDF monolayer and 
incubated for 24 hours followed by plating human dermal microvascular 
endothelial cells on the  NHDF/tumour cell layer for 24 hours. On day 5 and 
8, the cells were treated with low doses of PLX4720, BIX02189 and XMD8-
92 alone or in combination therapy followed by fixing and staining on day 
ten. 
Similar to the HDMEC/NHDF/A375 co-culture, SKMel5 cells induced tube-
formation when co-cultured with fibroblasts and endothelial cells compared 
with HDMEC/NHDF co-culture without cancer cells, which confirms that 
tumour cells produce massive amounts of growth factors which bind to 
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endothelial cells to trigger invasive sprouting to the tumour (Figure 4.12). 
Treating the co-culture with a single agent (PLX4720, BIX02189 and 
XMD8-92) decreased total tube length in PLX4720-sensitive cells SKMel5-
WT compared with PLX4720-resistant cells SKMel5R, and tube-formation in 
both cell lines were decreased compared with basal control (Figure 4.12). 
Combination therapy using PLX4720 with MEK5 inhibitor BIX02189, or 
ERK5 inhibitor XMD8-92, revealed that malignant melanoma cell-induced 
tube-formation in the HDMEC/NHDF co-culture was decreased by 9-10 fold 
compared with the basal control and 7-8 fold compared with PLX4720 alone 
(Figure 4.12).  
This data combined with data in section 4.6.2 suggests that the dual 
combination of a BRAF inhibitor (PLX4720) and the MEK5/ERK5 
signalling pathway inhibitor may give hope to inhibit tumour angiogenesis 
resulting in starvation and oxygen and finally shrinkage of the malignant 
cells.  
 
 
 
 
 
 
 
 
 
 
CHAPTER FOUR: The role of ERK5 in tumour angiogenesis and drug-resistance in 
metastatic melanoma cell 
 
134 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 The effect of MEK5/ERK5 inhibitors, BIX02189 and XMD8-92, on tumour 
angiogenesis in a HDMEC/NHDF/SKMel5s co-culture assay. (A) NHDF were seeded in 
fibroblast growth medium at 20,000 cells per well on gelatine-coated 24-well plates and 
incubated for 48 hours. On day 3, SKMel5 and SKMel5R cells were plated at 10,000 cells 
per well to the NHDF layer and incubated for 24 hours. On day 4 of the assay, HDMECs 
were plated at 45,000 cells per well onto the confluent NHDF and SKMel5 layers. On day 5 
and 8, co-cultures were treated with EBM MV2 basal medium containing 1% (v/v) FCS 
alone or with indicated amount of PLX4720, BIX02189 and XMD8-92, as shown in the 
treatment schedule (B). On day 10, cells were fixed and stained as described (section 
2.2.9.3.3), and total tube length was quantified using AngioQuant image analysis software. 
(C) Data is presented as total tube length from triplicate (n=3, mean ±SD) compared to basal. 
The result shown is representative of three independent experiments (*p< 0.05, **p<0.01, 
***p<0.001). 
A 
B 
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4.7   Discussion  
The study of the MEK5/ERK5 signalling pathway in cancer is important 
because of  the role of this pathway in cell proliferation, cell survival and 
angiogenesis (Wang and Tournier, 2006). The abnormal expression of 
MEK5/ERK5 has been demonstrated in many human cancers such as breast 
cancer, prostate cancer and oral squamous cell carcinoma (Montero et al., 
2009b, McCracken et al., 2008a, Sticht et al., 2008).  
The aim of this study was to analyse and investigate the role of ERK5 in 
malignant melanoma by exogenous activators such as growth factors and 
anti-cancer agent PLX4720. The activation of ERK5 in A375 vemurafenib-
sensitive or resistant cells by a variety of growth factors, VEGF, FGF-2, 
HGF, EGF, NRG-1 and PDGF-BB, with potent stimulation by EGF (Figure 
4.1), corroborates data from previous studies in different cell types (Kato et 
al., 1998b, Hayashi et al., 2004a). The extensive phosphorylation of ERK5 in 
these cells resulted in a mobility bandshift from ERK5 with conventional 
SDS-PAGE.  
The expression and activation of ERK5 in tumour cells correlates with 
relapsed patients which is associated with aggressive conditions and poor 
prognosis (Mehta et al., 2003a, Jin et al., 2011). MEK5 expression via 
STAT3 in breast cancer cells was reported to provide critical survival signals 
to tumour cells and lead to chemo-resistance (Song et al., 2004, Weldon et 
al., 2002). The development of resistance to therapeutic agents is considered 
a major barrier to effective cancer treatment. At the molecular level, drug 
resistance is distinguished by changes in signalling pathways and gene 
expression which support cell survival and proliferation and a more 
malignant phenotype. After preliminary data revealed that ERK5 was 
activated in malignant melanoma cells in response to growth factors, analysis 
of the role of ERK5 in resistant cells in response to PLX4720 was conducted. 
ERK5 phosphorylation was increased in PLX4720-resistant cells compared to 
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the parental cell line (Figure 4.2 and 4.6). Based on EGF-induced ERK5 
activation in melanoma cells (Figure 4.1), inhibition of EGFR, MEK5, ERK5 
and ERK1/2 was used to investigate the correlation between ERK5 activation 
and these kinases after incubation of the cells with PLX4720. This study 
showed that selective inhibition of EGFR activity using lapatinib inhibited 
EGFR activation as expected but did not prevent ERK5 activation in 
PLX4720-resistant cells, revealing that ERK5 activation in a melanoma 
resistant cell line is not mediated by EGFR (Figure 4.5). The first generation 
of ERK1/2 inhibitors (U0126, PD98059 and PD184352) have been reported 
to inhibit endogenous ERK5 in HeLa cells (Mody et al., 2001a). Therefore it 
was possible that an ERK1/2 inhibitor (trametinib) may block ERK5 
activation in A375R melanoma cells. As expected, trametinib was found to 
be an effective inhibitor of ERK1/2 activation in PLX4720-sensitive and 
resistant cells. By contrast, the phosphorylation of ERK5 was increased by 
trametinib treatment in both cell lines (Figure 4.4 and 4.5). These data 
suggest that trametinib-mediated inhibition of ERK1/2 activation leads to 
ERK5 activation in malignant melanoma cells (A375 and A375R). This 
effect is similar to the reported effect of PD184352 upon EGF-induced ERK5 
activation in HeLa cells (Mody et al., 2001a) Therefore, ERK1/2 may have a 
negative regulatory effect upon the MEK5/ERK5 signalling pathway and 
provides further evidence of cross-talk between the ERK5 and ERK1/2 
signalling pathway as first suggested by Mody et al. (2001). Furthermore, a 
recent study revealed that inhibition of the ERK1/2 signalling pathway results 
in phosphorylation of ERK5 as an alternative pathway that rescues cell 
proliferation in colorectal cancer (de Jong et al., 2016). 
After determining the role of ERK5 in vemurafenib-resistant A375 cells, the 
second aim was to attempt to reverse drug resistance in the A375R cell line 
by inhibition of the MEK5/ERK5 signalling pathway. Previous studies have 
focused on dual inhibition to overcome resistance in melanoma (Heppt et al., 
2015). As reactivation of the MAPK pathway is involved in acquired 
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resistance in more than half of cases of BRAF V600E melanoma, and 
ERK1/2 is involved in the RAS-RAF pathway, the combination of BRAF and 
MEK inhibitors such as dabrafenib and trametinib has improved the 
progression free-survival and response rates compared with the use of 
individual inhibitors (Shi et al., 2014, Wagle et al., 2014). Inhibition of the 
MEK5/ERK5 signalling pathway by BIX02189 and XMD8-92 
synergistically with the BRAF inhibitor, PLX4720, exhibited a vital role in 
the reversal of PLX4720-resistance in melanoma A375 and SKMel5 cells 
(Figure 4.9). Concurrent targeting of BRAF and MEK5/ERK5 in cells with 
BRAF V600-mutated malignant melanoma reversed resistance to PLX4720 
in both melanoma cell lines A375R and SKMel5R (figure 4.9). The reversed 
resistance levels were approximately similar to treated PLX4720-sensitive 
A375 and SKMel5 cells with PLX4720 alone, which mean the combination 
of these agents in resistant cells, reversed the cells back to the vemurafenib 
sensitive state (Table 4.2). 
These results demonstrate that ERK5 expression was up-regulated in 
vemurafenib-resistant melanoma cancer cells. In addition, use of the 
MEK5/ERK5 signalling pathway inhibitors, BIX02189 and XMD8-92, in 
combination with a BRAF inhibitor, PLX4720, could reverse vemurafenib-
resistance. 
The third aim was to assess the role of the MEK5/ERK5 signalling pathway 
inhibitors in combination with a BRAF inhibitor in tumour angiogenesis by 
using the melanoma tumour cells in a HDMEC/NHDF co-culture in vitro 
angiogenesis assay. 
In tumour progression, pro-angiogenic factors induce quiescent vasculature to 
sprout new blood vessels and maintain tumour growth by supplying nutrients 
and oxygen (Lochhead et al., 2012). The role of MEK5 and ERK5 in blood 
vessel formation has been demonstrated by deletion of mek5 and erk5 in mice 
(Wang et al., 2005). In B16F10 murine melanoma cells, the target deletion of 
CHAPTER FOUR: The role of ERK5 in tumour angiogenesis and drug-resistance in 
metastatic melanoma cell 
 
138 
 
ERK5 in endothelial cells decreased the tumour mass and vascular density 
(Hayashi et al., 2005b). ERK5 is required for VEGF induced tubular 
morphogenesis in an in vitro angiogenesis system (Roberts et al., 2010a). 
These findings demonstrate the central role of ERK5 in tumour angiogenesis. 
Comparison of the inhibitory effects of the BRAF inhibitor PLX4720 or the 
MEK5/ERK5 signalling pathway inhibitors BIX02189 and XMD8-92 
respectively alone or in combination with PLX4720 on malignant melanoma 
cell induced tumour angiogenesis, suggests that the effect of these agents are 
both additive and synergistic (Figure 4.10 and 4.11). Combination of BRAF 
inhibitor and MEK5/ERK5 inhibitor treatment was sufficient to reverse the 
resistance of melanoma cells to the BRAF inhibitor (Figure 4.9). Treatment 
with the same agents was able to reduce tumour cell-stimulated tube 
development in a HDMEC/NHDF/A375 or SKMel5 co-culture in vitro 
angiogenesis assay (Figure 4.10 and 4.11). It would be interesting to 
investigate the effect of siRNA mediated silencing of MEK5 and ERK5 
expression in HDMEC/NHDF/tumour cells to further validate this model.  
 
These findings together demonstrate that ERK5 expression is up-regulated in 
vemurafenib-resistant A375R and SKMel5R melanoma cells, and inhibition 
of the MEK5/ERK5 and BRAF could reverse PLX4720 resistance, and 
prevent tumour angiogenesis, presenting a possibility of ERK5 serving as a 
therapeutic target to overcome vemurafenib resistance in melanoma patients. 
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5.1   Introduction 
Ovarian cancer is the fourth common cancer in women after breast, bowl and 
lung cancer (Cancer Research UK, 2016). In the UK, 7000 cases of ovarian 
cancer are diagnosed yearly with approximately 4300 deaths from this cancer 
(Cancer Research UK, 2016). The reason for poor prognosis in females with 
ovarian cancer is that more than 50% of women are diagnosed at an advanced 
stage making treatment difficult. The diagnosis of ovarian cancer at the late 
stage is due to the lack of a regular screening test compared to breast and 
cervical cancer. The current five-year survival rate for patients diagnosed 
with advanced stage ovarian cancer is 46% compared to 90% of those 
diagnosed at early stage of this disease (Ovarian Cancer Awareness Month, 
2016). According to the International Federation of Gynaecology and 
Obstetrics (FIGO), ovarian cancer is classified into four stages based on the 
level of progression.  
 Stage I is confined to the ovary or fallopian tubes 
 Stage II has spread into pelvic tissue 
 Stage III has extended from the ovary to the peritoneal lining 
 Stage IV has penetrated the peritoneum and metastasised outside of the 
abdomen (Prat and Oncology, 2015) 
There are many contributing risk factors for ovarian cancer. A family history 
of ovarian cancer increases the risk of developing this disease. The 
appearance of ovarian cancer in a first degree relative such as a mother or 
sister increases the possibility of ovarian cancer by more than 5 times 
(Soegaard et al., 2009) and is a potent risk factor for earlier onset (≤ 50 years) 
ovarian cancer (Soegaard et al., 2009). Analysis of gene mutations in relation 
to ovarian cancer risk has shown that mutations in the BRCA1/2 genes play a 
major role in ovarian cancer susceptibility in addition to their role in breast 
cancer (Wooster et al., 1995, Modan et al., 2001). In addition, the tumour 
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suppression gene p53 is mutated in 50% of ovarian cancer cases especially in 
the late stage (Berchuck et al., 1994). Certainly, the risk of developing 
ovarian cancer increases with age (Chan et al., 2008). 
Treatment of ovarian cancer by using chemotherapy in the last few decades 
has had minimal effect on patient survival. Thus, new treatment approaches 
are needed to improve the outcomes in ovarian cancer. Patients with ovarian 
cancer are treated with chemotherapy; e.g. taxane or cisplatin. Most patients 
respond initially, however many of them relapse with drug-resistant disease 
within the first 5 years after initial diagnosis (Greimel et al., 2006).  
Angiogenesis, which is the formation of new blood vessels from a pre-
existing vasculature, is a crucial step in tumour proliferation and metastasis 
and is a promising target for cancer treatment. For tumours to grow larger 
than a few hundred microns in diameter, there must be growth of new blood 
vessels (Carmeliet and Jain, 2000). Angiogenesis is a complicated process 
which is tightly regulated by a balance between pro-angiogenic and anti-
angiogenic factors, which are synthesised by a range of cell types. Growth 
factors such as VEGF, PDGF and EGF beside IL8 represent the pro-
angiogenic factors while Ang1 and 2 and thromobospondin represent the anti-
angiogenic factors. Furthermore, angiogenesis plays a role in normal ovary 
physiology as new blood vessel formation and regression in the female 
reproductive system occurs in each cycle via complex interactions between 
steroid hormones and angiogenic factors (Ramakrishnan et al., 2005). 
Therefore, pre-clinical and clinical research studies have suggested that 
angiogenesis and its effectors have a pivotal role in ovarian cancer (Abu-
Jawdeh et al., 1996). 
It has recently been shown that ERK5 is critical in angiogenesis. Previous 
results from our group have revealed that the knockdown of ERK5 in 
HDMECs prevents tubular morphogenesis in vitro (Roberts et al., 2010a, 
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Nithianandarajah-Jones et al., 2014). In addition, the ablation of erk5 in mice 
results in embryonic lethality in vivo (Hayashi et al., 2004a).  
This chapter analyses the role of the MEK5/ERK5 signalling pathway in 
doxorubicin and cisplatin resistant ovarian cancer cells.  
5.2   Characterisation of ERK5 phosphorylation in drug 
resistant ovarian cancer cells  
5.2.1   ERK5 is activated in A2780-ADR and A2780-CP70 resistant 
ovarian cancer cell lines 
Human ovarian carcinoma A2780 cells and their doxorubicin-resistant 
substrain A2780-ADR and cisplatin-resistant substrain A2780-CP70 were 
obtained from Prof. Robert Brown, University of Glasgow, UK. The A2780 
human ovarian cancer cell line was established from tissue obtained from an 
untreated patient. The doxorubicin and cisplatin resistant cells were generated 
by exposure of the parental cell line to multiple and increasing concentrations 
of doxorubicin and cisplatin (Behrens et al., 1987, Brown et al., 1993, Rogan 
et al., 1984). 
Cisplatin is a platinum analogue that intercalates with DNA strands causing 
cross-linking; interfering with the DNA repair mechanism which 
subsequently induce apoptosis in cancer cells (Dasari and Tchounwou, 2014). 
It has been used in treatment of many types of cancer including head, neck, 
ovarian and bladder cancer. Doxorubicin is an anthracycline which interferes 
with DNA and prevents its replication and transcription (Jurisicova et al., 
2006). It is used to treat a variety of cancers such as breast, lymphoma, 
ovarian and leukaemia. Chemotherapeutic agents can trigger the signalling 
pathways that are implicated in drug resistance, for example the constitutive 
activation of ERK1/2 appears in many types of cancers such as mesothelioma 
(de Melo et al., 2006). ERK5 has been involved in the regulation of cellular 
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proliferation, cell death and tumourigenesis and with its upstream activator 
MEK5; is essential in vasculogenesis (Wang and Tournier, 2006).  
To validate the resistance of doxorubicin and cisplatin in A2780 ovarian 
cancer cell lines, an ATP viability assay was applied. The parental cell line 
and doxorubicin resistant cells were treated with dose response of 
doxorubicin and incubated for 72 hours. Also, A2780 and cisplatin resistant 
cells were treated with dose response of cisplatin and incubated for 72 hours. 
In the A2780 cells, the IC50 for doxorubicin is 0.976 μM while for cisplatin 
is 2.76 μM while in the A2780-ADR and A2780-CP70 cell lines, the IC50 of 
doxorubicin and cisplatin are 30.05 μM and 30.20 μM respectively (Figure 
5.1). The IC50 drug doses for the two cell lines A2780 and A2780-ADR 
differ by 31-fold for doxorubicin whereas the IC50 drug doses for A2780 and 
A2780-CP70 differ by 11-fold for cisplatin (Figure 5.1). 
 
 
 
 
Figure 5.1 Dose response curves of doxorubicin and cisplatin in A2780-WT, A2780-
ADR and A2780-CP70. A2780-WT, A2780-ADR and A2780-CP70 cells seeded in a 96-
well plate for 24 hours and then treated with different concentrations of doxorubicin (A2780-
WT and A2780-ADR) or cisplatin (A2780-WT and A2780-CP70) and then incubated for 72 
hours. After that, cells were analysed by using CellTiter-Glo® Luminescent Cell Viability 
Assay. This result is representative of three independent experiments. 
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The ovarian cancer cell lines, A2780 and A2780-ADR (ovarian cancer cells 
resistant to doxorubicin), were incubated with/without doxorubicin, whereas 
A2780 and A2780-CP70 (ovarian cancer cells resistant to cisplatin) were 
incubated with/without cisplatin for 1 hour.  
The cells were lysed and protein resolved on an 8% SDS-PAGE acrylamide 
gel. The band shift shown in Figure 5.2 revealed that ERK5 phosphorylation 
was increased in both resistant cell lines compared with the parental cell line 
(Figure 5.2a). Moreover, the densitometry of phosphorylated ERK5 bands 
confirmed that the cells incubated with 1μM of anti-cancer agents showed an 
increase in ERK5 activation in both resistant cell lines (Figure 5.2b). 
The levels of mRNA expression of mek5 and erk5 in A2780-WT, A2780-
ADR and A2780-CP70 were also assessed and showed that mek5 and erk5 
expression was increased in doxorubicin resistant cells compared to parental 
cells (Figure 5.3). These data together revealed that ERK5 could play a role 
in the resistance of ovarian cancer cell lines to doxorubicin and cisplatin. 
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Figure 5.2 ERK5 activation in A2780 ovarian cancer resistant cell lines. (A) A2780-WT, 
A2780-ADR and A2780-CP70 were seeded in a 12-well plate for 24 hours and then 
incubated with 1µM doxorubicin or cisplatin prior to lyse the cells with RIPA lysis buffer. 
Protein lysates from A2780-WT, A2780-ADR and A2780-CP70 were resolved on 8% 
acrylamide gel and analysed with western blot by using antibodies against ERK5, p-ERK1/2 
and GAPDH. (B) Analysis of a densitometry of protein phosphorylation or protein 
expression relative to basal control condition of each cell type was (set arbitrarily as 1.0). 
This result is typical of four independent experiments (*p<0.05). 
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Figure 5.3 mRNA expression of mek5 and erk5 in A2780 ovarian cancer resistant cell 
lines. The bar chart shows RT-PCR analysis for MEK5 and ERK5 mRNA level in A2780-
WT, A2780-ADR and A2780-CP70. The ovarian cancer cells RNA were extracted and 
cDNA prepared. Data were analysed by the ∆∆Ct value method and the expression was 
normalized to GAPDH expression and illustrated as fold change.  Both experiments are 
representative of four individual experiments.  
 
5.2.2   ERK5 is activated in response to a variety of other growth factors 
in all the A2780 ovarian cancer cell lines 
ERK5 is activated by a range of growth factors and cellular stresses including 
VEGF, FGF-2, EGF, NRG-1 PDGF-BB and HGF. Kato and colleagues 
revealed that EGF mediates cell proliferation in HeLa cells through ERK5 
signalling (Kato et al., 1998b). Furthermore, studies have shown that MEKK2 
regulates the activation of ERK5 in response to FGF-2 in embryonic stem 
cells (Kesavan et al., 2004a). The overexpression of NRG receptors are 
involved in cell proliferation in breast cancer cells through the ERK5 
signalling pathway (Esparis-Ogando et al., 2002a). In addition, the role of 
HGF in cell proliferation in malignant mesothelioma cells is dependent on 
ERK5 signalling (Shukla et al., 2013b). 
It was previously shown that drug resistance in ovarian cancer cells leads to 
upregulation of RTKs in these cells and increased responsiveness to growth 
factors. The response to a range of growth factors was studied in the ovarian 
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cancer cells. The cells of ovarian cancer (A2780-WT, A2780-ADR and 
A2780-CP70) were stimulated with 50ng of VEGF, FGF-2, HGF, EGF, 
NRG-1 and PDGF-BB for 10 minutes and analysed by western blot. In the 
parental A2780, EGF and NRG-1 were the potent stimulators of ERK5 
activation with about 2-fold more compared to the basal control (Figure 
5.4a).  
In doxorubicin and cisplatin resistant cells the NRG-1 and EGF also have a 
strong effect on ERK5 phosphorylation compared to the basal control (Figure 
5.4b, c).  
In contrast, PDGF-BB was the weakest ERK5 activator in both A2780 WT 
and A2780-CP70 compared with other growth factors. However, PDGF-BB 
in A2780-ADR was the third most potent inducer of ERK5 activation after 
NRG-1 and EGF while the HGF was the weakest stimulator of ERK5 activity 
in these cell line (Figure 5.4b). On the other hand, EGFR was phosphorylated 
in all three cell lines in response to epidermal growth factor at different 
levels.  
Altogether, these findings demonstrated that EGF and NRG-1 may play an 
important role in ERK5 activation in A2780 cell lines, especially in ADR and 
CP70 resistant cell lines.  
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Figure 5.4 Characterisation of ERK5 activation in A2780-WT, A2780-ADR and A2780-
CP70 in response to growth factors using electrophoretic mobility band shift. (A) 
A2780-WT, (B) A2780-ADR and (C) A2780-CP70 cells were seeded in 12-well plate for 24 
hours and then serum starved overnight. Cells were stimulated with 50ng/ml of VEGF, FGF-
2, HGF, EGF, NRG-1 and PDGF-BB followed by RIPA lysis. Protein lysates from A2780-
WT, A2780-ADR and A2780-CP70 were resolved on 8% acrylamide gel and analysed with 
western blot by using antibodies against p-EGFR, ERK5 and GAPDH. Analysis of 
densitometry of protein phosphorylation or protein expression was relative to basal control 
condition of each cell type which was (set arbitrarily as 1.0). This result is typical of three 
independent experiments (*p<0.05, **p<0.01) 
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5.2.3   EGF and NRG-1 mediate ERK5 activation in A2780 ovarian 
cancer cell lines 
On average, 48% of ovarian cancer cases are reported to express aberrant 
EGFR receptors and ligands (Lafky et al., 2008). The overexpression of 
EGFR in ovarian cancer has been associated with poor prognosis (Bull 
Phelps et al., 2008). NRG-1 is an important member of the neuregulin family 
which consists of a broad family of EGF-like signalling molecules (Britsch, 
2007). NRG-1 interacts with transmembrane tyrosine kinase receptors of 
ErbB family (Britsch, 2007). NRG-1 induced ErbB3 activation and promotes 
cell proliferation in human ovarian cancer cells (Sheng et al., 2010). 
Figure 5.5 showed that stimulation of ovarian cancer cells with EGF and 
NRG-1 for 10 minutes induced the activation of ERK5 in all three cell lines. 
In contrast, the stimulation of these cells with both ligands, EGF and NRG-1, 
for 1 hour induced ERK5 phosphorylation but with less effect compared with 
10 min stimulation. ERK5 activation in the parental cell line displayed more 
phosphorylation in response to EGF and NRG-1 compared with resistant cell 
lines ADR and CP70 (Figure 5.5). 
Four sites (Ser124, Thr450, Thr308 and Ser473) on AKT have been 
identified that are phosphorylated in vivo (Alessi et al., 1996); Ser124 and 
Thr450 are basally phosphorylated whereas Thr308 and Ser473 are required 
for AKT activation and phosphorylated in response to a range of extracellular 
stimuli (Datta et al., 1999). AKT was phosphorylated on Ser473 in A2780-
ADR and A2780-CP70 in response to growth factors compared to the basal 
control (Figure 5.5). 
BRAF and KRAS are associated with ovarian carcinogenesis and mutations 
in these genes lead to phosphorylation of the downstream target, MEK1/2, 
which in turn activates ERK1/2 resulting in phosphorylation of downstream 
cellular targets in ovarian cancer (Wan et al., 2004, Hsu et al., 2004). 
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Activation of the ERK1/2 pathway in response to EGF and NRG-1 was 
observed in all three ovarian cancer cell lines compared with the basal control 
(Figure 5.5). Furthermore, the ovarian cancer cell lines show a variable 
expression of EGFR activation in response to EGF (Figure 5.5).  
Overexpression of EGFR has been linked with poor prognosis in advanced 
stage ovarian tumour (Figure 5.5) (Psyrri et al., 2005, Niikura et al., 1997a). 
EGFR was activated in response to EGF in resistant ovarian cancer cells 
(A2780-ADR and A2780-CP70) (Figure 5.5 a). To assess the expression of 
the EGFR family in ovarian cancer cells, quantitative RT-PCR was used. The 
mRNA expression assay displayed a high expression of egfr-1 in CP70 and 
ADR in comparison to A2780-WT cells (Figure 5.5 c).  
In addition, gene expression of egfr-3 was expressed in both resistant cell 
lines and that may be associated with the finding that ErbB3 is present in a 
significant proportion of human ovarian cancers driven by NRG-1 which 
suggest that ErbB3 and NRG-1 are a possible treatment target in ovarian 
cancer (Figure 5.5 c) (Sheng et al., 2010). 
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Figure 5.5 ERK5 activation in response to EGF and NRG-1 for 1 hour and 10 minutes. 
(A) A2780-WT, A2780-ADR and A2780-CP70 cells were seeded in a 12-well plate for 24 
hours and then overnight serum starvation. Cells were stimulated with 50ng/ml of EGF and 
NRG-1 for 1 hour and 10 minutes followed by RIPA lysis. Protein lysates from A2780-WT, 
A2780-ADR and A2780-CP70 were resolved on 8% acrylamide gel and analysed with 
western blot by using antibodies against p-EGFR, EGFR, ERK5, p-AKT, AKT, p-ERK1/2 
and GAPDH. (B) Analysis of densitometry of protein phosphorylation or protein expression 
was relative to basal control condition of each cell type which was (set arbitrarily as 1.0). (C) 
The bar chart shows RT-PCR analysis for EGFR-1, 2, 3, 4 mRNA level in A2780-WT, 
A2780-CP70 and A2780-ADR. The ovarian cancer cells RNA were extracted and cDNA 
prepared. Data were analysed by the ∆∆Ct value method and the expression was normalized 
to GAPDH expression and illustrated as fold change. This result is typical of three 
independent experiments (*p<0.05, **p<0.01). 
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           5.3   Small molecule kinase inhibitors  
5.3.1   Treatment combination of doxorubicin with MEK5/ERK5 
inhibitors decreased ERK5 activation in A2780-ADR 
In order to investigate the role of combination treatment on activation of 
MEK5/ERK5 pathway in ovarian cancer cells, western blotting was applied 
to examine the phosphorylation of ERK5, ERK1/2 and EGFR proteins from 
extracts of cells treated with doxorubicin alone and in combination with small 
molecule kinase inhibitors of EGFR, ERK1/2, MEK5 and ERK5.  
Treatment of A2780-WT and A2780-ADR cells with doxorubicin confirmed 
the result in Figure 5.1 which revealed that ERK5 was more activated in 
resistant cells than in the parental cells (Figure 5.6a).  
Phosphorylation of ERK1/2 was increased in A2780-WT via doxorubicin 
compared to untreated cells, while in doxorubicin resistant cells there was no 
effect on ERK1/2 phosphorylation. In the parental cells, A2780-WT, the 
combination of doxorubicin with MEK5 inhibitor BIX02189, ERK5 inhibitor 
XMD8-92, EGFR inhibitor lapatinib and ERK1/2 inhibitor, trametinib, did 
not show a clear effect on the phosphorylation of ERK5 in comparison with 
the basal control (Figure 5.6a). The phosphorylation of ERK1/2 in A2780-
WT appeared to be decreased by treatment of doxorubicin with lapatinib and 
as expected was inhibited by doxorubicin with trametinib. The densitometric 
data showed that the level of EGFR-1 phosphorylation was not clearly 
affected by doxorubicin with BIX02189, XMD8-92 or trametinib (Figure 
5.6b). 
Applying dual treatment in A2780-ADR showed that the MEK5 and ERK5 
inhibitors, BIX02189 and XMD8-92 respectively, combined with 
doxorubicin, decreased the phosphorylation of ERK5 in comparison with the 
basal control. Furthermore, there were no obvious changes in ERK5 
activation in A2780-ADR cells in response to the combination of doxorubicin 
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with lapatinib compared to the basal control, while the combination of 
doxorubicin with trametinib appeared to increase the activation of ERK5 
(Figure 5.6).  
Interestingly, phosphorylation of ERK1/2 was increased when the cells was 
treated with doxorubicin and BIX02189 or XND8-92 in comparison with the 
basal control (Figure 5.6). The combination of doxorubicin with lapatinib 
decreased the activation of ERK1/2 as seen in the parental cells as well. The 
densitometry of EGFR-1 phosphorylation revealed that doxorubicin increased 
the phosphorylation of EGFR-1 in doxorubicin resistant cells (Figure 5.6b). 
The combination of doxorubicin with BIX02189, XMD8-92 or trametinib 
increased the activation of EGFR-1 in A2780-ADR. 
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Figure 5.6. Small-molecule kinase inhibitors in A2780-WT and A2780-ADR. (A) A2780-
WT and A2780-ADR cells were seeded in 12-well plate for 24 hours and then incubated with 
1µM doxorubicin for 24 hours and 0.1% DMSO vehicle control, 3µM XMD8-92, 3µM 
BIX02189, 3µM lapatinib and 3µM trametinib were added to the drugged cells and 
incubated for 1 hour prior to lysis of the cells with RIPA lysis buffer. Protein lysates from 
A2780-WT and A2780-ADR cells were resolved on 8% acrylamide gel and analysed with 
western blot by using antibodies against ERK5, p-EGFR, p-ERK1/2 and GAPADH which 
was used as a loading control. (B) Analysis of densitometry of protein phosphorylation or 
protein expression is relative to basal control condition of each cell type which was (set 
arbitrarily as 1.0). This result is typical of three independent experiments (*p<0.05) 
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5.3.2   Small molecule kinase inhibitors reduced ERK5 phosphorylation 
in A2780-CP70 
Treatment of A2780-WT and A2780-CP70 cells with cisplatin confirmed that 
the phosphorylation of ERK5 was increased in cisplatin resistant ovarian 
cancer cells compared with cisplatin-sensitive ovarian cancer cells (Figure 
5.7a).  
The combination of cisplatin with BIX02189 or XMD8-92 in A2780-WT did 
not show a clear effect on the activation of ERK5 compared with the basal 
control, while the effect of these treatment combinations clearly increased the 
phosphorylation of ERK1/2 (Figure 5.7a).  
The phosphorylation of ERK5 in A2780-WT was slightly increased in 
response to cisplatin with lapatinib or trametinib (Figure 5.7a). EGFR-1 
phosphorylation was increased in response to cisplatin in A2780-WT, 
whereas it decreased in response to the combined treatment of cisplatin with 
BIX02189 or XMD8-92. 
In cisplatin resistant cells (A2780-CP70), the phosphorylation of ERK5 was 
decreased in response to treatment combinations of cisplatin with BIX02189, 
XMD8-92, lapatinib or trametinib compared to cells treated only with 
cisplatin (Figure 5.7a).  
The combination of cisplatin with BIX02189, XMD8-92 or lapatinib in 
A2780-CP70 increased the activation of ERK1/2 compared with the basal 
control. As expected, the combination of cisplatin with trametinib abolished 
the activation of ERK1/2 in both cell lines (A2780-WT and A2780-CP70) to 
confirm its act (Figure 5.7a). In contrast to the parental cells, the cisplatin 
resistant ovarian cancer cells showed an increase in EGFR-1 phosphorylation 
level in response to the treatment combinations of cisplatin with MEK5 
inhibitor BIX02189, ERK5 inhibitor XMD8-92 or ERK1/2 inhibitor 
trametinib (Figure 5.7a and b). 
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Figure 5.7 Small-molecule kinase inhibitors in A2780-WT and A2780-CP70.  (A) 
A2780-WT and A2780-CP70 cells were seeded in 12-well plate for 24 hours and then 
incubated with 1µM cisplatin for 24 hours and 0.1% DMSO vehicle control, 3µM XMD8-92, 
3µM BIX02189, 3µM lapatinib and 3µM trametinib were added to the drugged cells and 
incubated for 1 hour prior to lysis of the cells with RIPA lysis buffer. Protein lysates from 
A2780-WT and A2780-CP70 cells were resolved on 8% acrylamide gel and analysed with 
western blot by using antibodies against ERK5, p-EGFR, p-ERK1/2 and GAPADH which 
was used as a loading control. (B) Analysis of densitometry of protein phosphorylation or 
protein expression is relative to basal control condition of each cell type which was (set 
arbitrarily as 1.0). This result is typical of three independent experiments (*p<0.05). 
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5.4   Doxorubicin resistance is prevented by inhibition of the 
MEK5/ERK5 signalling pathway  
Ovarian cancer treatment consists of a combination of surgery and 
chemotherapy, but patients usually experience disease relapse within two 
years of initial treatment due to the development of drug resistance (Mody et 
al., 2003). Thus, a better understanding of the mechanisms underlying drug 
resistance could improve treatment and extend survival time. 
The A2780-WT and doxorubicin resistant cell line A2780-ADR were 
investigated for their sensitivity to doxorubicin on its own and in combination 
with MEK5/ERK5 inhibitors, BIX02189 and XMD8-92, or the EGFR-1 
inhibitor, lapatinib. To assess the appropriate dose of inhibitors for 
combination with doxorubicin and avoid toxicity, dose response of 
BIX02189, XMD8-92 and lapatinib was applied in the A2780-WT, A2780-
ADR and A2780-CP70 cells. The IC50 of all of these inhibitors was around 
10 μM (Figure 5.8). Therefore 3 μM was selected as a minimal cell toxicity 
level. The parental cell line A2780-WT was sensitive to doxorubicin with an 
IC50 of 0.412 μM compared with the A2780-ADR cells which were more 
resistant to doxorubicin with an IC50 of 9.75 μM, which is a 23.7-fold 
increase in IC50 (Figure 5.9).  
There was no change in the sensitivity to doxorubicin with A2780-WT cells 
in combination with BIX02189, XMD8-92 or lapatinib (Figure 5.9a). In 
contrast, incubation of A2780-ADR cells with BIX02189, or XMD8-92, or 
lapatinib appeared to reverse sensitivity to doxorubicin by potentially 
reversing resistance (Figure 5.9b). 
These findings suggested that a combination therapy of doxorubicin with 
MEK5/ERK5 cascade inhibitors (BIX02189 and XMD8-92) or EGFR-1 
inhibitor (lapatinib) reduced the resistance of A2780-ADR cells to 
doxorubicin. 
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Figure 5.8 Dose response curves of MEK5 inhibitor BIX02189, ERK5 inhibitor XMD8-
92 and EGFR-1 inhibitor lapatinib in A2780-WT, A2780-ADR and A2780-CP70 cells. 
A2780-WT, A2780-ADR and A2780-CP70 cells seeded in 96-well plate for 24 hours and 
then treated with different concentration of inhibitors (A) BIX02189, (B) XMD8-92 and (C) 
lapatinib and then incubated for 72 hours. After that, cells were analysed by using CellTiter-
Glo® Luminescent Cell Viability Assay. This result is representative of three independent 
experiments. 
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Figure 5.9. Dose response curves of DOXORUBICIN combined with/without 
MEK5/ERK5 signalling pathway inhibitors and EGFR inhibitor in A2780-WT and 
A2780-ADR. (A) A2780-WT and (B) A2780-ADR cells seeded in 96-well plate for 24 hours 
and then treated with different concentration of doxorubicin on its own and with 3µM 
BIX02189, or XMD8-92 or lapatinib and then incubated for 72 hours. After that, cells were 
analysed by using CellTiter-Glo® Luminescent Cell Viability Assay. This result is 
representative of three independent experiments. 
 
 
 
Fold resistance is defined as the IC50 of the resistant cell line / IC50 of the parental cell line (Lidsky et al., 2014). 
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Table 5.1 The sensitivity of A2780-WT and A2780-ADR to doxorubicin -/+ BIX02189 or 
XMD8-92 or lapatinib 
DOXORUBICIN -/+ inhibitors (μM) 
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5.4.1   Inhibition of EGFR reduced cisplatin resistance in A2780-CP70 
cells 
The resistant cell line A2780-CP70 and parental cell line A2780-WT were 
treated with dose response of cisplatin alone and in combination with 3μM of 
BIX02189, XMD8-92 or lapatinib to analyse the effect of these kinase 
inhibitors on cisplatin resistance using a cell viability assay. The 
concentration was determined by using dose response of these inhibitors 
alone in all three ovarian cancer cell lines via a cell viability assay (Figure 
5.8). 
To assess the effect of the treatment combination of cisplatin with BIX02189, 
or XMD8-92 or lapatinib on cisplatin resistant ovarian cancer cells, cell 
viability of A2780-WT and A2780-CP70 cells in response to cisplatin alone 
and in combination with these inhibitors was applied.  
The parental cell line A2780-WT was sensitive to cisplatin with an IC50 for 
0.615 μM, while the cisplatin resistant cells A2780-CP70 were more resistant 
to cisplatin with an IC50 of 9.917 μM which gave 16.12-fold increase in IC50 
(Figure 5.10).  
In the parental cell lines A2780-WT, combination treatment of cisplatin with 
BIX02189, or XMD8-92 or lapatinib did not change the sensitivity of these 
cells to cisplatin (Figure 5.10a). However, incubation of A2780-CP70 cells 
with lapatinib reversed the resistance of these cells to cisplatin with an IC50 
of 0.830 μM compared to an IC50 of 9.917 μM for treatment with cisplatin 
alone (Figure 5.10b). 
This finding demonstrated that, the EGFR-1 inhibitor (lapatinib) in 
combination with cisplatin could potentially reverse the resistance of A2780-
CP70 to cisplatin. 
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Figure 5.10. Dose response curves of cisplatin combined with/without MEK5/ERK5 
signalling pathway inhibitors and EGFR inhibitor in A2780-WT and A2780-CP70. (A) 
A2780-WT and (B) A2780-CP70 cells seeded in 96-well plate for 24 hours and then treated 
with different concentration of cisplatin on its own and with 3µM BIX02189, XMD8-92 and 
lapatinib and then incubated for 72 hours. After that, cells were analysed by using CellTiter-
Glo® Luminescent Cell Viability Assay. This result is representative of three independent 
experiments. 
 
 
 
Fold resistance is defined as the IC50 of the resistant cell line / IC50 of the parental cell line (Lidsky et al., 2014). 
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Table 5.2 Sensitivity of A2780-WT and A2780-CP70 to cisplatin -/+ BIX02189, or 
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5.5   MEK5/ERK5 signalling pathway inhibitors decrease 
angiogenesis stimulated by A2780 ovarian cancer cells 
Angiogenesis is a crucial factor in tumour growth and invasion, and the 
formation of metastases. Clinical studies have suggested a specific role of 
angiogenesis and its effectors in ovarian cancer development (Abu-Jawdeh et 
al., 1996). 
In order to assess the effect of MEK5 and ERK5 inhibitor (BIX02189 and 
XMD8-92 respectively) treatment upon the angiogenic potential of A2780-
WT, A2780-ADR and A2780-CP70 ovarian cancer cell lines, a co-culture 
assay of NHDF/HDMEC/A2780s was performed. After plating the fibroblast 
cells on day 1, the ovarian cancer cells were added onto the fibroblast 
monolayer on day 3. HDMECs were added to the NHDF/ovarian cancer cells 
after 24 hours. On day 5, the co-culture of NHDF/HDMECs/A2780s was 
treated with BIX02189 or XMD8-92 and incubated at 37 ºC until day 8. 
Treatment of the co-culture with inhibitors was repeated and incubated in 37 
ºC for 48 hours. On day 10, the co-culture was fixed. Furthermore, a 
NHDF/HDMEC co-culture assay without tumour cells was run as a control. 
It was found that tumour cells induced tube-formation in the 
NDHF/HDMEC/A2780 co-culture assay compared to the co-culture without 
cancer cells (Figure 5.11). Moreover, the inclusion of doxorubicin and 
cisplatin resistant cells in the co-culture assay prompted the development of 
more networked capillary vessels compared to the basal control assay and the 
A2780-WT sensitive tumour cell assay, which could mean that the expression 
levels of angiogenic factors (VEGF-A, B, C and D) from tumour cells are 
reflective of the degree of aggressiveness of the tumour cells (Figure 12d). 
Quantification of total tube length revealed that the MEK5 inhibitor 
BIX02189 reduced tubule formation in the doxorubicin and cisplatin resistant 
cell lines by 3-fold respectively compared to non-treated cells (Figure 5.11b). 
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In addition, treatment with the ERK5 inhibitor XMD8-92, decreased tube-
formation more than 2-fold in A2780-ADR cells and A2780-CP70 cells 
compared to untreated cells. The decrease in the level of tube formation in 
resistant ovarian cancer cells after treatment with MEK5/ERK5 signalling 
pathway inhibitors, BIX02189 and XMD80-92, when compared to the 
sensitive ovarian cancer cells or basal control assay without tumour cells 
could indicate that ERK5 plays a role in resistant cancer cells and suggests 
that ERK5 is responsible in resistant cancer cell lines for inducing more 
capillary like-structures.  
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Figure 5.11. The effect of MEK5/ERK5 inhibitors, BIX02189 and XMD8-92, on tumour 
angiogenesis in a HDMEC/NHDF/A2780s co-culture assay. (A) NHDF were seeded in 
fibroblast growth medium at 20,000 cells per well on gelatine-coated 24-well plates and 
incubated for 48 hours. On day 3, A2780-WT, A2780-ADR and A2780-CP70 cells were 
plated at 5,000 cells per well on the NHDF layer and incubated for 24 hours. On day 4 of the 
assay, HDMECs were plated at 45,000 cells per well onto the confluent NHDF and A2780s 
layers with EBM MV2 basal medium FGM. On day 5, co-culture media were changed to 
EBM MV2 basal medium containing 1% (v/v) FCS and treated with indicated amount of 
BIX02189 and XMD8-92, as shown in the treatment schedule (C).The treatment was 
repeated on day 8. On day 10, cells were fixed and stained as described (section 2.2.9.3.3), 
and total tube length was quantified using AngioQuant image analysis software. (B) Data is 
presented as total tube length compared to basal. This result is typical of two independent 
experiments (**p<0.01). 
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Figure 5.12 mRNA expression of in ovarian cancer cells. The bar chart shows RT-PCR 
analysis of (A) mdr-1, (B) abcg2, (C) gst-pi and (D) vegf-a, vegf-b, vegf-c and vegf-d mRNA 
expression in A2780-WT, A2780-CP70 and A2780-ADR. The ovarian cancer cells RNA 
were extracted and cDNA prepared. Data were analysed by the ∆∆Ct value method and the 
expression was normalized to GAPDH expression and illustrated as fold change. 
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5.6   Discussion 
The purpose of conducting the experiments detailed in this chapter was to 
assess the role of the MEK5/ERK5 signalling pathway in doxorubicin and 
cisplatin resistant ovarian carcinoma cells by using the small molecule kinase 
inhibitors BIX02189 and XMD8-92. 
In this study, the ovarian carcinoma cell lines (A2780-WT, A2780-ADR and 
A2780-CP70) were exposed to doxorubicin and cisplatin to assess the effect 
of these chemotherapeutic drugs on ERK5 activation.  
Increased ERK5 activation was observed in the resistant cell lines in 
comparison with the sensitive cells which mean that the MEK5/ERK5 
signalling pathway could play a role in drug resistance in ovarian carcinoma 
(Figure 5.2).  
Furthermore, the resistant cells exposed to chemotherapeutic agents displayed 
increased ERK5 activation, which is considered an important contributor to 
the cell survival mechanism, suggesting that doxorubicin and cisplatin 
activate survival pathways in ovarian carcinoma cells (Wang and Tournier, 
2006).  
ERK5 activation is increased in response to growth factors (Mody et al., 
2003). Thus, Figure 5.4a, b and c showed that phosphorylation of ERK5 
increased in response to a variety of growth factors in all three ovarian cancer 
cell lines. Receptor tyrosine kinases of the ErbB family are activated when it 
interacts with ligands of the EGF family (Wang and Tournier, 2006).  
Resistance to chemotherapy, metastasis and poor prognosis in cancer are 
associated with over expression of EGFR receptors (Wang and Tournier, 
2006). EGFR is induced via epidermal growth factor (EGF) and other related 
ligands, whereas EGFR-2, 3 and 4 are activated by EGF-like ligands called 
neuregulins (NRGs) (Esparis-Ogando et al., 2002a). Analysis of ERK5 
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activation in human derived cancer cell lines such as breast cancer has 
illustrated that constitutive activation of ERK5 is associated with activated 
forms of ErbB2, 3 and 4 (Esparis-Ogando et al., 2002a).  Knockdown of 
ERK5 via siRNA induced apoptosis and decreased chemo resistance in HL-
60 acute myeloid leukaemia cells (Hayashi et al., 2005b). 
In this chapter, EGF and NRG-1 were the most potent ligands that increased 
ERK5 activation in ovarian cancer cell lines (Figure 5.4). EGFR was 
activated in ovarian cancer cells in response to EGF. The gene expression of 
erbb1 and erbb3 were increased in ovarian cancer resistant cell lines which 
demonstrated their role in poor prognosis and resistance to chemotherapy 
agents in cancer patients (Figure 5.5c).  
Inhibition of the MEK5/ERK5 signalling pathway by the small kinase 
inhibitors BIX02189 and XMD8-92 in combination with doxorubicin or 
cisplatin was investigated in doxorubicin and cisplatin resistant ovarian 
cancer cell lines (Figure 5.6 and 5.7). Combination therapies using 
chemotherapeutic drugs (doxorubicin and cisplatin) with MEK5/ERK5 
signalling pathway inhibitors (BIX02189 and XMD8-92) or EGFR inhibitor 
(lapatinib) were applied to evaluate the effect of these combinations on the 
resistance of A2780 ovarian cancer cell lines.  
BIX02189, XMD8-92 or lapatinib in combination with doxorubicin shifted 
the resistance in doxorubicin-resistant cells compared to cells treated with 
doxorubicin alone (Figure 5.9). The inhibition of EGFR combined with 
doxorubicin in A278-ADR cells restored sensitivity to doxorubicin to 
approximately the same level as the parental cell line (Figure 5.9). Moreover, 
treatment of cisplatin-resistant cells with a combination of lapatinib and 
cisplatin restored sensitivity to cisplatin to approximately the level of the 
parental cell line (Figure 5.10).  
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Different mechanisms have been considered for doxorubicin resistance, 
including the expression of many membrane efflux pumps; the gene 
expression of MDR-1 and ABCG-2 in A2780-ADR cells was increased more 
than 3500-fold and 20-fold respectively in comparison with A2780-WT 
(Gottesman et al., 2002) (Figure 5.12a and b). Furthermore, increased drug 
metabolism enzymes such as glutathione S-transferase P1 (GSTP1) affect 
doxorubicin cytotoxicity in cancer and the gene expression of GSTP1 in 
A2780-ADR cells was increased compared to the parental cell line (Harbottle 
et al., 2001) (Figure 5.12c).  
There are several mechanisms implicated in cisplatin resistance including 
increased DNA repair, decreased drug accumulation and increased 
detoxification via GSTP1 which is considered as a key limiting factor in 
cisplatin cytotoxicity (Pasello et al., 2008). Gene expression of GSTP1 in 
A2780-CP70 cells has been investigated and showed an increase compared to 
parental cell line (Figure 5.12c).  
Thus in future works, inhibition of certain ABC transporters such as MDR-1 
and ABCG-2 by MEK5/ERK5 could be a mechanism to assess the role of the 
MEK5/ERK5 signalling pathway in the regulation of chemoresistance in 
tumour cells that overexpress many ABC transporters. These findings 
suggested that the MEK5/ERK5 signalling pathway, along with EGFR, could 
be a possible therapeutic target to reduce drug resistance in ovarian cancer.  
Deletion of the erk5 gene revealed its involvement in tumour associated 
angiogenesis and its effect in the vasculature development of melanoma and 
lung carcinoma xenograft (Hayashi et al., 2005b). In addition, deletion of 
erk5 in flank region of mice reduced the number of large blood vessels in a 
growing tumour (Hayashi et al., 2005b).  
In this chapter, the role of the MEK5/ERK5 pathway in tumour angiogenesis 
was assessed by inhibition of this cascade via BIX02189 and XMD8-92 
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inhibitors in a NHDF/HDMEC/A2780s co-culture in vitro angiogenesis 
assay.  
Initially, embedding ovarian cancer cells in either sensitive or resistant state 
in NHDF/HDMEC co-culture revealed that tumour cells induced more 
capillary network vessels compared to co-cultures without tumour cells 
(Figure 5.11).  Previous data from our group revealed that ERK5 is required 
for AKT phosphorylation, and also involved in VEGF-mediated survival and 
tubular morphogenesis in HDMECs (Roberts et al., 2010c). The doxorubicin 
or cisplatin resistant cells triggered more tubular formation compared with 
A2780-WT cells which demonstrates the aggressiveness of resistant cells.  
The ability of tumour cells to increase tube-formation relates to increased 
secretion of VEGF-A to induce endothelial cells and increase tubule 
formation (Figure 5.12d). Treatment of the co-culture with MEK5 and ERK5 
inhibitors (BIX02189 and XMD8-92) revealed that tube formation was 
reduced, and this effect was more evident in resistant cancer cells.  
These data suggest that ERK5 plays a role in tumour angiogenesis and is 
required in resistant cancer cells to induce networked blood vessels; this may 
provide a possible means for therapeutic inhibition of angiogenesis in vivo. 
Future study should aim to investigate the effect of siRNA-mediated 
silencing of MEK5 and ERK5 expression in a NEHDF/HDMEC/cancer cells 
co-culture to further validate this model.   
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6.1   The role of ERK5 signalling axis in tumour angiogenesis 
and drug resistance 
The ERK5 protein is ubiquitously expressed and plays different roles in many 
cell types (Hayashi et al., 2004a, X and Tournier, 2006, Spiering et al., 2009). 
In addition to its role in regulating cellular processes such as survival, 
proliferation and differentiation, ERK5 has been involved in the progression 
of a number of pathologies such as cancer and ischaemia (Kato et al., 1998a, 
X and Tournier, 2006, Takeishi et al., 1999, Montero et al., 2009a). 
Gene targeting studies in mice highlighted the critical role of ERK5 in 
cardiovascular development and maintenance of vascular integrity (Hayashi 
and Lee, 2004, Hayashi et al., 2004b). Moreover, some studies have 
characterised the role of ERK5 activation in regulating intracellular signalling 
and gene expression in human endothelial cells (Abe et al., 1996, Yan et al., 
1999, Roberts et al., 2010b). In addition, several studies focused on the role 
of ERK5 activation in response to EGF in case of tumour cell proliferation 
and intracellular localisation (Kato et al., 1998a, Kamakura et al., 1999, 
Raviv et al., 2004, Kondoh et al., 2006, Yang et al., 2010d). Aberrant ERK5 
signalling has been already reported in various cancers such as breast cancer, 
hepatocellular, prostate cancer and malignant mesothelioma and associated 
with poor prognosis (Montero et al., 2009a, Zen et al., 2009, McCracken et 
al., 2008b, Shukla et al., 2013a). ERK5 appears to be critical factor in 
tumour-associated angiogenesis and has been presented to be vital for 
angiogenesis in melanoma and lung carcinoma, as well as prostate cancer 
metastasis (Hayashi et al., 2005a, Mehta et al., 2003b). 
This thesis has addressed the effect of the therapeutic inhibition of ERK5 
signalling in tumour angiogenesis by using melanoma and ovarian carcinoma 
as tumour cell models, as well as assessing the combination therapy of 
MEK5/ERK5 signalling inhibitors with chemotherapy agents in drug-
resistant cancer cells. 
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6.1.1   pro-angiogenic factors induce phosphorylation of ERK5 in 
HDMECs and HeLa cells 
The characterisation of ERK5 activation was investigated in this project by 
using VEGF stimulation of HDMECs and EGF stimulation of HeLa cells 
based on previous findings (Roberts et al., 2010c, Mody et al., 2001b). It was 
confirmed that VEGF and EGF stimulated ERK5 phosphorylation in 
HDMECs and HeLa cells respectively (Figure 3.1). In this project, the 
detection of ERK5 activation by phospho-ERK5 (Thr
218
/Tyr
220
) antibody for 
western blotting and through electrophoretic mobility bandshift on 
conventional SDS-PAGE was used. The activation of ERK5 by 
phosphorylation by its upstream MEK5 preferentially phosphorylates the 
threonine residue of the T-X-Y motif which is similar that of JNK activation 
by its upstream MEK4/7 (Mody et al., 2003), opposite to p38 MAPK and 
ERK1/2 which are phosphorylated on the tyrosine residue of the T-X-Y 
(Haystead et al., 1992, Fleming et al., 2000). However, ERK5 is distinct in 
comparison with JNK, p38 MAPK and ERK1/2, in addition to dual 
phosphorylation of threonine or tyrosine residues of T-X-Y motif, ERK5 is 
able to undergo autophosphorylation of its C-terminal tail residues (Mody et 
al., 2003, Buschbeck and Ullrich, 2005). 
This project in line with current studies, confirmed that EGF stimulated HeLa 
cells undergo phosphorylation of ERK5 on Thr
218
/Tyr
220 
residues in the 
activation loop of the kinase domain and residues in the C-terminal tail which 
resulted in a mobility bandshift with conventional SDS-PAGE. In endothelial 
cells (HDMECs), VEGF stimulated HDMECs analysed by conventional 
SDS-PAGE did not induce an ERK5 mobility bandshift, with ERK5 
activation only detected by using phospho-ERK5 (Thr 
218
/Tyr
220
) antibody for 
Western blotting. This data suggested that, VEGF has only the ability to 
induce the dual phosphorylation of the kinase domain of ERK5, without any 
effect on the phosphorylation of the C-terminal residues. Taken together this 
data suggests that phosphorylation of Thr
218
/Tyr
220 
in the kinase domain and 
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C-terminal phosphorylation are not mutually inclusive events and that ERK5 
can be activated in the absence of C-terminal phosphorylation. This suggests 
that in endothelial cells, ERK5 may play a different intracellular signalling 
role than in epithelial cells. Interestingly, the phenotype of erk5 -/- mice 
shows cardiovascular defects with loss of cardiac vascular integrity 
suggesting that endothelial cells have a unique requirement for ERK5 
activation (Nithianandarajah-Jones et al., 2014) 
The dose response data with the ERK5 inhibitor XMD8-92 on HeLa cells 
suggested that phosphorylation of ERK5 on Thr
218
/Tyr
220 
residues was not 
affected by the inhibitor; however a decrease in bandshift was observed 
suggesting that C-terminal phosphorylation was inhibited.  This is consistent 
with XMD8-92 affecting ERK5 kinase activity rather than phosphorylation of 
the T-E-Y motif which is accomplished by MEK5. The use of XMD8-92 in 
HDMECs showed that VEGF-stimulated AKT activity was not affected by 
use of this inhibitor (Figure.3.4).  
The dose response data of MEK5 inhibitor BIX02189 on HDMECs revealed 
that the phosphorylation of AKT requires VEGF-mediated MEK5 kinase 
activity and subsequently ERK5 activation to some degree (Figure 3.6). 
Previous data from the group has shown that in HDMECs, siRNA mediated 
silencing of ERK5 reduces VEGF-mediated AKT phosphorylation by 
approximately 50% when cells are on a gelatin matrix (Roberts et al., 2010b); 
this would appear to agree with the data generated with the BIX02189. In 
contrast, EGF-mediated ERK5 phosphorylation in HeLa with BIX02189 or 
even XMD8-92 did not affect AKT activity (Figure 3.3 and 3.5). XMD8-92 
inhibits ERK5 activity and supresses tumour growth in lung and cervical 
tumour model without inducing vasculature abnormalities (Yang et al., 
2010c, Yang and Lee, 2011). One potential concern with the development of 
ERK5 inhibitors is the profound cardiovascular abnormalities seen in the erk5
 
-/-
 gene KO studies (Nithianandarajah-Jones et al., 2012a). Considering that 
XMD8-92 appears to preserve VEGF-mediated AKT activation in contrast to 
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siRNA mediated gene silencing (Roberts et al., 2010b) it is interesting to 
speculate that inhibition of ERK5 kinase activity in endothelial cells may not 
have the detrimental effects seen with the erk5 
-/-
 gene knockout and that 
XMD8-92 may be a viable drug for use in patients. 
6.1.2   Activation of ERK5 increases tumour resistance 
All types of cancer virtually characterised by their ability to progress for 
increase malignancy. There are number of different methods for cancer 
treatment. Chemotherapy is one of the most important for treatment of 
cancer, but the major problem that limits the effectiveness of chemotherapy 
to treat cancer is drug resistance. Tumour cells can be intrinsically resistant to 
chemotherapy before receiving the treatment. However, drug resistance can 
be acquired and develop during treatment that were initially sensitive to 
chemotherapy and that can be caused by mutations during treatment or 
increased expression of therapeutic target and activation of alternative 
signalling pathway (Holohan et al., 2013). Mitogen activated protein kinases 
(MAPKs) are serine threonine kinases mediating intracellular signalling 
associated with different cellular activities including cell differentiation, 
proliferation and migration. The mammalian MAPK family is composed of 
ERK, p38 MAPK, JNK and ERK5 (Dhillon et al., 2007). MAPK plays a key 
role in development and progression of cancer (Kohno and Pouyssegur, 2006, 
Galabova-Kovacs et al., 2006, Bradham and McClay, 2006, Bubici and Papa, 
2014, Ortiz-Ruiz et al., 2014). ERK5 has been shown to mediate resistance to 
cytotoxic chemotherapy-induced apoptosis (Weldon et al., 2002). In this 
project, the role of ERK5 in drug resistance was investigated by using 
malignant melanoma A375 and SKMel5 cell lines harbouring mutation of 
BRAF V600E, as well as ovarian carcinoma A2780 cell lines that are 
resistant to doxorubicin and cisplatin. 
ERK5 is activated in malignant melanoma cells in response to various growth 
factors such as EGF (Figure 4.1). Increased phosphorylation of ERK5 is 
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significant (*p< 0.05) in resistant cells in comparison with sensitive cells 
(Figure 4.2 and 4.6). As vemurafenib can inhibit BRAF (V600E) 
→MEK→ERK signalling sufficiently, treatment of A375 or SKMel5 cells 
with PLX4720 inhibited ERK1/2 activation, while increase ERK5 activation 
in resistant cells (A375R and SKMel5R). Investigation of interplay between 
ERK1/2 and MEK5/ERK5 signalling pathway was applied by inhibiting 
ERK1/2 via trametinib aMEK1/2 inhibitor, in combination with PLX4720. 
Interestingly, inhibition of ERK1/2 increased the phosphorylation of ERK5 in 
A375R cells which could consider as alternative pathway that allows cancer 
growth to continue (Figure 4.5). This finding correlates with recent research 
which revealed that inhibition of ERK1/2 increased ERK5 activation 
providing a bypass route to rescue cell proliferation in colorectal cancer (de 
Jong et al., 2016). In addition, incubating A375 cells with XMD8-92 or 
BIX02189 in presence of PLX4720 increased ERK1/2 activation (Figure 4.4 
and 4.5). Furthermore, dose response curves of BIX02189, XMD8-92, 
lapatinib and trametinib via cell viability assay shows there is no effect of 
these inhibitors on A375R cells (Figure 4.8). Taken together, these data could 
confirm the recent study showing that ERK5 signalling is unlikely to play a 
role in cell proliferation in tumour cells with KRAS or BRAF mutations 
(Lochhead et al., 2016). Moreover, Lochhead and colleagues revealed that 
cancer cells that overexpress ERK5 are not addicted to MEK5/ERK5 
signalling pathway for proliferation and suggests that anti-tumour effects 
seen with ERK5 pathway targeted therapies are likely through other 
mechanisms (Lochhead et al., 2016). 
 The development of tumour resistance to single- targeted treatment, 
vemurafenib, seems to be unavoidable and it is important to identify an 
alternative way to overcome this resistance. Different mechanisms are being 
investigated that may have a role in the resistance to BRAF inhibitors which 
frequently reactivates the MAPK pathay through MEK (Van Allen et al., 
2014). Thus, appropriate drug combination strategies that target oncogenic 
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pathways along with BRAF are needed. There are preclinical and clinical 
studies show promising results to treat this problem such as a combination of 
BRAF inhibitor, dabrafinib and MEK inhibitor, trametinib which was 
approved by the FDA in patients with BRAF V600E mutated metastatic 
melanoma in 2014 which prolong progression-free and overall survival 
compared to dabrafinib alone. Here we investigated the up-regulation of 
ERK5 in vemurafenib-resistant melanoma cells and using MEK5/ERK5 
inhibitors, BIX02189 and XMD8-92 in combination with vemurafenib to 
overcome resistance. Based on the role of ERK5 as a compensatory pathway 
that rescue tumour proliferation upon inhibition of ERK1/2 pathway (de Jong 
et al., 2016), the combination of BRAF inhibitor (PLX4720) with MEK5 
inhibitor (BIX02189) or ERK5 inhibitor (XMD8-92) was analysed. 
Treatment combination of PLX4720 and BIX02189 or XMD8-92 increased 
the sensitivity of melanoma resistant cells to PLX4720 in both cell lines 
A375R and SKMel5R and shifting the dose response curve to the lift 
compared to PLX4720 alone (Figure 4.9). Therefore, inhibition of 
MEK5/ERK5 signalling in combination with vemurafenib can significantly 
reverse the resistance  and increase the sensitivity to this chemotherapeutic 
agent in malignant melanoma cells and could provide a potential therapeutic 
stratgey for vemureafenib resisatance in malignant melanoma. The activation 
of ERK1/2 induces the activation of negative feedback mechanisms that 
supresses the upstream kinases of ERK pathway such as RTK and Raf (de 
Jong et al., 2016). At cellular levels, vemurafenib efficiently inhibits ERK1/2 
activation and cell proliferation in most BRAF V600E melanoma cell line 
(Joseph et al., 2010). ERK5 is activated in response to EGF via a separate 
RAS-dependent pathway which in trun activates MEK5-ERK5 signalling 
cascade (Kamakura et al., 1999). Therefore, activation of ERK5 upon 
inhibition of ERK1/2 pathway could  be a consequence of rewiring of 
signalling pathways downstream of RAS which suggests that ERK5 plays a 
role as a bypass route downstream of EGFR-RAS and activated upon 
inhibition of ERK1/2 and continue the nuclear transduction in melanoma 
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resistant cells (A375R and SKMel5R), suggesting that MEK5/ERK5 
signalling pathway could play a pivotal role in vemurafenib resistance and 
inhibition of this pathway in combination with PLX4720, which targets 
BRAF V600E mutation and MEK-ERK signalling, could  provide a potential 
therapeutic strategy to overcome drug resistance (Figure 6.1). 
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Figure 6.1 The role of MEK5/ERK5 signalling pathway in vemurafenib drug resistance 
in malignant melanoma cells. (A) In vemurafenib sensitive cells, BRAF V600E mutant 
melanoma is constitutively active and no need for signalling between RAS and RAF which is 
disconnected because the constitutive active of BRAF mutant. Inhibition of BRAF V600E 
mutant by addition of vemurafenib inhibits downstream activation of ERK pathway, and 
thereby decreasing cell proliferation and inducing apoptosis. (B) In resistant cells, inhibition 
of MEK1/2-ERK1/2 pathway by vemurafenib leads to lack of negative feedback which in 
turn activates RTK-RAS-RAF-MEK5-ERK5 pathway which results in continues tumour cell 
proliferation in malignant melanoma. Treatment combination of vemurafenib with BIX02189 
or XMD8-92 can reverse the compensatory upregulation of MEK5/ERK5 pathway and also 
prevent the angiogenic and lympangiogenic effect of increased VEGF-A and VEGF-C 
secretion in the drug-resistant melanoma cells. 
 
A B 
Sensitive cell Resistant cell 
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In ovarian carcinoma cells, the phosphorylation of ERK5 was increased in 
response to growth factors specially EGF and NRG-1 as well as activation of 
ERK1/2 increased in response to these growth factors (Figure 5.4 and 5.5a). 
ERK5 was activated in resistant cell lines A2780-ADR and A2780-CP70 
compared to parental cells A2780-WT and also the expression of MEK5 
mRNA and erk5 mRNA in resistant cell lines was higher in comparison with 
sensitive cell (Figure 5.2 and 5.3). In addition, adding doxorubicin or 
cisplatin to tumour cells increased activation of ERK1/2 which correlates 
with studies showning that ERK1/2 is up-regulated in several types of cancer 
in response to DNA-dmaging chemotherapeutic agents such as doxorubicin 
and cisplatin (Taherian and Mazoochi, 2012, Tekedereli et al., 2012, Abrams 
et al., 2010, Tentner et al., 2012). This suggests that chemotherapeutic agents 
(doxorubicin and cisplatin) activate survival pathways in ovarian cancer cells.  
The activation of ERK5 in resistant ovarian cancer cells may be a 
consequence of activation of another pathway such as ERK1/2 or RTKs  such 
as EGFR. The kinase domain in N-terminal tail of ERK5 shares 
approximately 50% homolgy with ERK1/2 (Nishimoto and Nishida, 2006). 
Compared to ERK1/2, ERK5 has a unique C-terminal tail which has two 
prolin-rich regions, nuclear localisation signal (NLS) domain and a 
transcriptional activation domain (Nithianandarajah-Jones et al., 2012b). The 
molecular mechanism regulating transcriptional activation activity of ERK5 
C-terminal lies in that activated N-terminal (ERK5N) phosphorylates C-
terminal (ERK5C) at multiple autophosphorylation sites on ERK5C and the 
phosphorylation of C-terminal tail of ERK5 is important for improvement the 
transactivation activity of AP-1 (Morimoto et al., 2007b). Basid on this, 
Honda and colleagues investigated the interaction between ERK5 and 
ERK1/2 and they suggested that ERK1/2 may phosphorylates 
autophosphorylation of ERK5 on its C-terminal, ultimately they revealed that 
ERK1/2 phosphorylates ERK5 at Thr732 on transcriptional activation domain 
on C-terminal half of ERK5 (Honda et al., 2015). In doxorubicin resistant 
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cells A2780-ADR, treating cells with BIX02189 or XMD8-92 in combination 
with doxorubicin decreased ERK5 activation and increased ERK1/2 
phosphorylation. However, adding trametinib with doxorubicin to these cells, 
completely inhibited ERK1/2 activation and increased the phosphorylation of 
ERK5 compared to treated cells with doxorubicin alone (Figure 5.5a). This 
finding is similar to that in malignant melanoma resistant cells which means 
that ERK5 could potentially play a role in doxorubicin resistant ovarian 
cancer cells when ERK1/2 was abrogated. Moreover, inhibition of 
MEK5/ERK5 cascade via its inhibitors (BIX02189 and XMD8-92) or 
ERK1/2 by trametinib increased the activation of EGFR in A2780-ADR cells 
compared to treated cells with vehicle control (DMSO). Cell viability assay 
was applied to assess the role of MEK5, ERK5, EGFR and ERK1/2 inhibitors 
in A2780-WT and A2780-ADR alone as a single agent or in combined 
therapy with doxorubicin, there was no change or effect for inhibitors 
BIX02189, XMD8-92, lapatinib and trametinib alone on cancer cells 
compared to doxorubicin (Figure 5.8). However, the combination of 
doxorubicin with BIX02189 or XMD8-92 increased the sensitivity of A2780-
ADR to doxorubicin and could potentially reversed the resistance. Thus, 
ERK5 could play a role in doxorubicin ovarian cancer resistant cells but not 
cell proliferation which ERK1/2 could play this role in A2780-ADR and 
increase of ERK5 activation which in turn increase the resistance of A2780 
cells to doxorubicin. 
 The most important and common mechanism of drug resistance is the ability 
of cancer cells to eject the chemotherapeutic agents from the cells through 
transport proteins such as MDR-1 and ABCG2. Increased expression of 
MDR-1 (ABCB1) and ABCG2 is observed in A2780-ADR cells and this is 
likely responsible for drug resistance (Figure 5.12). Shukla revealed that 
inhibition of ERK5 decreased ATP-binding cassette (ABC) transporters and 
increased doxorubicin retention in malignant mesothelioma (Shukla et al., 
2013a). In cisplatin resistant cells (A2780-CP70), the combination of 
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BIX02189 or XMD8-92 did not affect the sensitivity of A2780 cells to 
cisplatin compared to cisplatin alone (Figure 5.10). This finding suggests that 
MEK5/ERK5 may not play a central role in cisplatin resistant cells and there 
is another activated pathway that increases the resistance to cisplatin. 
Treatment of CP70 cells with cisplatin in combination with trametinib 
decreased the activation of ERK5 to the same level of the effect of BIX02189 
or XMD8-92 (Figure 5.7). Therefore, triple combination BIX02189 or 
XMD8-92 with trametinib and cisplatin could be a potential target to 
overcome cisplatin drug resistance in ovarian cancer cells.  
Epidermal growth factor receptor-1 (EGFR-1) is expressed in ovarian cancer 
cells (Niikura et al., 1997a). Stimulation of EGFR-1 on the cell membrane 
leads to activate two important pathways; MAPK pathway and PI3K/AKT 
pathway which drive cell proliferation and survival (Grant et al., 2002, 
Normanno et al., 2006), and owing to this role in tumour (Corkery et al., 
2009), lapatinib (EGFR1-2 inhibitor) was approved for treatment of Her2 in 
breast cancer in combination with chemotherapeutic agents (Mukherjee et al., 
2007). The important interaction of lapatinib when combined with anticancer 
agents appears to be associated with its ability to inhibit ABCG2 and MDR-1 
activity (Dai et al., 2008, Chun et al., 2015).  Consistent with this studies, our 
findings indicate that lapatinib in combination with doxorubicin or cisplatin 
increased the cytotoxic effect of these chemotherapeutic agents in ovarian 
cancer cells and reversed the resistance of A2780 cells to doxorubicin or 
cisplatin in comparison to lapatinib alone (Figure 5.9 and 5.10). This finding 
suggests that combination of lapatinib with doxorubicin or cisplatin may offer 
more effective target for treatment of drug resistance in cancers. Doxorubicin 
inhibits tumour growth via intercalation with DNA and resulting to DNA 
damage and blocking cell replication. However, ovarian cancer cells up-
regulate pro-survival signals ERK1/2, ERK5 and EGFR-1 as a consequence 
of doxorubicin toxicity and this suggests that these signalling pathways could 
be implicated in doxorubicin resistance in ovarian cancer. 
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6.1.3   Targeting the MEK5/ERK5 signalling axis results in inhibition of 
VEGF-mediated angiogenesis 
Tumours require oxygen and nutrients to maintain cell growth and survival. 
In the absence of angiogenesis, tumour will be quiescent and limited at the 
early satges (Naumov et al., 2006). Tumour angiogenesis is charactarised by 
an imbalance between pro-angiogenic and anti-angiogenic, extracellular 
matrix remodeling, endithelial cell migartion, proliferation and differentiation 
which eventually results in sprouting new blood vessel. Tumour and stromal 
cells initiate this proccess by suppling an extensive pro-angiogenic growth 
factors and most notable is vascular endothelial growth factor (VEGF) which 
interact directly with receptor tyrosin kinase on the endothelial cell surface to 
promot invasive sprouting into the tmour and forming new blood vessel that 
proliferates tumour (Kerbel, 2008, Hanahan and Folkman, 1996a). Therefore,  
inhibition of tumour angiogenesis could be a promising strategy for treating 
solid tumours (Folkman, 1971). Gene ablation of erk5 in mice resulted in 
death at embryonic day E9.5-11.5 as a result of disruption of cardiovascular 
development and vascular integrity (Hayashi et al., 2004a). ERK5 is required 
for VEGF-mediated tubular morphogenesis in human microvascular 
endothelial cells (Roberts et al., 2010c). In this project, the role of ERK5 in 
tumour angiogenesis was characterised to assess the possibility of targeting 
MEK5/ERK5 signalling pathway for therapeutic  inhibiting of tumour 
angiogenesis by using in vitro angiogenesis co-culture assay. Judah Folkman 
was the first to demostrate in vitro angiogenesis that capillary endotheial cells 
were cultured on gelatin and stimulated to form tubule network when added 
tumour-conditioned media (Folkman and Haudenschild, 1980). Here, 
different cell types (endothelial, fibroblast and tumour) were successfully 
incorporated into controlled in vitro environment, demostrating reproducible 
angiogenic sprouting and inhibition in response to anti-angiogenic. Data 
presented in this study shows that inhibition of MEK5/ERK5 signalling 
pathway by the pharmacological inhibitors (BIX02189 and XMD8-92) 
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decreased VEGF-induced neovascularisation in a HMDEC/NHDF/tumour 
co-culture in vitro angiogenesis model. 
Inhibition of MEK5/ERK5 cascade via BIX02189 or XMD8-92 treatment in 
a co-culture assay  preferentially inhibited the growth of vessels undergoing 
angiogenesis compared to  established tubes in HDMEC/NHDF/HeLa co-
culture (Figure 3.9 and 3.10). This finiding sugests that early blood vessels 
are more sensitive to inhibition of ERK5 than the established capillary 
network. Based on the critical role of ERK5 for VEGF-induced endothelial 
cell survival by mediating activation of AKT (Roberts et al., 2010c), 
inhibition of MEK5/ERK5 signalling pathway in vivo by BIX02189 or 
XMD8-92 could prevent angiogenesis by preventing endothelial cell survival 
in response to stimulation with growth factors via inhibiting AKT activation. 
Furthermore, co-culture of A375 melanoma cancer cells with 
HDMEC/NHDF induced more tubule formation than HDMEC/NHDF co-
culture which demonstrates the ability of tumour cells to secrete more VEGF 
which is a potent inducer of angiogenesis (Hanahan and Folkman, 1996b)  
(Figure 4.11). Analysis of the MRNA expression of different VEGF family 
members revealed that in vemurafenib-resistant melanoma cells increased 
levels of VEGF-A mRNA and VEGF-C mRNA were observed (Figure 4.11). 
This data has been confirmed at the protein level with VEGF family members 
measured by ELISA (R.Marais, personal communication).  This suggests that 
the drug-resistant cells have potential to regulate angiogenesis via VEGF-A 
secretion and lymphangiogenesis via VEGF-C secretion. It is interesting to 
speculate that secretion of these VEGFs may be a potential biomarker of drug 
resistance in patients receiving vemurafenib and warrants further 
investigation by analysing patients plasma for VEGFs before and during 
vemurafenib treatment. The VEGFR-2 data shows that VEGFR-2 is only 
expressed on HDMEC and therefore strengthens the argument that VEGF-
A  secreted by drug resistant cells is not acting back on the melanoma cells 
Chapter Six: General Discussion 
 
184 
 
but on other cells such as endothelial cells in a paracrine manner (Figure 
4.11). 
Based on the role of ERK5 in VEGF-mediated tubular morphogenesis in 
HDMEC (Roberts et al., 2010b) and the role of combined therapy of 
MEK5/ERK5 inhibitors (BIX02189 or XMD8-92) with PLX4720 in 
reversing drug resistance in malignant melanoma cells one could speculate 
that ERK5 inhibitors directly target both the tumour cells and the angiogenic 
endothelial cells. This consistent with study revealed that combination of 
ERK5 inhibition with anticancer drug attenuated malignant mesothelioma 
(MM) tumour and decrease the level of many central cytokines and growth 
factors such as IL-8 and VEGF (Shukla et al., 2013a). In addition, the same 
finding was observed in ovarian cancer cells when they co-cultured with 
HDMEC/NHDF and increased the tube formation compared to 
HDMEC/NHDF co-culture without tumour cells and the resistant cells were 
more inducers of tubular network compared to sensitive cells and that could 
also prove the secretory VEGF from resistant cells to induce angiogenesis 
(Figure 5.11 and 5.12d). Treatment of HDMEC/NHDF/A2780 co-culture 
with BIX02189 or XMD8-92 decreased the tube formation compared to basal 
control (Figure 5.11). Shukla study the effect of ERK5 inhibition in MM 
tumour growth and found that inhibition of ERK5 significantly decreased 
tumour and this effect is far better when combined with doxorubicin (Shukla 
et al., 2013a). It would be interesting to analyse the effect of combiantion 
therapy of BIX02189 or XMD8-92 with doxorubicin or cisplatin on 
angiogenesis with ovarian cancer cells. 
 
Overall, this data has suggested that the ERK5 signalling axis is a viable 
target to restore sensitivity to chemotherapy in drug-resistant cells.  This 
effect was observed in vemurafenib-resistant melanoma cells and 
doxorubicin-resistant ovarian cancer cells.  It will be interesting to see what 
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other drug-resistant cancers show increased activation of the ERK5 signalling 
axis as this could offer a potential mechanism to reverse drug resistance in 
many different cancers. 
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Appendix I  
Primers sequence used in this thesis 
 
Primer 
name 
Forward sequence Reverse sequence 
VEGF-A CCTTGCTGCTCTACCTCCACC    TCCTCCTTCTGCCATGGG 
VEGF-B GGG CAC ACA CTC CAG GCC 
ATC 
CCT TGA CTG TGG AGC TCA TGG 
GCC 
VEGF-C TCAGGCAGCGAACAAGACC TTCCTGAGCCAGGCATCTG 
VEGF-D TCCAGGAACCAGCTCTCTGT TTTTTGGGGTGCTGGATTAG 
VEGFR-2 CAAACGCTGACATGTACGGTCT CCAACTGCCAATACCAGTGGA 
EGFR-1 TATGTTCCCTCCAGGTCAGC GCACCTGTAAAATGCCCTGT 
EGFR-2 CTACGGCAGAGAACCCAGAG CTTGATGCCAGCAGAAGTCA 
EGFR-3 CTTATCCGAGGGCAAATTCA TTTCCCTTAGTTCCCCATCC 
EGFR-4 TGTGTTCCAGTGATGGCTGT CCATTCTCAAACTCCCGAAA 
MEK5 ACGTGAAGCCCTCCAATATG GGCGCCATATAAGCATTTGT 
ERK5 TGTTCTCAGGCACACCAAAG GAGGCTGAGAGAGAGGCTGA 
MDR-1 GTGGGGCAAGTCAGTTCATT TTCCAATGTGTTCGGCATTA 
ABCG2 CCTGAGATCCTGAGCCTTTG AAGCCATTGGTGTTTCCTTG 
GST-PI ACCTCCGCTGCAAATACATC GACAGCAGGGTCTCAAAAGG 
